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1. INTRODUCTION 
 
The mevalonate- (MVA-) pathway is a crucial metabolic pathway for nearly all eukaryotic cells, 
of which the most recognized product is cholesterol (Figure 1).
1 This pathway also provides cells 
with  indispensable  lipids  including  isoprenoids.  The  long-chain  isoprenoids  dolichol  and 
ubiquinone  participate  in  membrane  organization  and  mitochondrial  oxygen  consumption, 
respectively.  The  short-chain  isoprenoids  farnesylpyrophosphate  (FPP)  and 
geranylgeranylpyrophosphate  (GGPP)  covalently  attach  to  small  GTPases,  which  act  as 
molecular switches in various biochemical pathways.
2 This essential attachment enables these 
proteins  to  be  inserted  into  membranes,  resulting  in  the  activation  of  pathways  involved  in 
inflammation, oxidative stress, and cell proliferation etc.
3,4,5,6,7 The Rho family of GTPases are 
one of the major regulators in synaptic plasticity, both in dendrite morphogenesis and stability as 
well as in growth cone motility.
8,9,10,11 Another vitally important role of FPP is that it is the key 
branch point for cholesterol and GGPP (Figure 1). There is keen interest in the role of FPP and 
GGPP  in  post-translational  modification  (PTM)  of  proteins  and  cell  function  in  Alzheimer’s 
Disease (AD).
3,12,13 FPP and GGPP like cholesterol are derived from mevalonate (Figure 1) but 
unlike cholesterol, there is little if any information on their regulation and abundance in the brain. 
The absence of such data is in stark contrast to the aforementioned interest in the role of those 
isoprenoids  in  protein  prenylation  and  cell  function.  The  following  sections  build  on  a 
comprehensive  review  by  Cole et  al.
3  and  summarize  the  current  knowledge  on  isoprenoids, 
recent findings regarding their regulation and targeted proteins with special focus on AD. 
 
1.1. Cholesterol  
1.1.1. Biosynthesis 
The mevalonate- (MVA-) pathway is a crucial metabolic pathway in all eukaryotic cells, with the 
exception  of  mature  red  blood  cells.
14  It  converts  mevalonate  via  a  complex  biosynthesis, 
including more than 30 intermediates, into cholesterol. It is most recognized for the biosynthesis 
of cholesterol, while it provides cells with further indispensable substrates, such as squalene and 
the isoprenoids FPP and GGPP.  
Initial  steps  of  the  MVA-isoprenoid  pathway  involve  the  synthesis  of  3-hydroxy-3-
methylglutaryl-  coenzyme  A  (HMG-CoA)  from  acetyl-CoA  via  acetoacetyl-CoA  (Figure  1).   10 
HMG-CoA  reductase,  the  rate  limiting  step  of  the  entire  pathway  then  forms  mevalonate.
1 
Biosynthesis mainly occurs in the endoplasmic reticulum (ER) but also in peroxisomes.
15 After 
mevalonate production mevalonate kinase (MK) catalyzes the phosphorylation of mevalonic acid 
to  phosphomevalonate.  Phosphomevalonate  kinase  catalyzes  the  reaction  of  mevalonate  5-
phosphate and adenosine triphosphate (ATP) to mevalonate 5-diphosphate where the latter is 
subjected to decarboxylation and forms isopentenyl pyrophosphate (IPP), which equilibrates with 
its isomer dimethylallyl pyrophosphate (DMAPP), catalyzed by the isopentenyl pyrophosphate 
isomerase. IPP or DMAPP then undergo subsequent condensation reactions to produce a 10-
carbon  lipid  geranylpyrophosphate  (GPP), the  15-carbon  FPP  and  the  20-carbon  GGPP.  The 
synthesis of GPP and FPP is catalyzed by farnesylpyrophosphate synthase (FPPS) while GGPP is 
synthesized by geranylgeranylpyrophosphate synthase (GGPPS).
16,17 FPP is a key branch point of 
the  pathway  leading  to  GGPP  synthesis  and  to  squalene,  which  is  catalyzed  by 
farnesyldiphosphate  farnesyltransferase  (FDFT),  also  known  as  squalene  synthase.  From 
squalene  two  subsequent  enzymatic  reactions  result  in  the  production  of  lanosterol,  this 
represents the basic chemical structure of all steroids. Subsequent reactions lead to the production 
of desmosterol and 7-dehydrocholesterol and finally to cholesterol. See Figure 1 for a summary 
of the MVA-pathway.  
 
1.1.2. Cholesterol homeostasis in the brain 
Cholesterol is an essential compound for the structure and functionality of cells. The mevalonate 
pathway, as described in the previous paragraph, underlies very complex regulatory mechanisms 
due to its immensely important role in cell and tissue physiology. Fundamental research, focusing 
on cholesterol biosynthesis was conducted by Clayton and Bloch in 1956 
18 and Goodman et al. 
in 1962 
19, and even today after more than roughly 50 years of research, there are still ambiguities 
concerning feedback mechanisms, transcription, translation and the regulation of the activity of 
enzymes within the MVA-pathway. 
The  role  of  cholesterol  in  the  brain  becomes  obvious  when  looking  at  the  sterols  enormous 
abundance  compared  to  any  other  tissue  in the  human  body. Approximately, 25% of  all  the 
cholesterol found in the body is located in the central nervous system (CNS), while the total 
weight  of  the  organ  only  accounts  for  about  2%  of  the  body  weight.
20,21  Within  the  brain 
cholesterol makes up 20-30% of all existing lipids
20 it has become generally accepted that most   11 
of it is derived from de novo synthesis and brain levels are generally independent from plasma 
cholesterol levels, due to the function of the blood brain barrier (BBB).
22 Investigations on age-
related brain cholesterol synthesis in different species ruled out possibilities that the synthesis rate 
is high in the fetus and newborn but declines considerably in later life.
23 Consequently, the levels 
of human brain cholesterol increases in average from ~ 6 mg/g in a newborn to a maximum of 23 
mg/g in the young adult brain 
23 with an estimated half-life of approximately 5 years for the 
sterol. Furthermore, the cholesterol half-life in rodent brain was estimated to be only 2-6 month.
24 
Many of the studies regarding cholesterol turnover are based on the measurement of its major 
metabolite, the 24S-hydroxycholesterol, for two reasons: it is the major oxysterol in the brain and 
it is also the main cholesterol metabolite crossing the BBB and therefore traceable in plasma.
25 
Björkhem et al. 
24 approximated the transfer of 24S-hydroxycholesterol from the CNS into the 
periphery to be ca. 4 mg/day where it can be subsequently excreted via the bile in a sulphated or 
glucuronidated form.
24,26 The cytochrome P450 isozyme CYP46A1 is located in neurons spread 
out in different regions in the brain and is responsible for the conversion in the brain.
27 A recently 
published  review  by  Farooqui  et  al.
28  also  emphasized  two  further  oxysterols,  25-  and  27-
hydroxycholesterol to be important for brain cholesterol homeostasis.
28  
For the most part the transport of cholesterol and its metabolites in the opposite direction, from 
the circulation into the CNS is prevented under physiological conditions by the BBB. However, a 
flux of 27-hydroxycholesterol into the brain compartment was shown by Heverin et al.
29 and in 
the  same  context  a  novel  elimination  route  via  7α-hydroxy-3-oxo-4-cholestenoic  acid  was 
recently described.
30 In general 27-hydroxycholesterol levels in the plasma are low, leading to a 
27-hydroxycholesterol/24-hydroxycholesterol ratio of ~ 2 and ~ 0.4, in the periphery and in the 
brain, respectively.
31 Moreover, the absolute concentration or the ratio is discussed by several 
groups  to  be  changed  under  pathological  conditions,  which  affect  the  brain  (e.g. 
neurodegeneration).
25,31,32 
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Fig. 1. Outline of the mevalonate/isoprenoid/cholesterol pathway. The overview depicts the major intermediates 
and enzymes involved in the biosynthesis of the isoprenoids and cholesterol. Single arrows (￿) depict a 
one step conversion, while double arrows (￿ ￿) omit one or several intermediates. - - - - symbolizes the 
blood brain barrier (BBB). A detailed description with all abbreviations can be found in section 1.1.1. 
and section 1.1.2. of the introduction. E- and Z-PT depict the prenyltransferases leading to the E- or Z- 
stereoisomers.   13 
1.1.3. The role and function of brain cholesterol 
As  briefly  mentioned  earlier  cholesterol  plays  a  fundamental  role  in  brain  development  and 
maintenance of function. It contributes to protein functionality and is an indispensable compound 
of neuronal membranes where it strongly influences their fluidity and stability in general. Besides 
being a component of plasma  membranes of neurons and astrocytes, the major part of brain 
cholesterol is associated with the myelin sheath, leading to especially high cholesterol content 
within the white matter.
20 Differences in cholesterol distribution between the white and the grey 
matter but also a difference in synthesis rate and abundance are apparent in various other regions 
of the brain.
33,34 Furthermore, neurons and astrocytes vary in cholesterol synthesis, e.g. astrocytes 
feature a higher rate. In the developed brain there is a possibility for the transport of cholesterol 
from astrocytes to neurons, when there is an excessive requirement for the sterol.
35,36 For the lipid 
transport,  the  brain  is  equipped  like  the  periphery,  with  apolipoproteins  (Apo).  The  proteins 
present in the brain are Apo-I, A-IV, D, E and J
37, while ApoE has the most dominant role and is 
widely  discussed  in  the  context  of  AD.
38,39,40  The  role  of  ApoE  after  brain  damage  and  for 
maintenance  of  neuronal  function  has  also  been  discussed  and  the  involvement  of  ApoE  in 
synaptic plasma membrane formation was indicated in studies with ApoE deficient mice.
41  
 
1.2. The physiology of the cell membrane 
Today’s fundamental conception of the assembly of biological cell membranes is based on the 
fluid mosaic model described in 1972
42, which was revisited in 1995
43 and is now regarded as a 
more complex entity consisting of caveolae, lipid rafts and other lipid sub-domains.
44 Depicted 
by the primary model the cell membrane can be considered as a two-dimensional oriented liquid, 
consistent of a lipid bilayer divided into a cytofacial and an exofacial (inner and outer) leaflet. 
The main constituent of this structure are the phospholipids thus building a hydrophilic surface 
layer  with  their  phosphate  groups  while  the  fatty  acids  paralleling  to  each  other  form  the 
lipophilic interlayer. The hydrophobic ´tails` of each layer oppose each other and fulfill two basic 
requirements: on the one hand the lipid bilayer provides the structural properties required for 
membrane bound proteins (integral or peripheral) such as ion channels, receptors and enzymes 
and on the other hand it provides a natural barrier especially for polar solutes or ions to diffuse 
freely  through  the  membrane  and  therefore  allows  the  cell  to  establish  certain  essential 
concentration gradients.    14 
Besides the aforementioned phospholipids and proteins, the cell membrane also consists of other 
lipids like cholesterol, sphingomyelin and glycolipids and other carbohydrates. The composition 
of the bilayer is very heterogeneous and can vary in a wide range depending on the function of 
the cell and in accordance to changes originating from age-dependant processes or pathological 
conditions.
45 For example, higher cholesterol content or elevated levels of saturated fatty acids 
can  lead  to  decreased  membrane  fluidity,  influencing  cell  activities  associated  with  the 
membrane.  It  was  shown  that  cholesterol  is  the  main  regulator  of  membrane  fluidity  as  it 
intercalates between the fatty acids of the membrane and sterically hampers their movements, 
overall leading to a more rigid behavior of the bilayer.
46  
The cholesterol distribution between the two leaflets of the cell membrane is asymmetric and 
undergoes substantial changes during aging. In young mice (3-4 months) approximately 15% of 
synaptosomal  plasma  membrane  (SPM)  cholesterol  was  found  in  the  exofacial  leaflet  and 
roughly doubled in aged mice (24-25 month).
47 Furthermore, this age-dependant distribution shift 
also affects lipid rafts, distinct island like domains in which a main proportion of membrane 
associated  cholesterol  is  found.
48  Besides  these  lipid  rafts,  also  called  detergent  resistant 
membranes (DRMs) caveolae harbor high concentrations of cholesterol. Both are cell surface 
micro-domains and rich in cholesterol and sphingolipids. Caveolae are primarily characterized by 
the abundance of caveolin, a membrane bound protein not present in lipid rafts and by its flask-
shape appearance.
49 They are involved in signal transduction, vesicle transport via endocytosis 
and  in  various  disease  pathologies  like  for  example  during  interactions  with  the  human 
immunodeficiency virus (HIV).
50,51,52 
Lipid  rafts  are  planar  micro-domains  creating  a  tightly  packed  lipid  aggregation  containing 
flotillin and alkaline phosphatase as marker proteins. They are plasma membrane reaction centers 
especially  for  protein-protein  interactions,  cell  signaling  and  trafficking.
53,54  Besides  being 
involved in several diseases
55 they are also discussed for their role in synapse formation and 
function
56  and  are  therefore  studied  with  interest  in  the  field  of  neurodegenerative  diseases 
including AD. 
In contrast to caveolae it is difficult to visualize these planar structures in the membrane by 
common  techniques  like  electron  microscopy.
57  Recent  advances  were  able  to  clearly 
demonstrate the existence of lipid rafts
58,59 devitalizing inconsistent argumentations on rafts being 
artifacts of detergent extractions
60,61 and emphasizing the impact of the isolation technique.
58    15 
To  widen  the  knowledge  on  raft  associated  proteins  several  groups  addressed  the  issue  by 
proteomic approaches, most notably the work  by  Mann in 2006.
62 The advancements in this 
relatively new field have been summarized by Zheng et al.
63 
The integrity of proteins and their functionality are highly dependant on the overall composition 
of  the  surrounding  membrane  and  especially  on  the  abundance  of  cholesterol,  sphingo-  and 
ganglioside  lipids.  Based  on  the  impact  of  lipid  rafts  on  multiple  biochemical  pathways, 
modulation of lipid raft composition is used to study related disease pathways and potentially 
offers a target for pharmacological intervention.
64 
 
1.3. Isoprenoids – Chemistry and Structure 
Isoprenoids are a large heterogeneous class of biologically active lipids. There is an estimated 
55.000 natural products, which virtually all derive from the C5-unit IPP or its isomer DMAPP.
65 
Two metabolic pathways are assumed to be responsible for the synthesis of higher isoprenoids 
(also known as terpenes) and their secondary products. The MVA-pathway which is the only 
source of isoprenoids in archaebacteria, fungi, animals and humans, and the 1-deoxy-D-xylulose 
5-phosphate/2-C-methyl-D-erythritol 4-phosphate (DOXP/MEP) pathway, which is only present 
in higher plants, most eubacteria and for example in the malaria parasite plasmodium falciparum. 
Moreover, plants are the only organisms using both pathways for isoprenoid biosynthesis, though 
in different compartments.
17,66 
Regarding the nomenclature, terpenes are generally classified with a prefix characterizing the 
number of isoprene units present. Compounds consisting of a single (C5-) isoprene unit are called 
hemiterpenes,  followed  by  monoterpenes  (C10-),  sesquiterpenes  (C15-)  like  for  example  FPP, 
diterpenes (C20-) like GGPP and further polyterpenes.  
In mammals the initially mentioned structural isomers IPP and DMAPP form GPP catalyzed by 
the  FPPS,  80  kDa  homodimer
67,  via  a  “head-to-tail”  condensation.  Following  this  step  the 
identical enzyme catalyzes the condensation of GPP and IPP to form the C15 FPP. While the 
subsequent “head-to-tail” reaction of an additional 5-carbon lipid via the GGPPS, a 195 kDa 
homo-oligomer
67, leads to the C20 GGPP. The “head-to-head” reaction of two FPP molecules 
results in the production of squalene (C30 unit) (see Figure 1).
17 These two mechanisms are the 
basic reactions for chain elongation concerning non-cyclic or cyclic isoprenoids.  
   16 
1.3.1. Longer chain isoprenoids – dolichol and ubiquinone 
In mammals FPP is the precursor of dolichol and ubiquinone. Ubiquinone (coenzyme Q) as part 
of  the  electron  transfer  between  complex  I,  II  and  III  of  the  respiratory  chain
68,69  is  mainly 
localized in the inner mitochondrial membrane. Its synthesis proceeds upon conversion of GGPP, 
leading to chain elongation and predominately takes place in the ER–Golgi system.
70 The enzyme 
trans-prenyltransferase  (also  known  as  E-prenyltransferase  or  E-PT)  is  involved  in  the 
biosynthesis of ubiquinone (see Figure 1).
17,71 The number of incorporated isoprene units and 
therefore the chain length varies among different organisms and is commonly indicated by the 
following number e.g. coenzyme Q10.
17,71 Ubiquinone is essential for normal cell function and 
misdirected biosynthesis results in pathological respiratory chain deficiencies.
72,73,74 
Dolichol biosynthesis involves the only cis-prenyltransferase (also known as Z-prenyltransferase 
or Z-PT) known in humans (see Figure 1).
17,71 This longer chain isoprenoid is widely distributed 
in all tissues and membranes and besides carrying a terminal free hydroxyl group it exists in a 
phosphorylated, dephosphorylated or in an esterfied form.
17,75,76 Although knowledge on dolichol 
function is limited, it has been proposed as a biomarker for aging.
76,77 Numerous in vitro and in 
vivo experiments reported on interactions of dolichol with cellular membranes. The unesterfied 
dolichol  was  shown  to  modify  the  organization  and  packing  of  phospholipids  in  model 
membranes.
78 The  free  and  the  phosphorylated  forms  were  found to  be mediators  of protein 
glycosylation  or  as  sugar  carriers.
17,71  The  lipophilic  molecule  dolichol  intercalates  into  the 
bilayer  of  cell  membranes  and  interacts  with  the  phospholipids.
76  A  study  by  Wood  et  al.
79 
showed that dolichol increased membrane fluidity of SPMs isolated from brains of young and old 
mice. The same study revealed higher endogenous dolichol levels in isolated SPMs of aged mice 
and  it  was  concluded  that  dolichol  might  act  as  a  regulator  of  membrane  fluidity.
79  Several 
studies have reported higher dolichol levels with increasing age in peripheral tissue and in the 
brain.
80,81,82 Besides dolichol potentially regulating membrane fluidity, another hypothesis is that 
membrane localization of free dolichol may act as an antioxidant to counteract cell toxicity.
81 It 
remains to be elucidated whether elevated dolichol levels with aging are a consequence of a loss 
of enzymatic regulation in the MVA-pathway, as proposed by Pallottini et al.
83 
 
1.3.2. Analytical approaches for the quantification of longer chain isoprenoids 
The following describes several methods, which have been employed to better understand the 
role of dolichol and ubiquinone in cell physiology. Early experiments for the quantification of   17 
dolichol and the synthesis rate of distinct enzymes were carried out with radioactive (
14C/
3H 
ratios)  labeled  acetate.  Incorporation  into  the  MVA-pathway  derived  products  (e.g.  dolichol, 
sterols)  was  monitored  by  scintillation  counters  following  sample  preparation  and  high 
performance  liquid  chromatography  (HPLC)  and  thin  layer  chromatography  (TLC) 
separation.
84,85  Later  on,  researchers  used  ultra  violet  light  (UV)  HPLC  detectors  for  non-
radioactive quantifications.
86 Such analytical enhancements made the applications available to a 
broader group of researchers based on the usual equipment of laboratories, where HPLC systems 
are  far  more  common  and  manageable  than  radioactive  facilities.  Another  enhancement  was 
achieved by the incorporation of an internal standard (IS) in the analysis of dolichol, thereby 
strengthening the application in respect to robustness and reliability of the data.
87 In the field of 
quantitative analytics the most state of the art detection and quantification of the whole spectrum 
of  analytes  is  via  mass  based  detectors.  Often  used  in  combination  with  HPLC  mass 
spectrometers  (MS)  allow  a  very  sensitive  and  selective  form  of  detection.  The  two  most 
conventional and convenient ways to couple a liquid chromatography system to a MS is via 
electro  spray  (ESI)  or  atmospheric  chemical  ionization  (APCI).  Consequently,  a  recent 
publication detailed the technically advanced quantification of dolichol via LC ESI-MS.
88 At this 
point  it  is  also  worth  mentioning  that  an  isolation  technique  with  subsequent  HPLC-MS 
quantification is described in the literature for the determination of human brain dolichol levels.
89 
Similar  analytical  techniques  can  be  found  for  the  quantification  of  ubiquinone  in  tissue  or 
plasma.
88,90,91 Interestingly, this MVA-pathway end-product drew growing attention in the last 
decade due to the developing sector of life science research and the possible beneficial effects of 
Q10 supplementation. 
 
1.3.3. Farnesyl- and geranylgeranylpyrophosphate 
1.3.3.1. Role and function of FPP and GGPP 
As described in the previous sections FPP and GGPP play a decisive role within the MVA-
pathway and for the synthesis of essential compounds involved in cellular processes. Notably, 
FPP plays a significant role as it is the branching point of the whole pathway and serves as a 
substrate for several enzymes. Figure 1 depicts the utilization of both isoprenoids for various 
downstream products. Aside from the well-known and previously described conversion of FPP 
into GGPP, cholesterol, Heme A and dolichol it also serves as a substrate for the FTase for the   18 
prenylation of various members of the superfamily of small GTPases (see section 1.6.). GGPP 
however,  undergoes  conversion  to  form  ubiquinone  and  is  further  utilized  by  two  different 
prenyltransferases, namely geranylgeranyltransferase I and II (GGTase I and II), described in 
further detail in section 1.6.1. 
 
1.3.3.2. Analytical approaches for the quantification of FPP and GGPP 
Despite the large interest in the two MVA-pathway intermediates, FPP and GGPP, with regards 
to cell physiological and pathological regulation, there is a lack of valid quantitative data on 
endogenous levels, especially for human tissue. As described in the following, early publications 
focused on FPP determination, while more recent studies attempted to simultaneously quantify 
both isoprenoids. 
One of the earliest publications describing the quantification of FPP alone uses the enzymatic 
conversion  into  the  free  alcohol  via  an  alkaline  phosphatase  followed  by  petroleum  ether 
extraction.  The  quantification  was  conducted  on  a  HPLC-UV  system.
85  The  quite  common 
determination with radioactive labeled substrates for enzymatic conversion in the 1980s was also 
applied for the quantitative analysis of FPP via comparative TLC and subsequent measurements 
in a scintillation counter. Within the same study IPP was determined via the same methodological 
setup.
92  The  general  term  for  this  sort  of  experimental  design  is  called  double-radio-isotope 
dilution  method.  An  improvement  for  the  detection  in  plasma  utilized  the  enzymatic 
dephosphorylation  into  farnesol  and  further  enhanced  the  detection  by  subsequent  chemical 
coupling to 9-anthroylcyanide. The resulting labeled C15 chain was separated and analyzed via a 
sensitive HPLC fluorescence detection (FLD) system.
93 The most relevant studies in regard to the 
current work were conducted by Tong et al., who simultaneously measured FPP and GGPP in 
cells.
94 After a liquid/liquid extraction the two diphosphates were enzymatically converted into 
two  different  dansyl-labeled  pentapeptides,  whereas  the  pre-column  derivatization  took 
advantage  of  the  physiology  of  the  isoprenoids  (for  a  more  detailed  description  see  section 
3.1.1.). The two enzymes which  were employed were  FTase and  GGTase  I and  as coupling 
reagents  two  distinct  artificial  dansyl-labeled  pentapeptides,  containing  the  respective  CaaX-
motives were used. The same group improved upon their own method during the development of 
the  current  work  and  published  their  developed  technique  for  the  quantification  in  different 
mouse tissues, including brain tissue.
95    19 
Last  but  not  least  it  should  be  noted  that  two  further  studies  determined  FPP  alone  and 
simultaneously  FPP  and  GGPP  after  conversion  to  their  respective  alcohols  via  gas 
chromatography  mass  spectrometry  (GC-MS)  in  yeast  and  Escherichia  coli  (E.coli).
96,97 
Furthermore, it is also worth mentioning that two recent publications addressed the quantification 
of  the  precursors  for  FPP.  One  publication  shows  the  HPLC-FLD  analysis  of  GPP
98  and  a 
different study used a HPLC-MS approach to simultaneously quantify mevalonate, IPP, DMAPP 
and GPP in cells.
99 The analytical approaches prior the onset of the current work are summarized 
in Table 1.  
 
Analyte  Applied 
biomaterial 
Isolation 
conditions 
Conversion / 
Derivatization 
Separation  
& Detection 
Reference 
FPP  rat liver  petroleum 
ether 
FOH (by AP)   HPLC-UV  Keller et al. 
1979 
85 
FPP  rat / mouse 
liver 
ammoniac  
1-butanol 
FOH (by AP)   TLC – double 
isotope 
dilution   
Bruenger et 
al. 1988 
92 
FPP  human / dog 
plasma 
n-hexane / 
ethanol 
FOH (by AP) /   
9-anthroylcyanide 
HPLC-FLD  Saisho et al. 
1997 
93 
FPP   E. coli  anion 
exchanger 
suspension 
FOH (by AP)  GC-MS  Song et al. 
2003 
96 
FPP 
GGPP 
cultured cells   ammoniac 
ethanol /     
1-butanol 
dansyl-labeled 
peptides 
HPLC-FLD  Tong et al. 
2005 
94 
FPP 
GGPP 
E. coli  ammoniac 
ethanol /     
1-butanol 
FOH, GGOH (by 
AP)  
GC-MS  Vallon et al. 
2008 
97 
FPP 
GGPP 
cultured cells  NH4CO3 /    
2-propanol  
  HPLC-
MS/MS 
Henneman et 
al. 2008 
99 
FPP 
GGPP 
cultured 
cells; mouse 
brain, liver 
kidney, heart  
ammoniac 
ethanol /     
1-butanol; 
SPE 
dansyl-labeled 
peptides 
HPLC-FLD  Tong et al. 
2008 
95 
 
Tab. 1. Summary of the published analytical methods for the determination of FPP and GGPP. The conversion by 
AP stands for an enzymatic conversion of the diphosphate to the free alcohol via alkaline phosphatase under 
basic conditions. Additional information about the methods is given in section 1.3.3.2. of the introduction.
   
 
 
 
   20 
1.4. Regulation of the mevalonate/isoprenoid/cholesterol pathway by sterols 
Mainly three processes determine the functionality of the HMG-CoA reductase:  
(1)  Decreased  cell  cholesterol  levels  lead  to  an  up-regulation  of  HMG-CoA  reductase  gene 
transcription,  triggered  by  sterol  regulatory  element-binding  proteins  (SREBPs).  Evidence 
implicates that not only HMG-CoA reductase transcription is regulated by SREBPs but also the 
transcription of other, if not all downstream enzymes of the MVA-pathway.
100  
(2) De-phosphorylation by lysosomal phosphatases activates the HMG-CoA reductase. Under 
physiological conditions 25-30% of the total enzyme are activated.
83,101  
(3) Further, the degradation of the HMG-CoA reductase is modulated by the cellular demand for 
cholesterol and isoprenoid compounds.
16 
The  predominant  regulation  of  isoprenoid  and  cholesterol  synthesis  is  achieved  by  the 
modulation of the HMG-CoA reductase protein abundance and activity as it constitutes the rate 
limiting step of the entire MVA-pathway. The families of membrane-bound sterol regulatory 
element  binding  proteins  (SREBPs)  represent  one  major  regulator  of  HMG-CoA  reductase. 
However,  SREBPs  also  affect  most  enzymes  involved  in  cholesterol  biosynthesis.
100  These 
transcription factors regulate the transcription of over 30 genes participating in cholesterol and 
fatty acid biosynthesis.
102,103 Upon synthesis of the three known isoforms of the protein (SREBP-
1a, - 1c and -2), in the ER, the precursor protein forms a complex with the insulin-induced gene 1 
protein (INSIG-1) and the SREBP cleavage-activating protein (SCAP), which serves as a sterol 
sensor and escort protein.
104 Following intracellular sterol depletion INSIG-1remains bound to 
the  ER  and  the  SREBP-SCAP  complex  migrates  to  the  Golgi  apparatus.  Consequently  two 
distinctive proteases cleave off SREBP in a process called regulated intermembrane proteolysis 
(RIP). The released SREBP migrates to the nucleus where it leads to an upregulation of the 
transcription of a number of genes involved in cholesterol biosynthesis, uptake and transport, by 
binding to the sterol element binding site (SRE).
105,106  
Cholesterol homeostasis is further regulated by oxidized cholesterol metabolites 24S- and 25S-
hydroxycholesterol. The oxysterol 24S-hydroxycholesterol was hypothesized to interact with the 
liver-X receptor (LXR). The LXR is a member of the nuclear receptors and two isoforms, LXR-α 
and LXR-β have been identified and both are expressed in the brain.
107 Neurons treated with the 
oxysterol  showed  an  up-regulation  of  Apo  E.  Apo  E  and  SREBP-1c  expression  are  under 
transcriptional regulation of the LXR
108,109 and it was concluded that 24S-hydroxycholesterol is a   21 
LXR  ligand.
110  25S-hydroxycholesterol  was  shown  to  bind  to  INSIG,  thus  inhibiting  the 
detachment of the SREBP-SCAP complex.
111 
As  stated  earlier  the  SREBP  pathway  influences  a  whole  range  of  enzymes  involved  in 
cholesterol  biosynthesis.
100  It  is  worth  mentioning  that  24S-hydroxycholesterol  treatment  in 
neurons led to a direct down-regulation of FPPS expression.
110 Additionally to regulation of gene 
expression,  enzymes  involved  in  the  MVA-pathway  are  modulated  by  protein  degradation, 
demonstrated by in vitro cell studies.
112,113    
 
1.5. Regulation of the mevalonate/isoprenoid/cholesterol pathway by non-sterols 
Activity of the FPPS (i.e., production of FPP) was reported to be several fold higher than activity 
of GGPPS (i.e., production of GGPP) in bovine brain cytosol.
114 Even though FPP is a substrate 
for  GGPPS,  there  are  data  suggesting  that  synthesis  of  GGPP  may  be  dependant  on  its 
distribution in the cytosol versus the membrane and it was reported that abundance of certain 
small GTPases might stimulate GGPP production.
115 In contrast to FPP, GGPP inhibited its own 
synthesis in rabbit reticulocytes.
116 Another study found similar results and it was also observed 
that GGPP could inhibit GGPPS activity.
117 
It was concluded from structural studies that GGPP does bind in an inhibitory manner to GGPPS 
and may be a means of regulating GGPP levels.
67 Another potentially novel regulatory role of 
GPPP is stimulation of the ubiquitination and degradation of HMG-CoA reductase.
113 FPP did 
not have a similar effect and it was suggested that GGPP might be prenylating a protein that is 
responsible  for  regulation  of  HMG-CoA  reductase.
113  There  is  evidence  that  SREBP-2  may 
activate FPP synthase gene expression. The promoter region of FPP synthase contains a binding 
site for SREBP-2, which is also present in other genes associated with cholesterol synthesis. 
What  is  not  well-understood  is  if  changes  in  FPP  levels  alone,  where  cholesterol  levels  are 
unaffected alter SREBP function. The idea that SREBP-2 activation may not be responsive to 
FPP levels is that depletion of mevalonate in Caco-2 cells stimulated SREBP-2 activation but 
adding FPP did not reduce activation
118, which would be expected if FPP was acting in a similar 
manner  as  cholesterol.  There  is  limited  information  on  the  transcriptional  regulation  of  FPP 
synthase.  FPP  synthase  gene  expression  was  directly  stimulated  by  the  transcription  factor 
LXR.
119  Activation  of  FPP  synthase  gene  expression  was  stimulated  by  the  LXR  agonist, 
hypocholamide,  in  immortalized  brain  cell  lines.
119  On  the  other  hand,  FPP  synthase  gene 
expression was significantly reduced in brain tissue of LXR-null mice.
107   22 
Taken  together,  the  regulation  of  the  HMG-CoA  reductase  expression  and  its  degradation 
involves  a  multivalent  feedback  mechanism  by  sterol  and  non-sterol  products  of  the  MVA 
pathway. The degradation of HMG-CoA reductase itself is assumed to be carried out by the 26 S 
proteasome.
120,121  
 
1.6. Protein prenylation – small GTPases 
Over  100  proteins  in  the  human  proteome  are  potential  substrates  to  undergo 
prenylation.
3,13,122,123 Many of those proteins belong to the super family of small GTPases, with 
molecular  masses  ranging  from  20  –  40  kDa.
124  Small  GTPases  are  integral  components  of 
complex signalling networks and control diverse cellular activities including intracellular vesicle 
transport,  cell  adhesion,  endocytosis,  cytoskeletal  organization,  receptor  signalling,  vesicle 
trafficking, cell cycle progression and gene expression.
124,125,126  
 
1.6.1. Prenylation – a post-translational modification 
Prenylated proteins include Ras and related small GTP-binding proteins such as Rho, Rab and 
Rac,  the  subunits  of  trimeric  G-proteins,  nuclear  lamins  and  other  proteins.
13  Prenylation  of 
proteins by FPP and GGPP is critical for enabling those proteins to be inserted into membranes, 
thus determining their localization and function.
13 Prenylation is a lipid based PTM involving the 
covalent attachment of either FPP catalyzed by FTase or GGPP catalyzed by GGTase I or II to 
the  cysteine  residue  in  defined  consensus  motives.
4,127,128,129,130  This  motive  is  the  so  called 
CaaX-box, where ‘C’ is a cystein, ‘a’ an aliphatic amino acid and ‘X’ the terminal amino acid 
mainly  determining  which  isoprenoid  will  be  attached.
131  Both,  the  Ftase  and  GGTase  are 
heterodimers sharing a common α subunit.
132 For the prenylation reactions the prenyltransferases 
require a zinc ion in the active centre of the binding site of the CaaX containing protein, allowing 
for enhanced affinity to the transferase.
128,133,134 Upon attachment to the protein substrate, the 
cysteine  residue  of  the  CaaX-motive  is  believed  to  coordinate  with  the  Zn
2+.  This  has  been 
verified through biochemical studies, which have demonstrated the need for Zn
2+ for catalytic 
activity as well as its coordination with the cysteine thiol of the CaaX-motive.
135 Mg
2+ is also 
required in millimolar concentrations for optimal enzymatic activity of the transferases, though it 
may not be strictly necessary for catalysis.
134   23 
It is generally accepted that Ftase substrates contain a CaaX-motive with a terminal ‘X’ amino 
acid, which is either serine, alanine, methionine or glutamine, and for the GGTase I the terminal 
amino  acid  must  be  a  leucine.
4,127,128,130,136    A  list  of  some  of  the  most  common  prenylated 
proteins with their respective C-terminal CaaX-motive can be seen in Table 2.  
 
Subfamily  Exemplified 
protein  
CaaX-
motive
* 
Predominant isoprenoid 
modification
** 
Ras GTPases   H-Ras 
K-Ras 
N-Ras 
-CVLS 
-CVIM 
-CVVM 
farnesylation  
Rho GTPases  Rac1 
Rac2 
Cdc42 
RhoA 
-LLL 
-SLL 
-VLL 
-LVL 
geranylgeranylation 
Rab1a 
Rab5a 
-GGCC 
-CCSN  double geranylgeranylation  Rab GTPases 
Rab8a 
H Rab11 
-CVLL 
-CQNI  geranylgeranylation 
Ran GTPases  Ran  -  - 
Sar1/Arf 
GTPases 
Sar1a 
Arl6  -  - 
 
Tab. 2. Brief overview over the 5 main subfamilies of the small GTPases (see also section 1.6.2.) with 
exemplified  protein  members  and  their  respective  CaaX-motives  (  -  no  CaaX-motive  and 
consequently no C-terminal prenlyation). 
* For some members of the small GTPases different 
isoforms with partly varying CaaX-motives were identified (not shown in table). ** Depending on 
the  small  GTPases  and  the  physiology/pathology  of  the  cell  prenylation  by  the  respective 
prenyltransferase is either stringent or the proteins partly undergo cross-prenylation (examples are 
given in section 1.6.1.). 
 
Nevertheless, these requirements do not seem to be ultimatively stringent as shown for example 
by kinetic studies with artificial CaaX-substrates.
137 Moreover, it was reasoned that the peptide 
sequence upstream of the CaaX-motive might also play a role in the substrate specificity of the 
two prenyltransferases.
138,139  
These studies also revealed that the binding of either isoprenoid to the prenyltransferases is not 
imperative and that variation of the ‘aa’ amino acids in the small GTPase can impact its affinity 
to the respective prenyltransferase; this was illustrated by means of crystallographic analysis.
140 
Furthermore, reports on cross-prenylation substantiate the notion that prenylation is flexible to a 
certain degree. One representative example is the cross prenylation of K-Ras occurring when 
Ftase is inhibited or when FPP is in limited supply. The GTPase contains a classical CaaX-
motive (cystein-valine-isoleucine-methionine = CVIM) for farnesylation, but becomes a substrate   24 
for GGTase I under the aforementioned conditions.
141 Another example indicates that GGTase I 
is capable of transferring the  farnesyl  moiety to RhoB, which possesses the GTPases CaaX-
motive CKVL (cystein-lysine-valine-leucine). Accordingly, farnesylated and geranylgeranylated 
versions of this protein are evident in cells, both reactions being catalyzed by GGTase I.
142 It is 
worth  mentioning  that  such  cross-prenylation  reactions  might  partly  explain  failures  of 
prenylation inhibitors as anti-cancer treatments.
143   
Besides the CaaX GTPases other family members, which contain a CC-, CXC- or CCXX-motive 
undergo di-geranylgeranylation where two GGPP lipids attach to the two cysteine residues of the 
motive.
130,144  These  motives  are  found  exclusively  amongst  the  Rab  subfamily  of  GTPases. 
Although the majority of Rab proteins possess such a di-cysteine motive, there is a select number 
of proteins such as Rab8, Rab11 and Rab13, which possess the CaaX-motive.
144 The process of 
di-geranylgeranylation is catalyzed by GGTase II, also known as Rab geranylgeranyltransferase. 
This enzyme specifically modifies Rab family members of the GTPases but only when they are 
associated with the Rab escort protein (REP), which is capable of binding to both prenylated and 
unprenylated Rab proteins. In the unprenylated form, REP presents a Rab GTPase to the GGTase 
II,  allowing  the  sequential  addition  of  two  GGPP  molecules  to  its  two  C-terminal  cysteine 
residues. Upon binding to the prenylated form of the GTPase, REP facilitates the incorporation of 
the protein within the intracellular membrane.
130,145  
Following prenylation, the prenylation motive containing proteins undergo two further processing 
steps. The diphosphate is cleaved off by the Ras converting enzyme (Rce1p) and the Ste24p 
endogenous proteases remove the terminal three amino acids (-aaX).
146,147,148 Upon cleavage of 
the terminal tripepetide, the remaining prenylated cysteine residue undergoes carboxymethylation 
by a methyl group, delivered from S-adenosyl methionine (SAM) (Figure 2). This conversion is 
catalyzed by isoprenylcysteine carboxyl methyltransferase (Icmt). Icmt is located in the Golgi 
apparatus,  ER  and  nuclear  membranes.
149  Under  physiological  conditions,  the 
carboxymethylation is reversible.
150 It is assumed that the intermediates during these subsequent 
enzymatic reactions exist only transiently and are rapidly converted into the mature prenylated 
protein.
127 Overall, prenylation enhances lipophilicity and favours lipid-lipid interactions of small 
GTPases  with  cellular  membranes.
151  Its  physiological  importance  is  further  underscored  by 
affinity studies of the enzymes utilizing FPP as a substrate. As summarized by Winter-Vann and 
Casey for the squalene synthase a Km value of 2 µM was found and the Km values of the GGPPS 
was calculated to be about 1 µM and of the Ftase about 5 nM for FPP.
123 These studies highlight   25 
the importance of the prenylation reactions for cell physiology and support the notion of a higher 
affinity of the isoprenoid pathway enzymes for FPP than those of the cholesterol pathway.
1,152  
Following  prenylation  some  proteins  like  for  example  N-Ras,  H-Ras  or  RhoB  are  also 
palmitolayted. This modification entails a thioester linkage of the palmitoleic acid chain to the 
sulphur  group of a  cysteine residue, which is in close proximity to the prenylated cysteine.
4 
Similar to the previously described processes of protein prenylation and carboxylmethylation, 
protein  palmitoylation  allows  membrane  binding  and  intracellular  localization  by  increasing 
lipophilicity of certain proteins.
153,154  
 
Fig.  2.  Exemplified  overview  describing  the  chronological  post-translational  modification  (PTM)  of  Rac1.  The 
newly translated protein becomes geranylgeranylated and subsequently modified by Rce1p or Step24p, two 
endopeptidases  cleaving  off  the  terminal  three  amino  acids  (-LLL)  of  the  CaaX-motive.  The  last  step 
describes the modification by the isoprenylcysteine carboxyl methyltransferase (Icmt), using S-adenosyl 
methionine (SAM). The latter two reactions are mainly taking place in the endoplasmatic reticulum (ER) 
and in the  Golgi  apparatus  (not  shown in the  figure).  The  final  products  (activated  GTPases)  possibly 
undergo further PTMs before being inserted into the target membrane. Final activation and deactivation 
depend on the GDP/GTP status governed by GEFs/GAPs and partially by the GDIs (refer to section 1.6.2. 
for further details). The activated, GTP loaded enzyme activates downstream, secondary messengers, finally 
leading to modulated gene transcription of distinct genes. Depicted in the current figure is the Rac1-MEKK-
JNK pathway.
155   26 
1.6.2. Prenylated proteins – the small GTPases 
Small GTPases are guanine nucleotide-binding molecules (G-proteins). Small GTPases play a 
fundamental role in a multitude of intracellular signal transduction pathways involving vesicle 
trafficking,  cell  growth,  differentiation  and  cytoskeletal  function.  The  small  GTPases  bind 
guanosine  triphosphate  (GTP)  when  activated  and  guanosine  diphosphate  (GDP)  when 
inactivated. In response to an upstream signal as for example proposed for amyloid beta (Aβ)
155, 
GDP dissociates from the GTPase and then binds a GTP molecule. Two types of regulatory 
proteins mainly execute the GDP/GTP exchange of all small GTPases. The guaninenucleotide- 
exchange factors (GEFs) promote the GTP bound and therefore active form of the G-protein
156, 
while the GTPase activating proteins (GAPs) lead to the GDP bound inactive form by stimulating 
the weak intrinsic GTP hydrolysis capacity of  the GTPases.
157 RhoA, Rac1, Cdc42 and Rab 
proteins possess the same GEFs and GAPs regulatory mechanisms while additionally regulated 
by a third class of proteins, the guanine nucleotide dissociation inhibitors (GDIs).
124,158 After 
complex  formation  of  a  GDI  with  a  GTPase,  GEF  stimulated  dissociation  of  GDP  from  its 
GTPase is inhibited and these GTPases cycle between membrane and cytosol.
124 Binding of GTP 
leads to a conformational change in the downstream effector associated region and to activation 
of secondary effector pathways, such as the MEKK-JNK/p38 – pathway (Figure 2).
156 
A classification of the small GTPase superfamily into at least five different families is generally 
accepted and briefly described below. The differentiation was based on sequence and functional 
similarities between the members of each branch.
3,124,159  
 
The Ras family. The family name of this group of small GTPases originates from Ras sarcoma 
(Ras) and these GTPases have been the most extensively studied proteins due to their well-known 
role in oncogenesis.
160 Signaling pathways including Ras GTPases are commonly activated in 
various tumors, including  glioblastoma multiforme (GBM).
161 Additionally, about 30% of all 
human cancers have been associated with mutations in the Ras proto-oncogen.
162 H-Ras, K-Ras 
and N-Ras are the most renowned members of this family and they are constantly activated as a 
consequence  of  the  mutation  in  the  proto-oncogen.
161  Furthermore,  the  majority  of  the  Ras 
subfamily members are known to be farnesylated and interestingly K- and N-Ras but not H-Ras 
can be geranylgeranylated when physiological farnesylation is inhibited .
161,163 Despite the fact 
that Ras proteins are associated with carcinogenesis, it is worth mentioning that other Ras family 
members, such as RhoB seem to act as tumor suppressors.
162    27 
The  Rho  family.  Extracellular  stimuli  activate  Ras  homologous  (Rho)  proteins,  which  are 
involved in proliferation, apoptosis, actin formation, adhesion, and motility.
159,162 RhoA, Rac1 
and  Cdc42  belong  to the  Rho  GTPases
164,  which effect  on more  than  30  secondary  effector 
proteins, such as ROKα/β or MEKK1,4.
165 While the classical members RhoA, Rac1 and Cdc42 
are known to be geranylgeranylated other Rho subfamily members were found to be farnesylated 
(Table 2).
166  
 
The Rab family. The 60 Ras-like proteins in the brain (Rab) represent the largest group within 
the  superfamily  of small GTPases.
167 These  proteins  and  their  effectors,  such  as  Rabex-5  or 
Coronin 3 are mainly involved in intracellular vesicular transport, including vesicle formation, 
organelle  motility  and  directing  vesicles  between  different  compartments.
168,169,170,171  As 
mentioned earlier Rab proteins, with the non-CaaX-motive undergo di-geranylgeranylation by the 
GGTase II.
129,172  
 
The Ran family. The Ras-like nuclear proteins (Ran) function in nucleo-cytoplasmic transport, 
mitotic  spindle  and  nuclear  envelope  assembly  and  DNA  replication.
173,174  The  transport 
mechanism relies on a unique gradient of Ran-GTP between the nucleus and the cytosol.
159  
 
The  Sar1/Arf  family.  The  ADP-ribosylation  factor  (Arf)  and  secretion-associated  and  Ras-
related (Sar) proteins are mainly involved in vesicle formation and intracellular trafficking.
124,175 
For example, Arf1 regulates the formation of vesicle coats at different steps in the exocytic and 
endocytic pathways. Beside others, Arf1 controls the formation of coat protein I (COPI)-coated 
vesicles involved in retrograde transport between the Golgi and ER, of clathrin/adapter protein 1 
(AP1)-complex-associated vesicles at the trans-Golgi network (TGN) and on immature secretory 
vesicles, and of AP3-containing endosomes.
159 In addition to prenylation, some members of the 
Arf family are post-translationally modified with a myristate fatty acid at their N-terminus.
159  
 
1.6.3. Analytical approaches for the quantification of farnesylated proteins 
A review by James P. in 1997 is titled as “Protein identification in the post-genome era: the 
rapid rise of proteomics” and shows the emerging role of the new field of proteomics in the 
90s.
84 Over 10 years later there is an enormous amount of publications available on this still 
relatively young topic and the numbers are growing by the month. Many of these advancements   28 
would have been possible without mass spectrometry. Many of these studies also included the 
identification of various small GTPases whereby one study should be highlighted herein due to 
its involvement of the farnesyl moiety. 
Appels et al. quantified farnesylated proteins in isolated cells by LC-MS/MS measurements. The 
idea behind their approach was the detection of the farnesylated methylcystein (Fmc) C-terminus, 
which is cleaved of by endogenous proteases upon cell lysis.
127 This fragment was further used 
for  multiple  reaction  monitoring  (MRM)  analysis  in  a  triple  quadrupole  mass  spectrometer 
(QqQ). In these measurements the first quadrupole selects the parent ion while the second one 
serves as a collision cell for this specifically selected ion, filled with an inert gas (e.g.: nitrogen) 
to induce fragmentation. The third quadrupole is set for a certain fragment ion mass deriving 
from the impact of the parent ion with the gas molecules. Such measurements are more selective 
and are used for quantification purposes. 
 
1.7. The aging brain and pathological implications of the MVA-pathway 
Aging  is  the  major  risk  factor  for  the  development  of  the  most  common  neurodegenerative 
diseases like AD, Parkinson Disease, Cerebrovascular Disease or Amyotrophic Lateral Sclerosis. 
In the developed industrial countries a clear link between the constantly aging population and the 
rising  prevalence  of  these  diseases  can  be  identified.  Aging  is  recognized  as  physiological 
process, which leads to specific structural, physiological and functional changes in the body, 
including the brain and affecting mental activity, social behavior and memory function.
176,177,178 
 
1.7.1. Cholesterol and aging 
As  previously  described  MVA-pathway  products  massively  impact  a  wide  range  of  cellular 
processes. Cholesterol as the best-established end-product of the pathway has been the focus of 
research for over 40 years. One of the very first publications in this area dates back to 1965 and 
investigated white and grey matter cholesterol content of human brains, between 19 months and 
55 years.
179 Since then a lot of research has circled around brain cholesterol alterations as a 
function of aging, some of which was summarized in comprehensive reviews.
23,180,181 The overall 
findings  indicate  that  cholesterol  de  novo  synthesis  declines  as  we  grow  older  while  total 
cholesterol levels steadily increase but with a different magnitude depending on the brain region 
and the developmental phase of the brain. For example, a significant change of cholesterol levels   29 
can be observed in distinct areas in mice brains or as mentioned earlier, in isolated SPMs from 
different aged mice (see section 1.2.). The cerebral cortex of 3, 6 and 25 month old mice showed 
a steady and statistically significant increase in cholesterol with aging
182, while another study 
reported  unchanged  levels  of  cholesterol  in  isolated  SPMs  of  young,  middle-aged  and  aged 
mice.
47 However, more than twice the cholesterol content in the exofacial leaflet of the aged mice 
from the same study, revealed a drastically altered leaflet distribution of the cholesterol in the 
SPMs.  Since  cholesterol  is  known  as  an important  component  of the  plasma  membrane  and 
additionally a potent modulator of membrane fluidity the same study found a decreased fluidity 
of the outer leaflet, as a consequence of the age-dependant cholesterol increase. Furthermore, 
studies on isolated lipid rafts from aged mice brains also showed increased cholesterol levels 
when compared to lipid rafts isolated from  young animal brains.
48 The importance of theses 
findings  lies  in  the  fact,  that  a  change  in  cholesterol  itself  and  consequently  in  membrane 
composition and membrane characteristics possibly affects a large facet of membrane associated 
intra- and intercellular physiological processes. Several studies were able to either show a link of 
an  altered  cholesterol  abundance  impacting  on  membrane  fluidity  or  on  lipid  raft  associated 
proteins  which  consequently  leads  to  an  aberrant  activity  of  distinct  physiological 
processes.
183,184,185,186 
The most prominent genetically caused disorders linked to a defective cholesterol homeostasis 
are the Smith-Lemli-Opitz syndrome, Huntington´s Disease and Niemann-Pick Disease, type C. 
Further details concerning causes, diagnosis, symptoms and treatments of these three diseases can 
be viewed in the following recently published reviews.
187,188,189,190 
 
1.7.2. Cholesterol-precursors and -metabolites in aging 
As described in the previous paragraph cholesterol de novo synthesis of the human brain is lower 
in older subjects as compared to younger ones, but the overall cholesterol abundance increases 
with  age.
23,181,182  Furthermore  Thelen  and  colleagues  were  able  to  demonstrate  a  declined 
synthesis  rate  of  cholesterol  accompanied  by  significantly  lower  lanosterol  and  lathosterol 
concentrations in the aged human hippocampus.
191 These two lipids are precursors of cholesterol 
(Figure 1). The same study revealed lower 24S-hydroxycholesterol levels in older subjects.
191 A 
study in rat brain further substantiated these findings by demonstrating a significantly reduced 
squalene synthase activity when comparing aged rats to young animals.
192 Taken together there is   30 
a  consensus  that  downstream  of  squalene  synthase  synthesis  rates  and  concentrations  of 
intermediates and metabolites of cholesterol decline in the aging brain.   
 
1.7.3. Isoprenoids in aging and neurodegeneration 
Normal cell function requires prenylated proteins and there is evidence that GGPP is required for 
long-term  potentiation  (LTP)  in  mouse  hippocampal  slices.
193  However,  it  is  becoming 
increasingly recognized that prenylated proteins are involved in certain diseases both within and 
outside of the central nervous system (CNS). Diseases largely outside the CNS in which FPP and 
GGPP potentially play a significant role are certain types of cancer, osteoporosis, Paget disease, 
and  atherosclerosis.
4,194,195,196  Moreover,  recent  evidence  suggested  that  inhibition  of  FPP-
induced protein prenylation using a farnesyltransferase inhibitor significantly improved motor 
function and survival in a mouse model of Hutchinson-Gilford progeria syndrome or what has 
been referred to by some as premature aging.
197,198 Diseases of the CNS in which isoprenoids and 
protein prenylation are drawing increasing attention are Parkinson disease, multiple sclerosis, and 
ischemic  stroke.
198,199,200  Recent  experimental  evidence  indicates  that  isoprenylated  small 
GTPases are involved in AD pathogenesis.
3,201,202,203  
 
1.7.3.1. Isoprenoids and aging 
Aging is a  process  which  leads  to  specific  structural,  biochemical  and  functional  changes  in 
multiple  organs  including  the  brain
176,177,178  and  represents  the  major  risk  factor  for  the 
development  of  the  most  common  neurodegenerative  diseases  like  AD,  Parkinson  Disease, 
cerebrovascular disease and amyotrophic lateral sclerosis.
28 Age-related processes in the brain 
have been extensively studied
28,204 and changes in various lipids have been examined in several 
studies on cholesterol homeostasis.
23 Isoprenoids on the other hand, have received only scant 
attention in aging research. Age related changes in FPP and GGPP levels have not been reported, 
which is in stark contrast to their important biological roles. Dolichol levels increase with aging
83 
and dolichols were identified as a potential biomarker of senescence.
76 Levels of dolichol were 
markedly higher in human brain tissue of aged  individuals (e.g.  approx. 19 vs. 26 µg/g ww 
hippocampus tissue in young and aged humans, respectively).
80,205 SPM of 18 and 28 month old 
C57BL/6 mice had a 5 fold and 11 fold increase, respectively, in dolichol levels when compared 
with 6 month old mice.
79 In the same study, it was found that dolichol had a greater fluidizing   31 
effect on SPMs of young mice than aged mice. Increased dolichol content has been observed in 
brain  tissue  of  individuals  with  AD  and  neuronal  lipofuscinosis.
206,207,208  Neither  has  it  been 
determined  whether  the  elevated  dolichol  levels  observed  with  increasing  age  and  certain 
neurodegenerative diseases are injurious to cell function nor the mechanisms of such changes 
have been established.
209  
Ubiquinone levels were found to decrease with age in human brain tissue (e.g. approx. 14 vs. 8 
µg/g ww hippocampus tissue in young and aged humans, respectively).
210 In rat brains however, 
the ubiquinone synthesis rate was shown to steadily increase with aging and ubiquinone levels 
(approx. 20 µg/g ww) were relatively constant throughout the entire life span.
192  
 
1.7.3.2. Prenylated proteins, synaptic plasticity and aging  
The isoprenoids FPP and GGPP serve as substrates for the prenlyation of the small GTPases (see 
section 1.6). Their role is not well understood in the context of aging; although they are known to 
play  a  distinct  role  in  synaptic  plasticity  (further  details  see  section  1.8.5.).  Long  term 
potentiation (LTP) is one form of synaptic plasticity (section 1.8.5.), which underlies an age-
dependant  decline.  However,  the involved  mechanisms  still need  to  be  elucidated.
211  A very 
recent  study  described  the  role  of  RhoB,  besides  other  small  GTPases  in  the  regulation  of 
dendritic and spine morphology.
212 The protein is expressed in the hippocampus and cortex, is 
induced during aging and has the ability to impact on actin regulation. Studies were carried out 
on  RhoB  knock-out  mice  and  clearly  demonstrated  the  involvement  of  RhoB  in  synaptic 
plasticity.
212  
 
1.7.3.3. The MVA-pathway and neurodegeneration 
The  MVA-pathway  and  its  described  various  intermediates  and  end  products  (Figure  1)  are 
involved in a wide range of crucial cell processes and functions including decisive signaling 
pathways. The distinct steps of the biosynthesis of different products involve a complex and not 
yet  fully  understood  regulation  of  transcription,  translation,  activation  and  degradation.  It  is 
obvious that due to the involvement of such a large number of directly participating enzymes, 
abnormal functioning or misdirected regulation will lead to severe consequences for the cell. The 
most known disorders with a disrupted MVA-pathway homeostasis are the Smith-Lemli-Opitz 
syndrome,  Huntington´s  Disease  and  Niemann-Pick  Disease,  type  C  as  mentioned   32 
earlier.
187,188,189,190 However, implications of an abnormal MVA-pathway regulation in respect to 
neurodegenerative  diseases,  like  AD  have  also  been  described  earlier.
3,13  The  following 
paragraphs will  give a  more detailed insight into AD pathology, will  give some background 
information on the disease and will summarize recent knowledge of the possible implications of 
the mevalonate/isoprenoid/cholesterol pathway. 
 
1.8. Alzheimer’s Disease 
1.8.1. Prevalence and characteristics 
Alzheimer’s  disease  (AD)  is  a  progressive  neurodegenerative  disorder  and  accounts  for  an 
estimate of up to 80% of all dementia forms. In 2005 the number of people with AD worldwide 
was estimated to be 24 million and it is predicted that the number will increase to more than 80 
million cases by 2040
213, a number equivalent to the population of Germany.  
It is thought that the molecular pathology, describing the formation of senile amyloid beta (Aβ) 
plaques and neurofibrillary tangles, containing the tau protein, develops 10 – 20 years before the 
first  symptoms  occur.
214,215  The  earliest  observable  signs  are  mostly  recognized  as  memory 
lapses, semantic impairment and anomia
216, clinical symptoms, which are rather unspecific. As 
the disease progresses the cognitive deficits aggravate and become more noticeable for relatives. 
These changes become apparent as the patients tend to forget recently learned information and 
show strongly affected language skills. Patients experience mood swings and consequently they 
become more withdrawn. In the advanced stages of the disease severe memory deficits prevent 
the independence of the patients and the mood and behavioral changes normally become more 
dramatic. Finally the physically weakened patients mostly die as a consequence of secondary 
diseases like pneumonia.
217 The life expectancy of AD patients is mostly depending on age and 
the time point of diagnosis. Patients with a diagnosis in their 60s or early 70s usually have a time 
span of 7 – 10 years.
218   
 
1.8.2. Etiology 
The most common form of AD is the sporadic type (SAD), which accounts for about 98% of all 
AD cases.
3 A minor proportion of AD cases occurs before the age of 65 and is known as early-
onset AD. The majority of these patients inherit genetic mutations, which are then called familial 
AD (FAD) cases. The three major gene mutations which are known to be associated with FAD   33 
are mutations in the presenilin 1 (PSEN 1) gene on chromosome 14, in the presenilin 2 (PSEN 2) 
gene on chromosome 1 and in the amlyoid precursor protein (APP) on chromosome 21.
219 Taken 
together these mutations lead to a preferential amyloidogenic processing of APP and increase the 
Aβ load in the brain.  
A multitude of risk factors for SAD are discussed and intensively investigated. Besides the most 
important one, which is age
220 several other factors including nourishment, lifestyle and other 
diseases are up for debate.
221,222,223,224 Regarding genetics ApoE is the only well established risk 
factor  for  increasing  the  predisposition  to  develop  SAD.  ApoE  is  significantly  involved  in 
cholesterol transport in the periphery and in the CNS. The inheritance of the ApoE-ε4 allele, one 
of three different isoforms (ApoE- ε 2, ApoE- ε 3 and ApoE- ε 4) of the ApoE gene is linked to 
an increased risk to develop AD.
225,226 The exact mechanism underlying the ApoE involvement is 
not yet clarified and various interactions are under investigation.
227 
 
1.8.3. Diagnosis 
Different forms of dementia can be roughly differentiated in primary and secondary forms. While 
primary  forms  like  AD  or  vascular  dementia  are  discrete  diseases,  secondary  forms  are  a 
consequence of other neurological diseases like Pick’s, Lewy bodies or Parkinson Disease. An 
exact diagnosis of AD is very complex and especially an early identification hard to achieve. 
Over the last years intensive research has been put into the discovery of reliable biomarkers in 
order to start an early therapeutic treatment and to monitor drug impact on disease progression.
228 
Most  studies  focus  on  Aβ,  phosphorylated  and  total  tau,  the  major  hallmarks  of  the  disease 
forming extra- and intercellular plaques as well as intracellular tangles, respectively.
214,229 Ante 
mortem measurements as for example in the cerebrospinal fluid (CSF)
230 or imaging techniques 
based on magnetic resonance imaging (MRI) or X-ray computed tomography (CT) scans are 
most  helpful  tools  to  exclude  other  diseases.  Besides  18-F-deoxy-glucose  positron  emission 
tomography (FDG-PET) the use of Pittsburgh Compound-B (PIB-PET) is one of the most studied 
and reliable amyloid imaging technique.
231 Despite these latest achievements and the use of state-
of-the-art analytical techniques there are still shortcomings in terms of reliability and availability 
of such methods, not to mention the enormous costs simply for diagnosis.  
On the other hand these clinical and scientific advances led in 2007 to a revision of the diagnostic 
markers defined by The National Institute of Neurological and Communicative Disorders and   34 
Stroke, and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) for 
the clinical diagnosis of AD.
232,233,234 
The clinical diagnosis is partly conducted with the help of test for cognitive impairment. These 
are  for  example  the  mini-mental  status  examination  (MMSE),  the  global  deterioration  scale 
(GDS) and the cognitive part of the Alzheimer’s Disease assessment scale (ADAS-Cog), which 
are compared in a study by Solomon et al.
235 
Despite  all  the  advances  a  definite  diagnosis  of  AD  can  only  be  carried  out  post  mortem. 
Furthermore, by this histological analysis the disease progression can be defined according to 
Braak stages I – VI, as the pathology begins in the entorhinal area of the cortex, proceeding to the 
hippocampus and finally to the entire neocortex.
236 Full clinical dementia appears at about Braak 
stage IV. According to this definition neurofibrillary tangles and neuropil threads are the main 
characteristics in AD brain morphology.  
 
A detailed description of AD etiology and neuropathology with its neurofibrillary tangels and 
amyloid plaques and a precise characterization of the formation and the processing of Aβ was 
recently published by our working group in form of two dissertations and the reader is referred to 
these two dissertations.
237,238 
.  
1.8.4. Involvement of the MVA-pathway products and intermediates in AD 
1.8.4.1. Cholesterol, statins and AD 
The aforementioned two forms of AD, SAD and FAD show the same pathological hallmarks, Aβ 
plaques and tau tangles. Over the last decade the main body of research centered on APP and Aβ 
and innumerable investigations aimed to influence their synthesis, processing and the overall cell 
load.
239,240,241,242 Regarding these mechanisms cholesterol metabolism is of special interest and its 
association with AD is described briefly herein. 
Based  on  evaluations  of  human  studies  there  is  a  well  investigated  link  between 
hypercholesterolemia and the development of AD.
3,243 The cholesterol link is further supported 
by the aforementioned inheritance of the ApoE-ε4 allele, as the only clearly demonstrated risk 
factor for the development of AD.
244 Albeit, it is worth mentioning that a recent review critically 
summarizes the latest studies on the cholesterol Aβ link, which challenges the question of the 
detrimental influence of high cholesterol levels.
245 Furthermore, the initially described beneficial   35 
effects of cholesterol reducing statin intake in lowering the incidence for developing AD became 
disputable. Relying on retrospective evaluation of patient data the authors concluded a reduction 
in AD prevalence among patients with a statin treatment history.
246,247,248 These studies were later 
critically discussed by a prospective study with a small patient collective and over a relatively 
short  period  of 36 weeks.  Aβ measurements  after  statin  treatment  could not  substantiate  the 
previous findings.
249 Another study was able to demonstrate a statin influence of human cerebral 
cholesterol homeostasis in clinical relevant doses, but did not succeed in showing changes in Aβ 
brain levels.
250  
A  similar,  not  yet  fully  elucidated  discrepancy  was  described  by  studies  focusing  on  24S-
hydroxycholesterol in AD patients. A few publications by one group described elevated oxysterol 
levels in AD plasma, discussing it consequently as a possible early AD biomarker.
251,252 Authors 
from the same group revealed a cerebral 24S-hydroxycholesterol reduction in an advanced stage 
of the disease, while the 27S-hydroxy derivative was markedly elevated simultaneously.
29,253 
 
Taken together, the central cholesterol metabolism seems to be involved in AD pathology. This is 
further connected to lipid raft formation and Aβ generation. However, it remains a matter of 
discussion which MVA-pathway involving process underlies the development and progression of 
AD.
243  
Regarding the aforementioned statin investigations, it is well  established that the HMG-CoA 
reductase  inhibitors  show  a  multitude  of  pharmacological  effects  beyond  simply  lowering 
cholesterol.  This  pleiotropic  effects  includes  peripheral  antithrombotic  and  plaque  stabilizing 
mechanisms, improvements of endothelial function, antioxidative effects, a reduction of vascular 
inflammatory  processes,  etc.
254  Most  of  these  effects  are  generally  accepted  to  be  due  to  a 
reduction of isoprenoids, notably FPP and GGPP reduction. Since it was shown that simvastatin, 
lovastatin and to a lower extent pravastatin cross the BBB in mice
255 it seems more than feasible 
that they also exert an inhibitory effect on the central mevalonate/isoprenoid/cholesterol pathway. 
However, it is questionable if the concentrations achieved by clinical doses in humans and the 
low concentrations measured in human CSF
256 are relevant.  
 
1.8.4.2. Isoprenoids and neurodegeneration 
The MVA-pathway and its several products are involved in a wide range of critical cell functions. 
Biosynthesis of different products involves a complex and not fully understood regulation of   36 
transcription,  translation,  activation  and  degradation.  Abnormal  functioning  or  misdirected 
regulation of genes and protein products associated with the MVA-pathway will lead to severe 
consequences for the cell. A defective cholesterol homeostasis is causal for the Smith-Lemli-
Opitz  syndrome.  Other  disorders  that  have  been  at  least  partly  linked  to  cholesterol  are 
Huntington´s Disease, AD and the lysosomal storage disease Niemann-Pick type C.
187,188,189,190,257  
 
1.8.4.3. Isoprenoids in AD 
There is some evidence that dolichol and ubiquinone levels are altered in AD.
210 Dolichol levels 
were decreased in all brain regions of AD patients (e.g. approx. 199 vs. 111 µg/g ww frontal 
cortex  tissue  from  controls  and  Alzheimer’s  Disease,  respectively).
210  In  contrast,  dolichyl 
phosphate levels increased in those regions that exhibited morphological changes (e.g. approx. 21 
vs. 32 µg/g ww frontal cortex tissue from controls and Alzheimer’s Disease, respectively). In the 
same study, a significant elevation in ubiquinone content was observed (e.g. approx. 13 vs. 17 
µg/g  ww  frontal  cortex  tissue  from  controls  and  Alzheimer’s  Disease,  respectively).  It  was 
concluded that the increase in the sugar carrier dolichyl phosphate might reflect an increased rate 
of glycosylation in the diseased brain whereas the increase in ubiquinone may be an attempt to 
protect the brain from oxidative stress.
210 A recent study reported increased oxidized ubiquinone 
levels in the cerebrospinal fluid of AD patients.
258 Experimental studies in animal AD models 
suggested  that  ubiquinone  may  protect  against  neuronal  damage.
259  However,  a  synthetic 
analogue  of  ubiquinone  (Idebenone)  clinically  failed  to  slow  cognitive  decline  in  AD.
260 
However,  the  exact  roles  of  dolichol  and  ubiquinone  in  AD  pathogenesis  have  not  been 
established yet.  
There  is  evidence  that  prenylated  small  GTPases  are  involved  in  AD  pathogenesis.
202,261  A 
straightforward prediction was that FPP and GGPP levels would be elevated in AD brains as 
compared with normal neurological controls.
3,262 However, due to methodological problems such 
data had not been reported. 
Tong et al. described the first method for the simultaneous determination of FPP and GGPP in 
cultured cells.
94 Up to now, FPP and GGPP were determined in mouse embryonic fibroblasts and 
human cancer cells such as immortalized colorectal adenocarcinoma, myelogenous leukemia and 
multiple myeloma cells (Table 3a).
94,95,98,118 Cellular levels of FPP and GGPP are generally in the 
picomolar range as depicted in Table 3a, however significant differences in isoprenoid abundance 
can be observed between different cell lines. Moreover, the relative distribution between FPP and   37 
GGPP  varies  between  different  cell  lines.  Such  variances  were  also  observed  in mammalian 
tissue (Table 3b).
95  
 
Cell line  FPP  GGPP  unit  Reference 
NIH3T3  0.125 ± 0.010  0.145 ± 0.008  pmol/10
-6 cells  Tong et al.
94 
NIH3T3  0.131 ± 0.008  0.133 ± 0.003  nmol/g ww  Tong et al.
94 
K562  0.112 ± 0.008  0.238 ± 0.003  nmol/g ww  Tong et al.
95 
Caco-2  0.65 ± 0.02  -  pmol/well  Murthy et al.
118 
RPMI-8226  0.19 ± 0.001  0.29 ± 0,02  pmol/10
-6 cells  Holstein et al.
263 
H929  0.16 ± 0.001  0.16 ± 0.02  pmol/10
-6 cells  Holstein et al.
263 
U266  1.4 ± 0.001  0.58 ± 0.03  pmol/10
-6 cells  Holstein et al.
263 
SY5Y-APP695  17.2 ± 1.2  13.4 ± 1.3  pmol/mg protein  Hooff et al.
264 
 
Tab. 3a. Levels of FPP and GGPP in different cell lines. Levels were determined using a fluorescence HPLC 
method
94 in mouse embryonic fibroblast cells (NIH3T3), in human immortalized myelogenous leukemia 
cells  (K562),  in  human  immortalized  colorectal  adenocarcinoma  cells  (Caco-2)  and  in  human  multiple 
myeloma cells (RPMI-8226, H929, U266). Human neuroblastoma SY5Y cell results were generated within 
the current work. Means ± SD. 
 
 
Tissue 
 
FPP  GGPP  unit  Reference 
Mouse kiney
a  0.320 ± 0.019  0.293 ± 0.035  nmol/g ww  Tong et al. 2008 
95 
Mouse liver
a  0.326 ± 0.064  0.213 ± 0.029  nmol/g ww  Tong et al. 2008 
95 
Mouse heart
a  0.364 ± 0.015  0.349 ± 0.023  nmol/g ww  Tong et al. 2008 
95 
Mouse brain
a  0.355 ± 0.030  0.827 ± 0.082  nmol/g ww  Tong et al. 2008 
95 
Human brain
b 
white matter 
grey matter 
 
2.88 ± 1.04 
3.02 ± 1.32 
 
14.34 ± 8,40 
 9.66 ± 7.72 
 
ng/mg protein 
ng/mg protein 
 
Hooff et al.
265 
Human brain
b 
white matter 
grey matter 
 
5.53 ± 0.63 
2.95 ± 0.25 
 
11.88 ± 1.26 
7. 43  ± 0.81 
 
pmol/ mg protein 
pmol/ mg protein 
 
Eckert et al.
266  
Alzheimer 
brain
b 
white mater   
grey matter 
 
7.93 ± 0.91 
4.03 ± 0.38 
 
18.61 ± 3.00 
11.81 ± 1.69 
 
pmol/ mg protein 
pmol/ mg protein 
 
Eckert et al. 
266 
 
Tab. 3b.   Leves of FPP and GGPP in different tissues.
95 Mouse tissue was isolated from athmic nu/nu mice. Human 
brain tissue results were generated within the current work. Means ± 
aSD, 
bSEM. 
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Compared to FPP, GGPP levels are lower in mouse kidney and liver tissue, equal in mouse heart 
tissue  and  higher  in  mouse  brain  tissue  (Table  3b).
95  The  differences  in  FPP  and  GGPP 
distribution may be due to the demand for intermediates of the MVA-pathway in specialized 
cells. There is a dearth of data on FPP and GGPP regulation and no more so than in brain.  
It is well established that APP processing is influenced by cholesterol abundance
267,268,269,270 and 
that  the  reduction  of  cellular  cholesterol  levels  using  inhibitors  of  the  MVA-pathway  or 
extraction by methyl-β-cyclodextrin (MβCD) results in lower Aβ levels in vitro and in vivo.
271,272 
However, evidence exists that FPP and GGPP are also involved in the cellular production of Aβ. 
It has previously been reported that γ-secretase is stimulated by geranylgeraniol
203 and incubation 
of H4 neuroglioma cells with FPP or GGPP were found to increase Aβ levels.
201 In those studies, 
APP processing was modified after incubation of cells with an extraordinarily high concentration 
of geranylgeraniol, FPP or GGPP (10 µM).  
 
1.8.4.4. Prenylated proteins in AD 
Prenylation  of  specific  small  GTPases  has  been  associated  with  the  processing  of  APP.
273 
Activation of effectors downstream of prenylated small GTPases, such as the protein kinases 
ROCK  (Rho  associated  coiled-coil  forming  protein  kinase)  have  been  implicated  in  APP 
metabolism.
274,275 GGPP stimulates γ- secretase to increase cleavage of APP and Aβ secretion
273 
and inhibition of the Rho/Rock pathway reduced Aβ production.
276,277 Several small GTPases 
have been associated with AD in other pathways than those discussed in the preceding paragraph. 
There is evidence that Rab6 may be involved in APP processing and intracellular trafficking
278, 
Rab11  may  contribute  to  vesicular  transport
279  and  Rac1  as  a  participant  in  Aβ  induced 
generation of reactive oxygen species (ROS), which could damage neurons.
280 Moreover, Rac1 
was shown to down-regulate transcriptional activity of the APP gene
281 and additionally, Rac1 
and Rho-A appear to be involved in the production of actin-based morphological plasticity in 
dendrites and spines in hippocampal neurons.
282 Rab3 as a pre-synaptic protein was significantly 
reduced in AD brains.
283 Protein levels of Ras and Racl in both the cytosolic and membranous 
fractions and that of Rap2 in the cytosolic fraction were significantly decreased, while Rab8 was 
significantly increased in the membranous fraction in AD brains compared with controls.
284  
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1.8.5. Prenylated proteins, synaptic plasticity and AD 
Long-term storage of information is, at least in part, achieved by structural changes in neuronal 
connectivity, particularly changes in the structure and number of synapses. As a consequence, 
attention has focused on the rearrangement of specialized structures, termed dendritic spines, 
found at many synapses in the mammalian CNS. Increased synaptic activity has been shown to 
lead to LTP of synaptic efficiency via the formation of new spines.
285 Pronounced loss of neurites 
and synapses  represents one of the  most relevant histopathological lesions in AD brain with 
respect to neuronal function.
286,287,288 Failures of synaptic plasticity are thought to represent early 
events in AD.
289,290  
Synaptic plasticity is dependant on the structural regulation of the actin cytoskeleton in dendritic 
spines.
10,11,291  The  Rho  family  of  GTPases  such  as  RhoA,  Rac1,  and  Cdc42  monomeric  G-
proteins,  are  the  major  regulators  in  synaptic  plasticity,  both  in  dendrite  morphogenesis  and 
stability as well as in growth cone motility and collapse
6,8,9,10,11, affecting neuronal architecture 
and  synaptic  connectivity.
282  Small  Rho  proteins  act  as  molecular  switches  between  inactive 
GDP-bound and active GTP-bound forms under the regulation of several Rho GEFs and Rho 
GAPs  (section  1.6.2.).
6,292  Representative  of  all  Rho  proteins,  the  role  of  Rac1  in  synaptic 
function is highlighted: Rac1 is expressed in the adult mouse hippocampus
293, a brain area that 
exhibits robust synaptic plasticity and is crucial for the acquisition of associative memories.
294 In 
neurons,  Rac1  is  associated  with  neuronal  development,  participating  in  the  morphological 
changes required for migration of newborn neurons to extension of axons and dendrites into 
proper target regions, and formation of synapses with appropriate partners. Its participation in 
neuronal morphogenesis is a contributor to synaptic plasticity and synapse formation.
295 In vitro 
studies  in  hippocampal  slices  indicated  that  activation  of  NMDA  (N-methyl  D-aspartate) 
receptors results in membrane translocation and activation of Rac1.
293,296 Furthermore, in vivo 
studies in adult mice revealed that Rac1 activation of NMDA receptors is linked with associative 
fear learning. Thus, Rac1 is recognized as an important molecule required for synaptic plasticity 
and is involved in the morphological changes observed at neuronal synapses during hippocampal 
learning and memory.
293,296 Recently, a small G-protein Rac dependant forgetting mechanism, 
which  contributes  to  both  passive  memory  decay  and  interference-induced  forgetting  was 
identified in Drosophila and it was suggested that Rac’s role in actin cytoskeleton remodelling 
may contribute to memory erasure.
297 Recent studies described the Rac-specific GEF Tiam1 as a 
critical mediator of NMDA receptor-dependant spine developments. Tiam1 regulates spine and   40 
dendrite development by activating Rac1- dependant signalling pathways which promote actin 
cytoskeletal  re-organization  and  protein  synthesis.
298  This  process  is  triggered  by  the  brain-
derived neurotrophic factor (BDNF) and its tyrosine kinase receptor B (TrkB), which binds and 
phosphorylates  Tiam  1,  leading  to  activation  of  Rac-1  and  induction  of  changes  in  cellular 
morphology.
299 TrkB activity is increased in aging and correlates with changes in cholesterol.
300 
TrkB activates GGTase I, which mediates geranylgeranylation of Rac 1
273 and the GGTase I 
substrate GGPP acts on NMDA receptors and restores LTP dysfunction.
193 Hence, GGPP seems 
to be directly involved in Rac1 related actin cytoskeletal remodeling, which mediate dendritic 
spine formation,  motility,  and  morphology,  which are thought to be important for functional 
synaptic plasticity. FPP and GGPP levels in grey and white matter are speculated to be elevated 
in  AD  brains,  which  further  suggests  that  abundance  of  prenylated  small  GTPases  may  be 
increased  in  AD.
3,261  Phospho-Rac/Cdc42  protein  levels  were  increased  in  hippocampal 
membrane fractions isolated from AD brain and phospho-Rac/Cdc42 labeled only weakly and 
diffusely in hippocampal slices from normal controls, but appear as abnormal granular structures 
in AD brain.
301 The antibody used in that study detects endogenous levels of Rac1/Cdc42 only 
when phosphorylated at serine 71. Phosphorylation at that site may inhibit GTP binding of Rac1, 
attenuating the signal transduction pathway downstream of Rac1.
302 These findings are indicative 
for RhoA/Rac/Cdc42 dysfunction in AD brain. BDNF and its receptor TrkB also play important 
roles in synaptic plasticity and findings that BDNF and TrkB levels are severely decreased in the 
hippocampus and some cortical areas of AD patients
303,304,305 further support synaptic dysfunction 
in AD brain. Further, in vitro and in vivo findings support the idea that synaptic plasticity goes 
awry  when levels of small GTPases are abnormally  enhanced. Alzheimer related Aβ peptide 
increased the levels of the active GTP-bound form of RhoA in SH-SY5Y cells and increased 
levels of RhoA were found in neurons surrounding amyloid plaques in the cerebral cortex of 
APP(Swe) Tg2576 mice.
306 It was suggested in that study that Aβ-induced neurite outgrowth 
inhibition could be initiated through increased Rho GTPase activity that, in turn, phosphorylates 
the collapsin response mediator protein-2 and interferes with tubulin assembly in neurites.
306 
 
1.8.6. Prenylated proteins, oxidative stress and AD 
AD  elevated  abundance  of  prenylated  Rac1  could  possibly  also  contribute  to  Rac1-NADPH 
oxidase-regulated generation of ROS causing oxidative stress, which has been reported in AD 
brain.
307,308,309 In the brain, microglia cells are prominent sources of ROS through expression of   41 
the phagocyte oxidase, which generates superoxide ions. However, a recent study showed that 
microglia also express NADPH oxidases (NOX) and Rac1.
310 Immunohistochemical evaluations 
of  NOX  expression  in  human  post-mortem  tissue  indicate  that  while  microglia  express  high 
levels of the regulatory subunit gp91phox, moderate levels of gp91phox are also expressed in 
neurons.
311 Activation of NOX via Rac1 is a source of ROS generation in the brain
312, which 
plays  a  role  in  cerebral  dysfunctions,  such  as  stroke,  BBB  damage  or  seizure  induced 
hippocampal damage.
313,314,315 A recent study found that NOX-associated redox pathways might 
participate  in  the  early  pathogenesis  of  AD.  NOX  expression  and  activity  are  up-regulated 
specifically  in  the  temporal  gyri  of  mild-cognitive-impaired  (MCI)  patients  as  compared  to 
controls, but not in preclinical or late stage AD samples, and not in the cerebellum.
311 Moreover, 
in vitro studies identified Rac1 as an essential component of the Aβ signalling cascade leading to 
generation of ROS.
280 
 
1.9. Aims of the thesis 
Aging represents the  major risk factor for AD. In western countries a clear link is observed 
between a steadily increasing life expectancy and the prevalence of AD. Numerous publications 
indicate an involvement of cholesterol in both, brain aging and in AD. Analytical methods allow 
the  measurement  of  cerebral  cholesterol  levels  and  its  metabolites.  Later  ones  are  partially 
excreted into the blood-stream allowing the investigation of cholesterol turnover in the CNS by 
oxysterol  analysis  in  the  periphery.  Although,  data  indicated  that  other  MVA-pathway 
intermediates, especially  FPP and GGPP also seem to be involved in cellular aging  and AD 
progression, knowledge on relative or absolute isoprenoid brain levels and their regulation was 
clearly lacking. Impeding progress on advancing knowledge of FPP and GGPP regulation and on 
protein targets was mainly due to analytical difficulties and there was no technique available for 
the  simultaneous  quantification  of  FPP  and  GGPP  levels  in  human  brain  tissue.  Hence,  the 
primary aim of the current work was to develop a validated method for the isolation and accurate, 
precise and sensitive quantification of FPP and GGPP levels in brain tissue. Moreover, further 
aims were to investigate the central regulation of these two key players of the MVA-pathway and 
to address their involvement in AD pathology and during aging. 
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FPP and GGPP are precursors of cellular lipids such as dolichol, ubiquinone and cholesterol. 
Furthermore, and of greatest relevance to the current work, the aforementioned molecules serve 
as  substrates  for  the  post-translational  modification  of  members  of  the  superfamily  of  small 
GTPases, including Rac1, RhoA and Cdc42. Small GTPases are crucial enzymes in a wide array 
of  physiological  processes.  Due  to  their  involvement  in  the  activation  of  secondary  effector 
pathways, a disease related modulation of intracellular abundance or localization potentially has 
critical  effects  on  cell  morphology  and  especially  physiology.  Their  proper  localization  and 
functional activity in biological membranes primarily depends on the attachment of either of the 
two isoprenoids, FPP or GGPP. 
As  mentioned  above,  the  involvement  of  the  MVA-pathway  in  AD  progression  has  been 
intensely  discussed  in  literature.  Previous  studies  mainly  focused  on  cerebral  and  peripheral 
cholesterol and oxysterol levels, while more recent studies raised the interest in FPP and GGPP 
regulation in AD and during normal aging.  
Due to the potential role of cholesterol in the onset and the progression of the AD, statins are 
discussed for their possible beneficial effects in AD. Statins are inhibitors of the rate limiting step 
of the MVA-pathway and therefore of the cholesterol synthesis. Hence, inhibition of mevalonate 
production may also affect the abundance of isoprenoids. 
 
The development, validation and employment of a robust method for the quantification of FPP 
and GGPP in brain tissue was the pre-condition, required to begin to understand the isoprenoid 
homeostasis during aging and in AD. The knowledge of absolute levels of these two isoprenoids 
is the first step for a profound discussion of their involvement and regulation in the diseased 
stage. Furthermore, a comparison of isoprenoid levels in relation to cholesterol levels allows a 
better understanding of the regulation of the mevalonate/isoprenoid/cholesterol pathway. 
To build upon the method for FPP and GGPP detection in human brain tissue, an extension of the 
analytical method was to demonstrate its applicability for measuring brain samples from in vivo 
studies  in  mice.  Previous  studies  by  our  working  group  indicated  cerebral  statin  levels  after 
chronic  treatment  of  animals.  These  studies  suggested  the  potential  for  drug  impact  on  the 
expression of an array of genes and on brain cholesterol levels. The aim of this part of the current 
work was to elucidate the impact of statin treatment on isoprenoid distribution in an in vivo 
model and to determine FPP and GGPP levels in various mouse models. 
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Since  aging  represents  to  most  prominent  risk  factor  for  AD,  the  cerebral  isoprenoid  and 
cholesterol levels in three different generations of mice were investigated to further understand 
the physiological regulation of the mevalonate/isoprenoid/cholesterol pathway during brain aging 
processes. 
 
A  further  goal  of  the  current  work  was  to  detect  differential  effects  of  various 
mevalonate/isoprenoid/cholesterol pathway inhibitors on FPP and GGPP levels in an in vitro cell 
model  using  neuroblastoma  derived  SY5Y  cells  mimicking  AD  pathology  in  terms  of  Aβ 
formation. The aim of the current study was to provide information on isoprenoid regulation in 
this cell model under drug treatment using substances targeting this specific pathway. 
 
After the successful implementation of the HPLC-FLD assay and the investigation of human AD 
brain samples the next technical aim of the current work was to transfer the method to a state of 
the art UHPLC-MS/MS system to significantly reduce analytical run times, while simultaneously 
increasing  sensitivity.  Over  the  last  years  MRM  measurements  on  triple  quadrupole  mass 
spectrometers became the gold standard technique for absolute quantification and the number of 
new  applications  is  increasing  rapidly  as  the  machine  finds  its  way  into  an  ever  increasing 
number of laboratories. 
 
 
 
 
 
 
 
 
 
 
   44 
2. MATERIALS 
2.1. Chemicals 
Chemical  Company / Source 
[
3H]FPP (26.2 Ci/mmol)  Perkin Elmer, Waltham (USA) 
[
3H]GGPP (23.0 Ci/mmol)  Perkin Elmer, Waltham (USA) 
[
14C]- HMG-CoA  Sigma Aldrich, Munich 
1-butanol  VWR International, Darmstadt 
2-propanol  VWR International, Darmstadt 
4-nonylphenol  Sigma Aldrich, Munich 
Acetone   Merck, Darmstadt 
Acetonitrile (ACN)  Carl Roth, Karlsruhe 
Agar  Sigma Aldrich, Munich 
Ammonium acetate  VWR International, Darmstadt 
Ammonium hydroxide (NH4OH) 28-30%  Alfa Aesar, Karlsruhe 
Bovine Serum Albumin (BSA)  Sigma Aldrich, Munich 
Brij 35  Sigma Aldrich, Munich 
Bromphenol blue  Sigma Aldrich, Munich 
Complete
® protease inhibitor cocktail  Roche Diagnostics GmbH, Mannheim 
D*-GCVLL (dansyl gly-cys-val-leu-leu)  Calbiochem, Darmstadt 
D*-GCVLS (dansyl gly-cys-val-leu-ser)  Calbiochem, Darmstadt 
Dansyl chloride  Sigma Aldrich, Munich 
Diethyl ether   VWR International, Darmstadt 
Diisopropyl ether  VWR International, Darmstadt 
Dimethyl sulfoxide (DMSO)  Merck, Darmstadt 
Dimethyl sulfoxide deuterated (C2D6OS)   Carl Roth, Karlsruhe 
Dithiothreitol (DTT)  Sigma Aldrich, Munich 
Dulbecco´s Phosphate Buffered Saline  Gibco/Invitrogen, Karlsruhe 
Dulbecco´s Modified Eagle Medium 
(DMEM)  Gibco/Invitrogen, Karlsruhe 
EDTA (K- and Na-salt)  Sigma Aldrich, Munich 
Ethanol (EtOH)  Merck, Darmstadt 
Ethyl acetate  VWR International, Darmstadt   45 
Farnesyltransferase (FTase)  Jena Biosciences, Jena 
Fetal Calf Serum (FCS)  Gibco/Invitrogen, Karlsruhe 
Formic acid  Merck, Darmstadt 
FTi 277  Calbiochem, Schwalbach 
Gentamycine Sulfate (G418)  Gibco/Invitrogen, Karlsruhe 
Geranylgeranyltransferase (GGTase)  Jena Biosciences, Jena 
GGTi 286  Calbiochem, Darmstadt 
Glucose-6-phosphate  Sigma Aldrich, Munich 
Glucose-6-phosphate dehydrogenase  Sigma Aldrich, Munich 
Glycine  Sigma Aldrich, Munich 
Hank´s Balanced Salt solution (HBS)  Sigma Aldrich, Munich 
HEPES  Merck, Darmstadt 
Hybond P PVDF Membrane  GE Healthcare, Munich 
Hydrochloric acid (HCl)  Merck, Darmstadt 
Hygromycin B  Gibco/Invitrogen, Karlsruhe 
Imidazole  Sigma Aldrich, Munich 
KCl  Sigma Aldrich, Munich 
KH2PO4  Sigma Aldrich, Munich 
KOH   Sigma Aldrich, Munich 
Lovastatin  MSD Sharp & Dohme GmbH, Haar 
Methanol (MeOH)  Merck, Darmstadt 
MgCl2  Merck, Darmstadt 
Milk powder (low-fat)  AppliChem, Darmstadt 
Milli-Q Wasser  Millipore, Schwalbach 
N-(5-dimethylamino-1-naphthalenesulfonyl)-
1, 2-dioleoyl-sn-glycero-3-phosphoethanol-
amine  
Sigma Aldrich, Munich 
Na2CO3  Merck, Darmstadt 
NADP  Sigma Aldrich, Munich 
NaF  Sigma Aldrich, Munich 
n-hexane  Merck, Darmstadt 
Non-essential amino acids MEM (100 x)  Gibco/Invitrogen, Karlsruhe 
NuPAGE 4-12% gradient gels  Gibco/Invitrogen, Karlsruhe   46 
NuPAGE MES SDS running buffer (20 x)  Gibco/Invitrogen, Karlsruhe 
NuPAGE reducing agent (10 x)  Gibco/Invitrogen, Karlsruhe 
NuPAGE sample buffer (4 x)  Gibco/Invitrogen, Karlsruhe 
NuPAGE transfer buffer (20 x)  Gibco/Invitrogen, Karlsruhe 
Octyl-β-D-glucopyranoside  Sigma Aldrich, Munich 
OptiMEM  Gibco/Invitrogen, Karlsruhe 
Penicillin/Streptomycin (PenStrep)  Gibco/Invitrogen, Karlsruhe 
Petroleum ether  VWR International, Darmstadt 
Phosphate buffered saline (PBS) (10 x)  Gibco/Invitrogen, Karlsruhe 
Phosstop
® phosphatase inhibitor  Roche Diagnostics GmbH, Mannheim 
Preciset Cholesterol standards  Roche Diagnostics, Mannheim 
Precision Plus, StrepTactin-Horse radish 
Peroxidase (HRP) Conjugate  Bio-Rad, Munich 
Precision Plus, WesternC
TM, Protein standard  Bio-Rad, Munich 
Pyruvate, sodium MEM  Gibco/Invitrogen, Karlsruhe 
Rotiszint ecoplus  Carl Roth, Karlsruhe 
Simvastatin (Zocor
® 40 mg)  MSD Sharp & Dohme GmbH, Haar 
Sodium azide (NaN3)  VWR International, Darmstadt 
Sodium chloride (NaCl)  Merck, Darmstadt 
Sodium dodecyl sulfate (SDS)  Merck, Darmstadt 
Sucrose  Sigma Aldrich, Munich 
Super Signal
® West Femto  Thermo Scientific, Bonn 
Tetrahydrofuran  Merck, Darmstadt 
Tris(hydroxymethyl)aminomethane (Tris)  Sigma Aldrich, Munich 
Trypsin-EDTA (1 x)  Gibco/Invitrogen, Karlsruhe 
U 18666A  Calbiochem, Darmstadt 
Ultraglutamin  Gibco/Invitrogen, Karlsruhe 
Vitamin solution MEM (100 x)  Gibco/Invitrogen, Karlsruhe 
ZnCl2  Merck, Darmstadt 
All solvents for analytical procedures were of HPLC grade or higher. 
Listed chemicals were purchased at the respective German subsidiary unless stated otherwise.   47 
2.2. Western Blot Antibodies 
Primary antibodies  kDa  Source  Catalogue # 
GAPDH  36  Millipore, Schwalbach  MAB374 
GGPPS   37  Abgent, Heidelberg  AP2419b 
IL-13 alpha 2  50  Abcam, Cambridge (UK)  ab37631 
NeuN  46  Millipore, Schwalbach  MAB377 
Pan Rho + Rac(1,2,3) + Cdc42  21  Abcam, Cambridge (UK)  ab69091 
Pan Ras (F-132)  21  Santa Cruz, Heidelberg  sc-32 
Rac1 (C-11)  21  Santa Cruz, Heidelberg  sc-95 
Secondary antibodies:  
anti-mouse, -rabbit, -goat    Santa Cruz, Heidelberg  sc-2055, sc-2054, 
sc-2961 
All primary antibodies were diluted 1:1.000 and all secondary antibodies 1:10.000 
 
2.3. Kits 
Name  Company  Catalogue # 
BCA Protein Assay reagent  Thermo Scientific, 
Bonn  23225 
CHOD-PAP (Cobas
TM) Cholesterol kit   Roche Diagnostics, 
Mannheim 
11491458 216 
(Preciset Cholesterol 
standards not continued) 
   
2.4. Laboratory equipment and materials 
Name  Company 
Biological samples / animals   
Human brain samples  
 
Human brain and Spinal Fluid Center, Los 
Angeles (USA) 
Pig brain  Metzgerei Friedrich Schreiber, Frankfurt 
C57Bl/6 mice 
 
Centre d'Elevage R. Janvier, Le Genest-St 
Isle (France) 
SAMP1/KaHsD  Harlan-Winkelmann, Borchen (Germany) 
               SAMP8/TaHsD  Harlan-Winkelmann, Borchen (Germany) 
HPLC columns/guard columns   
Ascentis
® Express
 C18 RP 
(100 x 2.1 mm, 2.7 µm)  Sigma Aldrich, Munich 
Security guard column C18  
(4 x 2.0 mm)  Phenomenex, Aschaffenburg   48 
Nucleodur 100-5 C18 end-capped 
(250 x 4.0 mm)  Macherey-Nagel, Düren 
CC 8/4 Nucleodur 100-5 CN  
(8 x 4.0 mm)  Macherey-Nagel, Düren 
Zorbax SB-C18  
(150 x 2.1 mm, 5 µm)  Agilent, Böblingen 
   
Extraction   
Extrelut
®-NT1   Merck, Darmstadt 
Manifold (20 position)  Varian, Darmstadt 
Oasis
® HLB 3cc, 60 mg  Waters, Eschborn 
Oasis
® WAX  Waters, Eschborn 
Oasis
® MAX  Waters, Eschborn 
Supelco DSC-CN  Sigma Aldrich, Munich 
Supelco DSC-Si  Sigma Aldrich, Munich 
Supelco DSC-diol  Sigma Aldrich, Munich 
Supelco DSC-18  Sigma Aldrich, Munich 
Strata X-AW  Phenomenex, Aschaffenburg 
Strata X  Phenomenex, Aschaffenburg 
Ion exchange column AG1-X8  Bio-Rad, Munich 
   
Materials   
(Ultra-) Centrifuge tubes  Beranek Laborgeräte, Weinheim 
HPTLC RP-18 W / UV 254 silica gel 
glass plates (5 x 20 cm, 0.25 mm)  Carl Roth, Karlsruhe 
Hybond ECL nitrocellulose 
Transfer Membrane  GE Healthcare, Munich 
Microplate, 96-well, IWAKI  Dunn Labortechnik, Asbach 
PVDF Transfer Membrane  GE Healthcare, Munich 
Reaction vials  Eppendorf, Hamburg 
Tissue culture dish, IWAKI  Dunn Labortechnik, Asbach 
   
Laboratory equipment   
HPLC (1)   
Jasco  Jasco, Gross-Umstadt   49 
DG-1580-53 Degasser   
LG-980-02 Binary solvent 
mixer   
PU-980 Pump   
AS-950 Autosampler   
Column thermostat  W.O. electronics, Langenzersdorf 
Gilson 122 Fluorometer  Gilson, Middleton (USA) 
   
HPLC (2)   
LaChrome Elite System  VWR-Hitachi, Darmstadt 
L-2130 pump (2x)   
L-2200 Autosampler   
Column oven   
L-2485 Fluorescence detector   
   
UHPLC-MS    
Waters Acquity system   Waters, Elstree (UK) 
API 4000 QTrap Sciex  
mass spectrometer 
 
Applied Biosystems, Foster City (USA) 
   
QFT 9.4 T triple-quadrupole Fourier 
transform ion cyclotron resonance (FT-ICR) 
mass spectrometer 
IonSpec, Lake Forest (USA) 
   
Further Equipment   
   
Beckman GS-6R centrifuge  Beckman Coulter, Krefled 
Beckman J2-HS centrifuge 
(Rotor JA-20.1)  Beckman Coulter, Krefled 
Beckman L7 ultracentrifuge  
(Rotor SW41)  Beckman Coulter, Krefled 
Beckman Microfuge R            
(Rotor F241.5)  Beckman Coulter, Krefled 
Bio Rad Power Pac 300  Bio-Rad, Munich 
Biofuge pico (Heraeus)  Thermo Scientific, Bonn 
Bruker Avance 300 NMR     50 
spectrometer  Bruker Daltonic, Bremen 
Canberra Packard Tricarb – 1900 
scintillation counter  Canberra, Rüsselsheim  
Combi-tips  Eppendorf, Hamburg 
Cryo-vials, model Cryo-S  Greiner, Frickenhausen 
ELISA reader, Digiscan   ASYS Hitech, Eugendorf (AUT) 
Fortuna
® Optima
® glass Syringes  Poulten&Graf, Wertheim 
Gauge needle (1427a LL)  Acufirm, Dreieich 
Heraeus CO2 incubator  Thermo Scientific, Bonn 
Incubator, GFL 4010   GFL, Burgwedel 
Laminar Flow box, Hera Safe  Thermo Scientific, Bonn 
Magnetic stirrer, IKA Combimag 
RCT  IKA
®  Werke, Staufen 
Pellet chow (standard 1320 
maintenance diet)  Altromin, Lage 
pH-meter (Inolab)  WTW, Weilheim 
Pipettes (various volumes)  Gilson, Middleton (USA) 
Platform shaker, Promax 1020  Heidolph, Kehlheim 
Potter S  B.Braun, Melsungen 
Refrigerated Condensation Trap  Savant/ Thermo Scientific, Bonn 
Scale AB204  Mettler Toledo, Giessen 
SNAP i.d. Protein detection system  Millipore, Schwalbach 
Sonifier, Cell Disruptor B15  Branson, Danbury (USA) 
Speedvac
® Plus SC210 A  Savant/ Thermo Scientific, Bonn 
Syringe pump  Harvard Apparatus, Holliston (USA) 
Transferpette
® (2 – 200 µL)  Brand, Wertheim 
Ultra Turrax T25  IKA
®  Werke, Staufen 
Ultrasonic bath, Sonorex Super  
RK 510H  Schalltec, Mörfelden-Waldorf  
Universal Hood II (Photometrics 
Cascade:1K camera)  Bio Rad, Munich 
Vacuum pump Millivac,  
Maxi SD1P014M04  Millipore, Schwalbach 
Vacuum pump, Diaphragm pump   Vaccubrand, Wertheim 
Vortex Genie 2  Scientific Industries, New York (USA)   51 
Water bath (shaking), GFL 1083  GFL, Burgwedel 
Xcell II
TM Blot Module  Gibco/Invitrogen, Karlsruhe 
 
2.5. Software 
Name  Company 
Analyst 1.4.2  Applied Biosystems, Foster City (USA) 
Borwin 1.50  Jasco, Gross-Umstadt 
EZ Chrome Elite
®  VWR, Darmstadt 
GraphPad Prism 4.0  GraphPad Software, La Jolla (USA) 
MIDAS molecular formula calculator   NHMFL, Tallahassee (USA) 
MS Office 2003  Microsoft, Redmond (USA) 
Quantity One 4.6.5  Bio-Rad, Munich 
Reference Manager Version 10  ISI Researchsoft, New York (USA) 
 
2.6. Buffers and Solutions 
2.6.1. General buffers 
Buffers  listed  in  the  following  section  were  prepared  with  Millipore  water  and  the  pH  was 
adjusted using a pH meter, which was calibrated daily.  
 
PBS - buffer 
For the PBS buffer a concentrate (10 x) was used and diluted 1:10 using Millipore water. 
Sterile conditions were applied when necessary. 
 
Tris-HCl – buffers 
Buffer I      Tris HCl 50 mM, pH 7.4 
  Buffer II    Tris HCl 100 mM, pH 8.5 
Buffer III    Tris HCl 5 mM, pH 7.4 
Buffer IV    Tris HCl 5 mM, pH 8.5 
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Various – buffers 
  Buffer V    HEPES 10 mM, 0.32 sucrose, pH 7.4 
  Buffer VI    Buffer V, 0.25 mM Na-EDTA, pH 7.4 
  Buffer VII    0.1 M sucrose, 50 mM KCl, 40 mM KH2PO4, 30 mM K-EDTA 
  Buffer VIII    10 mM DTT in buffer VII 
  Buffer IX    17.5 mM NaCl, 25 mM glucose-6-phosphate, 5 mM NADP 
 
Gradient solutions 
  Gradient 1    7.5% (w/v) ficoll, 0.25 mM Na-EDTA in buffer V   
  Gradient 2    14%  (w/v) ficoll, 0.25 mM Na-EDTA in buffer V   
  Gradient 3    1.5 M sucrose, 10 mM HEPES, 0.25 mM Na-EDTA 
 
2.6.2. Buffers and solutions for the isoprenoid isolation and derivatization 
 
Reaction buffer 
Reaction buffer used for the enzymatic reaction of the according dansyl-labels: 
Dithiothreitol    5 mM 
MgCl2       5 mM   
ZnCl2   10 µM
   
O-β-D-Glucopyranosid   1% (m/v) 
Tris-HCl (pH 7.5)   50 mM
   
   
Stop solution 
  Stop solution, used for the termination of the enzymatic reaction: 
ACN /10% HCl      10 : 1 (v/v)     
 
Dansyl-peptides 
FPP substrate D*-GCVLS    50 µM in buffer I 
GGPP substrate D*-GCVLL   50 µM in buffer I 
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Isoprenoid diluting solvent 
  Dilution agent used for isoprenoid solutions: 
MeOH / 10 mM NH4OH    7 : 3 (v/v)  
 
Enzyme dilutions 
      FPTase        250 ng/µL reaction buffer 
      GGTase I        250 ng/µL reaction buffer 
 
Phosphatase inhibitor mixture 
      NaF          100 mM 
      imidazole        200 mM 
 
Elution mix 1 (for Extrelut
®) 
      1-Butanol / H2O / NH4OH     10 : 2 : 1 (v/v/v) 
Elution mix 2 (for SPE) 
      n-hexane / 2-propanol / NH4OH  12 : 7 : 1 (v/v/v) 
 
Elution mix 3 (for cell extraction) 
      1-Butanol / NH4OH / EtOH    4 : 5 : 11 (v/v/v) 
 
2.6.3. Western Blot buffers and solutions 
 
TBST - solution       
Tris-base      3 g 
NaCl      8 g 
TBS  500 mL 
Tween 20      1 mL 
H2O  ad 1 liter 
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Running buffer   
       
NuPage MES SDS 
running buffer (20x) 
 
  50 mL 
H2O  950 mL 
NuPage Antioxidant       1 mL 
 
Transfer buffer   
 
NuPage transfer buffer    50 mL 
Methanol  100 mL 
H2O    850 mL 
NuPage Antioxidant       1 mL 
 
Blocking solution   
     
TBST (1x)      10 mL 
Milk powder    750 mg 
               
Azide- solution (100x)  
     
Sodium azide  2% 
 
Secondary antibody (sec. AB) solutions   
 
TBST (1x)    10 mL 
Sec. AB    3 µL 
StrepTactin-HRP 
Conjugate 
 
  3 µL 
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2.6.4. Cell culture media and inhibitors 
The following cultivation medium was used for the APP transfected (SH-SY5Y-APPwt) cells: 
DMEM  500 mL 
FCS    50 mL 
MEM vitamins      5 mL 
NEA      5 mL 
Pyruvate      5 mL 
P/S      3 mL 
Hygromycin        3 mL 
 
The following medium was used for the incubation with the various MVA-pathway inhibitors 
listed in Table 4:  
OptiMem  500 mL 
P/S      3 mL 
Hygromycin      3 mL 
 
 
 
Inhibitor  Enzyme target  Solvent  concentration 
FTi 277  farnesyltransferase  DMSO  1 µM 
GGTi 286  geranylgeranyltransferase  DMSO  1 µM 
Lovastatin  HMG-CoA reductase  EtOH  5 µM 
U 18666A  desmosterol reductase 
oxidosqualene cyclase  H2O  1 µM 
 
Tab. 4. Inhibitors for in vitro cell assays on human SY5Y cells (see section 3.6.). 
Depicted are the inhibitors, their respective enzyme target, the solvent they 
were dissolved in and the final concentration in the cell medium. An overview 
of the enzyme targets can be seen in Figure 41. 
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3. METHODS 
3.1. Pre-column derivatization 
Based  on  the  work  published  by  Tong  et  al.  FPP  and  GGPP  were  determined  using  high 
performance liquid chromatography and fluorescence detection (HLPC-FLD) after pre-column 
labeling  of  FPP and  GGPP using dansyl  labeled pentapeptides.
94  The  published  method  was 
modified as follows: 
 
3.1.1. Standard prenylation assay (standard F-G-Assay) 
The following solutions were combined in a reaction vial for the enzymatic attachement of FPP 
and  GGPP  to  dansyl  labeled  pentapeptides  (dansyl-glycine-cysteine(farnesyl)-valine-leucine-
serine  and  dansyl-glycine-cysteine(geranylgeranyl)-valine-leucine-leucine,  respectively)  shown 
in  Figure  5.  This  assay  is  referred  to  as  standard  F-G-Assay  throughout  the  entire  text. 
Concentrations ranging from 0.5–1000 ng/mL of FPP and GGPP were employed. The dansyl 
labeled FPP and GGPP derivatives are designated as FPP* and GGPP* throughout the entire text. 
 
Reaction buffer  42 µL 
FTase  1 µL 
GGTase I  1 µL 
FPP   1 µL 
GGPP  1 µL 
Dansyl-GCVLS (FTase substrate)  2 µL 
Dansyl-GCVLL (GGTase I substrate)  2 µL 
   
                         Total  50 µL 
 
3.1.1.1. Incubation protocol I 
The mixture of the F-G-Assay was incubated in a water bath for 120 min at 37 °C. Subsequently, 
the enzymatic reaction was terminated by the addition of 50 µL stop solution followed by a 
centrifugation step (15.000 x g; 5 min; 4 °C). For HPLC analysis 95 µL of the final solution were 
transferred to HPLC vials.   57 
Both enzymes, farnesyltransferase (FTase) and the geranylgeranylteransferase I (GGTase I) were 
tested for their optimum concentrations. For each enzyme a prenylation assay, as described in 
section 3.1.1. was conducted with 46 µL reaction buffer and the respective enzyme, isoprenoid 
and dansyl-label. The enzyme concentrations tested were 62.5, 125, 250 and 1000 ng/µL.  
 
3.1.1.2. Incubation protocol II   
The mixture of the F-G-Assay was incubated in an Eppendorf thermomixer, comfort programmed 
for 90 or 120 min cycles (37 °C; per min: 10 sec; 500 rpm). Subsequently, the enzymatic reaction 
was terminated by the addition of 50 µL stop solution followed by a centrifugation step (15.000 x 
g; 5 min; 4 °C). For HPLC analysis 95 µL of the final solution were transferred to HPLC vials. 
 
The incubation time for each enzymatic reaction was tested individually. The time dependant 
conversion  of  each  isoprenoid  to  its  respective  dansyl-labeled  product  was  monitored.  Eight 
individual assays were prepared in a thermomixer and the reaction was terminated by the addition 
of 50 µL stop solution at the following time points: 0, 15, 30, 45, 60, 90, 120 and 180 min and 
processed as described above. 
 
3.1.2. Prenylation assay following FPP and GGPP extraction 
Following  extraction from cells or tissue samples, dried residues from  the applied extraction 
procedure were dissolved in 44 µL reaction buffer by vigorously mixing the reaction vial for 1 
min, followed by 3 min in the ultrasonic bath. Subsequently 1 µL FTase, 1 µL GGTase and 2 µL 
of each dansyl-label were added and the mixture was incubated for 90 min as described in section 
3.1.1.2. 
 
3.2. Internal standard 
3.2.1. Synthesis  
The synthesis of dansyl-para nonylphenol (DNP) as the internal standard (IS) was conducted 
according to Naassner et al. with the following changes:
316 
For the chemical reaction 25 mg 4-n-nonylphenol were dissolved in 2 mL acetone, 25 µL 0.5 M 
Na2CO3 and 200 mg of dansyl chloride were added. The reaction mixture was stirred for 18 h at   58 
room temperature (RT), the solution was evaporated to dryness under reduced pressure (400 
mbar; 35 °C) and re-dissolved in 2 mL ACN.  
 
3.2.2. Product confirmation using thin layer chromatography 
Following  synthesis  of  DNP  the  reaction  product  was  firstly  confirmed  using  thin  layer 
chromatography. Commercially available, modified silica gel glass plates (HPTLC RP-18 W / 
UV254) were used with the following mobile phase composition: Acetone/MeOH/H2O (25:5:4 
v/v/v). The product was detected under UV light (366 nm) with a retention factor (Rf-value) of 
0.5. The silica gel showing the spot was scratched of the glass plate and collected in a reaction 
tube.  
 
3.2.3. 
1H-NMR product confirmation 
The silica gel with the product was scratched of the HPTLC plates and extracted with deuterated 
DMSO  (C2D6SO)  prior 
1H-NMR  analysis.  The  solution  was  then  subjected  to  a 
1H-NMR 
measurement (300 MHz) for product confirmation. 
1H-NMR spectra were measured on a Bruker 
AV  300  spectrometer.  Chemical  shifts  were  reported  in  parts  per  million  (ppm)  using 
tetramethylsilane (TMS) as an internal standard. 
 
3.2.4. Preparative HPLC clean-up 
Prior to the preparative clean-up via HPLC, the DNP solution (see section 3.2.1.) was centrifuged 
at 3000 x g for 5 min and the supernatant was transferred to HPLC vials. Repeated clean-up was 
conducted using a Nucleodur 100-5 C18 end-capped column and the fraction collector on the 
Jasco HPLC system. Chromatographic conditions are described in section 3.4.2. 
Stock  solution  (2.8  µM)  aliquots  were  evaporated  to  dryness  and  stored  under  nitrogen 
atmosphere at 4 °C in the dark. 
 
3.3. FPP and GGPP extraction procedure for matrix samples  
3.3.1. Sample preparation 
Frozen tissue samples were homogenized with a rotor-stator homogenizer at 1100 rpm in 1.1 mL 
of  buffer  II  containing  5  µL  Halt
®  and  10  µL Phosstop
®  phosphatase  inhibitor.  Two  50  µL   59 
aliquots of homogenate were retained for protein and total cholesterol determination (see section 
3.8. and 3.9.). Subsequently, 1 mL homogenate was spiked with 15 µL of a 2.8 µM IS solution 
and vigorously mixed with 1 mL of buffer II. 
 
3.3.2. Matrix assisted liquid/liquid extraction via Extrelut
® 
3.3.2.1. Generic Extrelut
® protocol 
A generic protocol for the Extelut
®-NT1 columns is provided for the extraction of lipophilic 
compounds from aqueous solution with a volume of 0.1–1 mL. After the addition of the solution 
onto the columns and 15 min of incubation, the lipophilic compounds were eluted by the addition 
of an organic phase or a mixture thereof.  
 
3.3.2.2. Adapted Extrelut
® protocol 
The matrix homogenate (section 3.3.1) was loaded onto an Extrelut
®-NT1 column, and after 15 
min washed of with three 2 mL steps of Elution-mix 1. The eluent was centrifuged (29.000 x g; 
10 min; 4 °C) and the resulting supernatant decanted in a glass vial after evaporation to dryness 
under reduced pressure, in a SpeedVac (5 h; 55 °C; 30 mbar). The resulting residue was re-
dissolved in 3.75 mL of 5% methanol in water (v/v). The solution was vigorously shaken for 1 
min and placed in an ultrasonic bath for 10 min (see Figure 3). 
 
3.3.3. Solid phase extraction (SPE) 
3.3.3.1. Generic SPE protocol 
A generic protocol for SPE applications is divided into the 5 following steps, all of which are 
carried out with negative pressure on a manifold: 
 
Step 1: Conditioning (C) 
Step 2: Equilibration (E) 
Step 3: Sample (S) 
Step 4: Wash (W)  
Step 5: Elution (Elu) 
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During step C each solvent, which was subsequently used for step 3 – 5 was flushed through the 
column. In step 5 (E) the pure solvent in which the sample was present was employed. Finally, 
the whole volume of the sample was applied to the column (Step 3 (S)). For the following wash 
step (Step 4 (W)) a solution similar to that of the sample was chosen, generally a methanol or 
formic  acid  solution.  Subsequently,  the  columns  were  dried  under  reduced  pressure  prior  to 
eluting in the final step (Elu). During step 1 – 3 the columns were maintained wet. 
 
3.3.3.2. Developed HLB protocol 
Following the adapted Extrelut
® protocol (section 3.3.2.2) further sample clean-up was conducted 
on a manifold connected to a vacuum pump using HLB solid phase extraction cartridges (3cc; 60 
mg) pre-conditioned with 2 mL n-hexane, followed by 1 mL 2-propanol and 1 mL methanol. 
Afterwards, the columns were equilibrated with one tube volume of water. Following these initial 
conditioning steps (organic solvents) and the equilibration step (water), the solution resulting 
from  the  Extrelut
®  clean-up  was  introduced  to  the  cartridges  and  washed  with  1  mL  of  2% 
methanol in water (v/v). For the final elution, 2 mL of Elution-mix 2 were applied to the columns 
and the eluent containing the isoprenoids was collected in 2 mL reaction vials. This solution was 
evaporated to dryness under reduced pressure in a SpeedVac (2 h; 55 °C; 30 mbar), prior the 
enzymatic pre-column derivatization (see Figure 3). 
 
3.3.4. Extraction procedure for in vitro cell culture experiments 
The isolation from cells was conducted according to Tong et al.
94 Cultivated cells were scraped 
from the cell culture dish, transferred to a reaction vial and centrifuged (1000 x g, 10 min; RT). 
The resulting cell pellet was washed with 1 mL PBS and subsequently centrifuged again under 
the same conditions. After the final centrifugation step the pellet was dissolved in 300 µL buffer 
I, containing 5 µL Halt
® and 10 µL Phosstop
® phosphatase inhibitor; the cells were constantly 
kept on ice. Following protein determination via the BCA assay (see 3.8.), 600 µg of total protein 
from the cell suspension were transferred to a vial and the volume for each sample was adjusted 
to maintain equal volumes in all vials, ready for extraction procedure and analysis.  
 
For the calibration samples, 600 µg of SH-SY5Y cell suspension was used and was spiked as 
follows: 0, 5, 10, 20, 60 and 100 ng/mL for FPP and 0, 5, 10, 20, 75 and 100 ng/mL for GGPP.   61 
To begin the isolation, 1 mL elution mix 3 (70 °C) was added to the cell suspension in each vial. 
Subsequently  the  mixture  was  shaken  vigorously  for  1  min  and  incubated  in  a  thermomixer 
programmed for 20 min (70 °C; per min: 10 sec; 500 rpm). For further processing the samples 
were cooled to RT and centrifuged (9000 x g; 5 min; RT). The supernatant was transferred to a 
new  vial  and  the  pellet  re-suspended  by  the  addition  of  1  mL  elution  mix  3  (70  °C)  and 
subsequent  sonication  for  15  s.  After  vortexing  the  vials  for  one  minute  the  samples  were 
subjected to incubation in the thermomixer using the aforementioned conditions. After cooling 
the samples to RT and following centrifugation (9000 x g; 5 min; RT), the supernatants were 
combined and evaporated to dryness under reduced pressure in a SpeedVac (2 h; 55 °C; 30 mbar) 
and then subjected to enzymatic pre-column derivatization (see Figure 3). 
For the calibration samples, un-spiked samples (endogenous control) were used to determine the 
endogenous FPP and GGPP levels (cell matrix). After measurement of the calibration curve, the 
peak  areas  for  FPP  and  GGPP  of  the  endogenous  control  were  subtracted  from  each  of  the 
calibration samples. 
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Fig.  3.  Flow-chart  of  the  final,  complete  sample  preparation  for  brain 
tissue and cultured cells prior HPLC-FLD analysis.    62 
3.4. Analytical methods 
3.4.1. HPLC-FLD analysis (Jasco HPLC system) 
The gradient elution and HPLC settings shown below describe the final settings for the routine 
analysis of standard F-G-Assays and for assays with matrix samples on the Jasco system. 
 
Chromatographic conditions:  
mobile Phase:       Solvent A   20 mM ammonium acetate in 40% ACN 
          Solvent B  20 mM ammonium acetate in 90% ACN 
gradient: 
 
 
 
guard column:       Security guard column C18 (4 x 2.0 mm) 
analytical column:      Ascentis
® Express
 C18 RP (100 x 2.1 mm, 2.7 µm) 
temperature:        35 °C 
flow:          0.5 mL/min 
injection volume:      80  L 
total run-time:        20 min 
autosampler temperature:    4 °C 
fluorescence wavelength:    excitation 340 nm / emission 525 nm  
 
3.4.2. IS clean-up (Jasco HPLC system) 
The settings for the gradient elution on the Jasco HPLC system with the fraction collector are 
described below. The preparative clean-up, following IS synthesis, was repeatedly conducted to 
ensure a higher purity of the IS.  
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Chromatographic conditions:  
mobile Phase:       Solvent A   H2O 
          Solvent B  ACN 
gradient: 
 
 
 
guard column:       CC 8/4 Nucleodur 100-5 CN (8 x 4.0 mm) 
preparative column:      Nucleodur 100-5 C18 end-capped (250 x 4.0 mm) 
temperature:        20 °C 
flow:          1.5 mL/min 
injection volume:      120  L 
total run-time:        20 min 
autosampler temperature:    4 °C 
fluorescence wavelength:    excitation 340 nm/emission 525 nm  
fraction collector:      peak collection from 15–16 min  
 
3.4.3. Comparative analysis (Hitachi HPLC–FLD system) 
The gradient elution and HPLC settings shown below describe the final settings for the routine 
analysis  of  standard  F-G-Assays  and  for  assays  with  matrix samples  on  the  LaChrome  Elite 
system from Hitachi. 
 
Chromatographic conditions:  
mobile Phase:       Solvent A   20 mM ammonium acetate in 40% ACN 
          Solvent B  20 mM ammonium acetate in 90% ACN 
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gradient: 
 
 
 
analytical column:      Ascentis
® Express
 C18 RP (100 x 2.1 mm, 2.7 µm) 
temperature:        20 °C 
flow:          0.35 mL/min 
injection volume:      1 - 75  L 
total run-time:        16 min 
autosampler temperature:    RT 
fluorescence wavelength:    excitation 320 nm/emission 520 nm  
 
3.4.4. Fast separation analysis (UHPLC–MS/MS) 
The gradient elution and UHPLC-MS/MS settings shown below describe the final settings for the 
routine  analysis  of  standard  F-G-Assays  and  for  assays  with  matrix  samples  on  the  Waters 
Acquity system coupled to the QTrap 4000 triple quadrupole MS. 
 
Chromatographic conditions:  
mobile Phase:       Solvent A  20 mM ammonium acetate in water 
           Solvent B  20 mM ammonium acetate in 90% ACN  
 
gradient: 
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analytical column:      Ascentis
® Express
 C18 RP (100 x 2.1 mm, 2.7 µm) 
temperature:        20 °C 
flow:          0.6 mL/min 
injection volume:      10  L (partial loop) 
total run-time:        3 min 
autosampler temperature:    10 °C 
 
Mass spectrometer settings (API 4000 QTrap) 
 
Ion source (turbo spray) dependant parameters 
Ionization  ESI 
Polarity  positive 
Curtain gas (CUR)  10.0 a.u. 
Collision gas pressure (CAD)  medium 
IonSpray voltage (IS)  4500 V 
Temperature (TEM)  600 °C 
Ion source gas 1 (GS1)  40.0 a.u. 
Ion source gas 2 (GS2)  0.0 a.u. 
Interface heater (ihe)   On 
De-clustering potential (DP)  120.0 V 
Entrance potential (EP)  10.0 V 
Collision energy (CE)  30.0 V 
Collision cell exit potential (CXP)  10.0 V 
 
 
3.4.5. Characterization of FPP* and GGPP* using FT-ICR MS 
Accurate  mass  measurements  were  performed  on  a  QFT  9.4  T  triple-quadrupole  Fourier 
transform ion cyclotron resonance MS (FT-ICR MS) in the negative ion mode. FPP* and GGPP* 
fractions were collected using the Jasco fraction collector while running spiked brain samples on 
the Jasco HPLC system. Solutions were infused into the ESI source after mixing with internal   66 
mass calibration solution at a flow rate of 7 mL/min using a syringe pump. The needle potential of 
the ESI source was set to –3.8 kV, the cone voltage to –45 V and the extractor to –10 V. Ion 
accumulation times between 500 and 1000 ms in Q3 were used. Chirp excitation was performed 
at 155 V for 16 ms (from m/z 75 – 2500). Mass accuracies were calculated using the MIDAS 
molecular  formula  calculator  software  with  atom  constraints  for  C,  H,  N  and  O  set  to  the 
respective number of atoms in the precursor ions. 
 
3.5. Method validation 
3.5.1. Validation samples for HPLC-FLD application 
3.5.1.1. Human brain matrix 
In order to minimize interference with endogenous FPP or GGPP sealed human frontal cortex 
samples  from  8  different  donors  were thawed  and kept  at  RT  for  48  h  prior  to  preparation. 
Following  the  storage  at  RT,  the  brain  samples  were  homogenized  with  a  rotor-stator 
homogenizer at 1100 rpm in buffer II resulting in a stock solution with 200 mg wet weight (ww) 
tissue per milliliter. Two separate batches from different brain samples were prepared, one for the 
calibration samples (CCs) and one for the quality control samples (QCs). 10 mL aliquots were 
stored at -20 °C for the duration of the validation and the measurement of the human brain study 
samples. 
 
3.5.1.2. Calibration curve samples (CCs) 
Separate stock solutions (1 mg/mL) of FPP and GGPP in MeOH/NH4OH (7:3, v/v) were kept at -
20 °C. Different working solutions containing FPP and GGPP were prepared by diluting the 
stock solution with the isoprenoid dilutent solution (see section 2.6.2.). The IS was prepared by 
dissolving  the  dried  residue  in  an  appropriate  volume  of  acetonitrile  resulting  in  a  2.8  µM 
solution. Calibration standards were prepared daily by adding 1 mL of brain homogenate to 1 mL 
buffer II spiked with 15 µL of IS solution, 5 µL Halt
® and 10 µL Phosstop
® phosphatase inhibitor 
and 10 µL of the appropriate FPP-GGPP working solutions, resulting in concentrations of 10, 20, 
40, 60, 80, 100, 200 and 400 ng/mL for FPP and 50, 75, 100, 125, 150, 250, 500 and 1000 ng/mL 
for GGPP. A fresh set of CCs was prepared daily.  
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3.5.1.3. Quality control samples (QCs) 
Analogue to the calibration standards (see section 3.5.1.2.) three different concentrations of QCs 
(FPP-GGPP: QC-L 30/80, QC-M 150/400 and QC-H 300/800 ng/mL; low, medium and high) 
were prepared in a different batch of human brain matrix. These QCs were prepared without the 
addition of the IS and phosphatase inhibitors prior to the validation and stored in 1 mL aliquots at 
-20 °C throughout the validation and the measurement of the human brain study samples. For 
each  day  the  respective  amount  of  QCs  was  thawed  and  prepared analogue  to the  CCs  (see 
section 3.5.1.2), without the addition of isoprenoid standards. 
 
3.5.2. Validation protocol 
The  preparation  procedure  combined  with  the  analytical  method  was  subjected  to  validation 
according to the latest FDA bioanalytical method validation guideline.
317  
Fundamental parameters to ensure the acceptability of the performance of a bioanalytical method 
are  selectivity,  linearity  including  the  LLOQ,  accuracy  and  precision  (inter-  and  intraday), 
reproducibility, and stability. 
Endogenous  isoprenoid  levels  were  removed  from  the  tissue  matrix  as  described  in  section 
3.5.1.1. To ascertain sufficient degradation of FPP and GGPP chromatograms of zero samples 
(matrix  sample  spiked  with  IS),  blank  samples  and  spiked  matrix  samples  were  compared, 
respectively.  
 
3.5.2.1. Selectivity 
The  selectivity  of  the  method  was  shown  by  the  comparison  of  blank  and  zero  sample 
chromatograms from six brain homogenate samples of different origin to confirm the absence of 
interfering peaks.  
 
3.5.2.2. Linearity 
Linearity  in  brain  homogenate  was  verified  using  five  calibration  curves  measured  on  five 
separate  days.  Each  standard  curve  consisted  of  eight  non-zero  calibration  standards  with 
concentrations ranging from 0.03 to 1.06  mol (10 – 400 ng/mL) for FPP and 0.11 to 2.15  mol 
(50 – 1000 ng/mL) for GGPP. The calibration curves were calculated by linear regression using 
weighting for both analytes. According the FDA requirements, the back-calculated values have to   68 
be within 15% of the relative standard deviation (RSD) and 20% of RSD at the lower limit of 
quantification (LLOQ) of the nominal concentration. The acceptance criterion for the correlation 
coefficients (r
2) of the calculated regression curves was > 0.99.  
 
3.5.2.3. Lower limit of quantification (LLOQ) 
To determine the  LLOQ, six different brain homogenate samples were spiked with  FPP  and 
GGPP at the lowest level of the calibration curve (10 ng/mL and 50 ng/mL, respectively) and re-
calculated with a freshly prepared calibration curve.  
 
3.5.2.4. Inter- and intraday accuracy and precision 
The intraday accuracy and precision were determined by analyzing four replicates of each QC 
sample  (in  the  lower,  middle  and  upper  range)  together  with  a  complete  set  of  calibration 
standards  in  one  analytical  run  within  one  day.  The  interday  accuracy  and  precision  were 
established by measuring four replicates of each QC sample on four consecutive days together 
with all calibration standards freshly prepared for each day. The mean, the standard deviation 
(SD), the RSD and bias were calculated.  
 
3.5.2.5. Recovery 
The  recoveries  of  FPP  and  GGPP  from  brain  homogenate  were  determined  by  analyzing 
triplicates of each QC sample (low, medium and high). Responses were compared to extracted 
blank  brain  homogenate  (n=3  for  each  concentration)  spiked  with  the  same  nominal 
concentrations prior to the prenylation assay. For further proof of reproducibility, both recoveries 
were additionally determined by analyzing each QC sample after extraction using [
3H]FPP and 
[
3H]GGPP. Counts were measured on a Canberra Packard Tricarb 1900 scintillation counter and 
referred to those obtained from samples spiked with the same nominal concentrations.  
 
3.5.2.6. Stability 
The stability of FPP and GGPP was tested in the presence of both phosphatase inhibitors (Halt
® 
and Phosstop
®)
 in brain homogenate (n=4) for  two concentration levels (low and high)  after 
storage at RT for 2 h, after three freeze and thaw cycles, and after storage for one and three   69 
months at −80 °C. Furthermore, the auto sampler stability was tested using QC-M samples (n=4) 
and measured at the following time points: 0, 5, 10 and 20 h storage at 4 °C in the auto sampler. 
 
3.5.3. Method transfer to the UHPLC-MS/MS application 
In order transfer the fully validated HPLC-FLD method to a faster and more sensitive UHPLC-
MS/MS  application  the  following  selected  experiments  were  conducted  to  demonstrate  the 
feasibility of the improved technique. The sample preparation protocol including the enzymatic 
derivatization of FPP and GGPP remained unchanged. Chromatic conditions and the applied MS 
settings are described in section 3.4.4.   
 
3.5.3.1. Linearity and LLOQ 
The 7-point calibration curves were measured in a concentration range of 5 – 250 ng/mL for both 
isoprenoids  in  an  isoprenoid-free  human  blank  brain  homogenate  (see  section  3.5.1.1.). 
Calibration standards were prepared for the following concentrations for each isoprenoid: 5, 10, 
40, 60, 100, 200, 250 ng/mL. The same weighting factors (1/x
3 and 1/x
2 for FPP* and GGPP*, 
respectively) were used for the determination via HPLC-FLD and UHPLC-MS/MS.  
The LLOQ was determined with five different brain homogenate samples, spiked with 5 ng/mL 
for FPP and GGPP, respectively. Values were recalculated with a freshly prepared calibration 
curve and met the criteria of the FDA guideline for bioanalytical method validation.
317 Samples 
without the addition of the respective dansyl-labeled pentapeptide were used as blank samples, 
which were run with each batch of samples. 
 
3.5.3.2. Data correlation  
For the correlation of the data generate via the HPLC-FLD and the UHPLC-MS/MS application, 
human  brain  samples  were  prepared  as  described  in  section  3.5.1.1.  After  the  enzymatic 
conversion and addition of 100 µL stop solution 80 µL were analyzed via HPLC-FLD and 10 µL 
via  UHPLC-MS/MS.  Values were  calculated  with  a  calibration  curve  processed  in  the same 
manner. 
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3.6. Cell culture 
3.6.1. Cultivation 
Frozen SH-SY5Y-APP695 cells were gently thawed in a water bath at 37 °C. Before the cells 
were completely thawed they were transferred into falcon tubes (15 ml) containing fresh medium. 
After centrifugation (1000 x g; 10 min; RT) the resulting cell pellet was re-suspended in 1 mL 
fresh medium and transferred into a Petri dish with 10 mL medium. 
Cells were grown to about 80-90% confluence, subsequently the medium was removed from the 
Petri dish and replaced by 10 mL of sterile PBS. After 2-3 min incubation the PBS was removed 
and 1 mL of trypsin was added, followed by another incubation of 2-3 min till half of the cells 
detached from the bottom of the plate. The trypsinization was stopped by the addition of 9 mL of 
fresh medium. Subsequently the cells were carefully triturated and a varying number (1: 3 to 1: 8 
splits)  of  aliquots  were  taken  and  added  to  Petri  dishes  prepared  with  fresh  medium.  The 
maximum number of consecutive splits was 13 before new cells were thawed.  
3.6.2. Inhibitor incubation protocols 
For  the  incubation  of  the  SH-SY5Y-APP695  cells  with  MVA-pathway  inhibitors,  it  was 
necessary to exchange the FCS containing DMEM medium with serum free OptiMem medium 
(see section 2.6.4.). The cells are capable to circumvent reduced intracellular cholesterol levels, 
caused by inhibitors targeting the mevalonate (MVA-) pathway, by the uptake of cholesterol 
from the normal DMEM medium. 
The selected inhibitors are listed in section 2.6.4. and the different targets within the MVA-
pathway  are  shown  in  Figure  41.  The  following  table  (Table  5)  gives  an  overview  of  the 
conditions for applied incubation protocols. Conditions were adapted from former studies in our 
working group.
238,270 Solvent controls were always performed. 
Inhibitor  Incubation time / conditions 
Lovastatin  24 h / 5 µM 
FTi 277  24 h / 1 µM at the following time points: 0, 5, 10, 15, 20 h 
GGTi 286  24 h / 1 µM at the following time points: 0, 5, 10, 15, 20 h 
U 18666A  24 h / 1 µM 
 
Tab. 5. Respective in vitro incubation conditions for each inhibitor applied in the cell experiments with 
human SY5Y cells.   71 
3.7. Western Blot analysis 
3.7.1. Sample preparation 
Aliquots  of  the  homogenate  from  either  tissue  or  cell  experiments  were  protected  against 
endogenous proteases by the addition of 10 µL á 500 µL sample from a 1 mL (volume for 1 
tablet) stock solution of Complete
® protease inhibitor. Total protein was determined using the 
BCA method (see section 3.8.). All samples for one run were diluted to maintain the same protein 
concentration in the same total volume by the addition of buffer II. Subsequently sample buffer 
(10 x) and reducing agent (4 x) were added and the samples incubated for 10 min at 90 °C. After 
centrifugation (9000 x g; 2 min; RT) each sample was loaded on the gel. Depending on the 
matrix and antibody between 30 and 80 µg of protein were separated per lane. 
 
3.7.2. Electrophoreses and transfer 
Electrophoretic  separation  of  the  samples  and  the  molecular  weight  marker  (Precision  Plus, 
WesternC
TM, protein standard) was achieved using a XCell II
TM Blot Modul with a Bio Rad 
Power Pac 300 and the following settings: 8 min at 60 volts to collected the samples in the gel 
pockets followed by 190 volts for 40  min. The protein transfer was  carried out using either 
polyvinylidene fluoride (PVDF) or nitrocellulose (NC) as the blotting membrane. The PVDF 
membranes were activated in methanol for 5 min before being transferred into transfer buffer for 
another 20 min. As for the NC membranes water was used instead of methanol. Using the above 
mentioned Blot module proteins were transferred from the gel to the membrane according to the 
manufacturers´ instructions at 30 volts for 2 hours. 
 
3.7.3. Blot processing 
To  avoid  unspecific  binding  of  the  applied  antibody,  as  described  in  the  following,  the 
membranes were incubated with 7.5% fat free dry milk in TBST for 30 min at RT and washed 
with  water  before  the  antibody  was  applied.  Depending  on  the  primary  antibody  blots  were 
incubated with the antibody solution under constant shaking for 2 h at RT or at 4 °C over night. 
Further processing was achieved by using the SNAP i.d protein detection system from Millipore. 
Membranes  were  washed  with  six  10  mL  aliquots  of  TBST.  Subsequently  membranes  were 
incubated for 10 min with 3 mL of the secondary antibody solution. After 10 min the washing 
procedure was repeated as described above.   72 
For final detection the Thermo Fisher Super Signal
® West Femto reagents were used. An aliquot 
of  500  µL  of  both  solutions  were  combined  with  500  µL  of  TBST  prior  incubation  of  the 
membrane  for  5  min  in the  dark.  Bands were  detected  and  analyzed  with  the  Quantity  One 
software, in a Bio-Rad Universal Hood II equipped with a Photometrics Cascade: 1K camera. 
 
3.8. BCA protein determination 
Total protein amounts were determined using the BCA protein assay from Thermo Scientific. 
The assay was conducted in a 96-well plate format. Samples were diluted to an estimated protein 
concentration between 100 and 1000 µg/mL. Prior to the addition of the samples on the plate, 
Reagent A and B were mixed in a 50 : 1 (v/v) ratio. Furthermore, the BSA standard was prepared 
in  the  following  concentrations: 0.1,  0.2,  0.33,  0.5  and  1  mg/mL.  Depending  on  the sample 
volume, 10 or 25 µL standards were prepared and pipetted into the wells, 200 µL of the reagent 
A/B mixture was added and the plate incubated for 30 min at 37 °C. All values were measured in 
triplicates with the ELISA reader at 570 nm. The correlation coefficients (r
2) were > 0.99.  
 
3.9. Total cholesterol determination 
Total  cholesterol  levels  were  determined  using  the  CHOD-PAP-method  (cholesterol  oxidase 
peroxidase 4-aminophenazone phenol method). Cholesterol Preciset standards were used in 50, 
100, 200, 300 and 400 mg/dL (~ 1.29, 2.59, 5.17, 7.76 and 10.35 mmol/L). All samples and 
standards  were  measured  in  triplicates  on  a  96-well  plate.  To  enhance  solubilization  of  the 
cholesterol from the matrix, 10 µL of the sample/standard were incubated on the 96-well plate 
with 5 µL of the Brij35-solution (15% Brij35 in buffer III). After 15 min incubation time, 200 µL 
of the Roche cholesterol kit solution (section 2.3.) were added, followed by another 60 min of 
incubation time at RT. The photometric measurement was performed using an ELISA reader at 
490 nm. All sample values were normalized to total protein. 
 
3.10. Brain preparations 
3.10.1. Crude fraction 
The protocol for the purification of the crude membranes from brain tissue was adapted from 
Eckert et al. and modified for smaller tissue samples.
318 Frozen tissue was homogenized in 7.5   73 
mL of buffer III (4 °C) using a rotor stator homogenizer at 1100 rpm. Pistil and glass vial were 
washed with 3 mL buffer III and solutions were combined prior centrifugation (48.000 x g; 20 
min; 4 °C). The samples were kept at 4 °C at all times. The supernatant was discarded and the 
resulting  pellet  was  re-dissolved  in  10  mL  buffer  III  (4  °C).  The  resulting  suspension  was 
homogenized using an Ultra Turrax at 13.500 rpm for 15 seconds. Subsequently the solution was 
centrifuged again with the aforementioned conditions. The resulting pellet was used for protein 
and cholesterol determinations.  
 
3.10.2. Sub-cellular membranes 
The protocol for the preparation of SPMs was adapted from Eckert et al. and was applied for 
either for whole mouse brains or single hemispheres (~200 – 400 mg ww).
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Frozen brain tissue was homogenized in 5 mL buffer VI using a rotor-stator homogenizer at 1100 
rpm. Pistil and glass vial were rinsed with 2 mL buffer VI and solutions were combined prior to 
centrifugation (585 x g; 10 min; 4 °C). The pellet was discarded and the supernatant centrifuged 
at 17.400 x g for 20 min at 4 °C to remove heavy myelin and cell fragments. The resulting 
supernatant  was  either  used  for  the  preparation  of  brain  peroxisomes  (supernantant  A  –  for 
further processing see section 3.10.3.) or centrifuged again under the same conditions. In case of 
the latter the pellets from both centrifugations were homogenized in 1.5 and 0.5 mL buffer V, 
respectively  with  an  Ultra  Turrax  at  13.500  rpm  for  15  s.  The  resulting  suspension  was 
transferred into an ultracentrifuge 15 mL Beckmann plastic tube followed by the injection of 3 
mL gradient (via syringe) to form the bottom layer in the tube. Subsequently, 5 mL of gradient 2 
were  carefully  layered  to  the  bottom  of  the  tube.  The  following  centrifugation  step,  in  an 
ultracentrifuge (87.300 x g; 60 min; 4 °C) yielded a protein layer between gradient 1 and 2 which 
was  removed  with  a  syringe  and  diluted  (1:3)  with  buffer  V.  To  further  clean  up  the 
synaptosomes the suspension was subjected to centrifugation (14.600 x g; 20 min; 4 °C) and the 
pellet used for further processing by re-suspension in 2 mL buffer IV followed by another 5 mL 
buffer IV. The solution was kept on ice for one hour and shaken vigorously every 20 min to lyse 
the synaptosomes. Following the next centrifugation step (43.000 x g; 20 min; 4 °C) the pellet 
was re-suspended in 3 mL of water (4 °C), transferred to a ultracentrifuge tube and 3 mL gradient 
3 were underlayed with a syringe to build the bottom layer. After ultracentrifugation (41.000 x g; 
45 min; 4 °C) the top aqueous layer with the SPMs was removed and transferred into a centrifuge   74 
tube while diluting it with 5 mL water (4 °C). The final centrifugation step (43.000 x g; 30 min; 4 
°C) yielded the SPM pellet which was re-suspended in 1 mL buffer 1.  
 
3.10.3. Peroxisomes preparation 
For the preparation of the peroximsomes, the supernatant A from the preparation protocol of the 
SPMs (see section 3.10.2) was used and transferred into an ultracentrifuge tube. The solution was 
centrifuged  (154.000  x  g; 1.5  h;  4  °C)  in  an  ultracentrifuge  and  the  resulting  pellet  was  re-
suspended in 200 µL buffer VIII and stored at -80 °C prior to protein determination via BCA and 
activity measurements (see section 3.10.4.). 
 
3.10.4. HMG-CoA reductase activity measurements 
The HMG-CoA reductase activity assay was conducted with brain peroxisomes obtained from 
brains of the AD brain investigation (see section 3.11.1.3.). Activity of the HMG-CoA reductase 
was determined according to a modified protocol by Edwards et al. 1979.
319 Briefly, 200 µL of 
the  re-suspended  pellet  was  incubated  together  with  200  µL  buffer  IX,  10  µL  glucose-6-
phosphate dehydrogenase (2.2 units) and 90 µL HMG-CoA (containing 150 nmol 
14C with an 
activity of 0.34 Ci/mol, equal to 12.6 GBq) in a tempered water bath at 37 °C for one hour. The 
reaction was stopped by the addition of 30 µL KOH. The solution was further maintained at 37 
°C for 30 min, to which 25 µl of bromphenol blue and 65 µL HCl (5N) were then added; the 
solution  was  incubated  for  approximately  1  h  (37  °C),  until  a  yellow  color  was  apparent. 
Subsequently,  this  solution  was  centrifuged  (10.060  x  g;  3  min;  RT)  and  the  supernatant 
transferred to an ion exchange column. Elution was performed with 3.4 mL of water, whereas the 
first 0.9 mL of the eluate was discarded and the remaining 2.5 mL were combined with 2.5 mL 
scintillation cocktail, vortexed and radioactivity was  measured via scintillation counting. The 
determined counts per minute (cpm) were re-calculated to the according protein values of the 
applied samples and declared in enzyme activity / mg protein / minute.  
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3.11. Tissue samples 
3.11.1. Human brain samples 
Human brain tissue samples were obtained from the Human Brain and Spinal Fluid Resource 
Centre (HBSFRC, LA, USA).  
HBSFRC post mortem samples were prepared according to the brain bank protocols, provided on 
their  homepage  [http://www.loni.ucla.edu/uclabrainbank/index.html],  shipped  on  dry  ice  and 
stored at – 80 °C prior analysis. For tissue preparation prior analysis specific areas of the brain 
slices were cut on ice at 4 °C, followed by homogenization (as described in section 3.5.1.1.). 
 
3.11.1.1. White and grey matter brain study 
Frontal cortex brain slices from 5 different, neurological healthy donors (see relevant patient 
information in Table 7) were prepared and ~ 250 mg pieces of frozen white and grey matter were 
cut from each brain prior to homogenization. Besides visual differentiation (see Figure 4) into 
both areas an additional WB analysis was performed using NeuN as a neuronal marker for grey 
matter brain areas. 
 
 
Fig. 4. Frozen tissue section (~2 x 2 cm) 
of  human  frontal  cortex  for  the 
visual  differentiation  of  white 
and  grey  matter  prior  the 
preparation. 
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3.11.1.2. Human brain study – analytical correlation 
Post-mortem human brain samples from the cerebral cortex of each hemisphere of patients, who 
died of brain cancer were used to correlate measurements on the HPLC-FLD and the UHPLC-
MS/MS system. All samples were obtained from the HBSFRC and a report including relevant 
patient information on disease progression, age,  gender etc. can be found in Table 6. Tissue 
preparation of brain white matter samples was conducted upon visual differentiation.  
 
  Left and right hemisphere (n = 7) 
Demographic     
Age at death (years)  70 ± 9 
Gender  3 female, 4 male 
     
Histological     
Post mortem interval (h)  13.19 ± 2.69 
Brain hemisphere (left:right)  1:6 
WHO grade   6 times IV, 1 w/o classification 
 
Tab.  6.  Patient  information  of  post  mortem  brain  samples.  At  autopsy,  brains  were  cut  into 
coronal sections and a sample from each hemisphere was freshly frozen and stored at −80 
°C. Glioblastoma multiforme (GBM) was the cause of death regarding this sample set 
and individual cancer progression was classified according to the WHO classification of 
tumors (I – IV) of the central nervous system.
320 Means ± SD. 
 
 
3.11.1.3. Alzheimer’s Disease brain study 
Post-mortem brain samples from the frontal cortex of Alzheimer’s Disease (AD) patients were 
compared to age-matched controls. All samples were obtained from the HBSFRC and a report 
including relevant patient information on disease progression, age, gender etc. can be found in 
Table 7. A careful separation of white and grey matter was conducted upon visual differentiation. 
Additional samples were collected for the HMG-CoA reductase assay and PCR analysis. 
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  Control (n = 13)  Alzheimer (n = 13)  P value 
Demographic       
Age at death (years)  77.8 ± 3.5  80.4 ± 4.8  0.133 
Gender  13 male  13 male   
       
Histological       
Post mortem interval (h)  15.0 ± 4.4  16.5 ± 5.0  0.433 
Brain hemisphere (left:right)  0:13  3:10   
Braak – Stage (I-VI)  -  5.1 ± 0.7   
 
Tab. 7. Patient information of post mortem samples. At autopsy, brains were cut into coronal sections (2-4) and a 
sample of frontal cortex tissue of each sample was freshly frozen and stored at −80 °C. Patients were 
classified as AD or control (neurological healthy) cases according to the Consortium to Establish a Registry 
for Alzheimer's Disease (CERAD). CERAD have developed standardized instruments for the evaluation of 
individuals clinically diagnosed with AD.
321 Means ± SD. 
 
3.11.2. Mouse brain tissue 
All mice were maintained on a 12-h dark–light cycle at constant air temperature of 25 °C and 
with pelleted chow and tap water ad libitum. Animals were kept in separate groups of maximum 
10 animals per cage according to their sex and age. All experiments were carried out according to 
the European Communities Council Directive (86/609/EEC)
322, after appropriate training of the 
personnel.  Animal  numbers  were  chosen  according  to  the  study  design  and  statistical 
requirements. At the end of the study, animals were euthanized by cervical displacement 2 h after 
the  last  drug  treatment.  The  cerebrum  was  removed  and  immediately  snap  frozen  in  liquid 
nitrogen, and stored at -80 °C prior to isolation and analysis. 
 
3.11.2.1. Mouse strains 
 
Three different mouse strains were used for the current work. All animals were kept under the 
conditions described in section 3.11.2. 
C57Bl/6 mouse (♂ + ♀) 
The C57Bl/6 mouse represents a multipurpose, easy to handle inbred mouse model 
widely used in research laboratories. Genetic modifications serve as models for 
human diseases.    78 
Thy-1-APP transgenic mouse (♀) 
The  Thy-1 APP  mice  represent  a  C57Bl/6 transgenic  mouse  model  possessing 
both the Swedish double and the London mutation. The human APP expression 
with both mutations is controlled by the murine Thy-1 promoter leading to a high 
and  selective  expression  in  neurons  and  consequently  an  accelerated  plaque 
formation, becoming visible at an age of approximately 6 month.
323 
Mice used for the experiments described in the current work were of ~ 12 month 
of age. 
 
3.11.2.2. Aging Study 
Female and male C57Bl/6 mice were obtained in three different age-groups, young (3 month), 
middle-aged (12 month) and aged (24 month) from Janvier, France. The mice were kept for one 
week under the new conditions of the breeding facility prior to cervical displacement. 
 
3.11.2.3. Sub-chronic simvastatin treatment study 
The subchronic treatment study was conducted with simvastatin. The drug suspension (verum 
group) was prepared daily in 0.2% (w/v) aqueous agar gel at a final concentration of 10 mg/mL. 
Female  C57Bl/6  mice  (~3  month  of  age)  received  vehicle  (control  group)  or  50  mg 
simvastatin/kg body weight daily for 21 days. The drug or vehicle solution was applied by oral 
gavage with a maximal dosing volume of 0.5 mL. 
 
3.11.3. Pig brain tissue 
Pig brain was used to partly during the method development (indicated in text) and to generate 
calibration curves for the evaluation of mouse brain data. This brain matrix was chosen to avoid 
sacrificing additional mice to generate data for technical samples, such as calibration standards. 
For tissue preparation frontal cortex samples were cut and homogenized (as described in section 
3.5.1.1). 
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4. RESULTS 
4.1. Method development 
A  systematic  approach  for  the  isolation  and  subsequent  quantification  of  farnesyl-  and 
geranylgeranylpyrophosphate  (FPP  and  GGPP)  in  human  brain  tissue  is  described  in  the 
following. The step-by-step procedure includes the optimization of the enzymatic attachment of 
fluorescence tags to each analyte, the optimization of a HPLC method, including the introduction 
of  an  internal  standard  and  the  novel  development  of  the  simultaneous  extraction  of  both 
isoprenoids from brain matrix. 
 
4.1.1. HPLC method development 
4.1.1.1. Background 
The chemical structures of the two isoprenoids FPP and GGPP (see Figure 5) do not possess a 
distinct chemical group which would allow for a straightforward and accessible analysis via most 
commonly used HPLC detectors like ultraviolet light (UV), diode array detector (DAD) or via a 
mass  spectrometer  (MS).  The  enzymatic  linkage  via  the  farnesyl-geranylgeranyl  assay  (F-G-
Assay) of either analyte to its respective dansyl-label enables the detection using a fluorescence 
detector (FLD), which was previously described by Tong and colleagues.
94 The dansyl-labeled 
FPP and GGPP are referred to as FPP* and GGPP* throughout the entire work (see Figure 5). 
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Fig. 5. Pre-column derivatization of FPP (n=2) and GGPP (n=3) to their specific dansyl 
labelled  pentapeptide  (R=  -hydroxyl  for  D*GCVLS  and  R=  -isopropyl  for 
D*GCVLL) by specifically FTase or GGTase I. Enzymatic reaction occurs under 
hydrogen sulphide (H2S) and diphophate (-PP) cleavage. Analytes detected after 
separation are FPP* (=F-D*GCVLS) and GGPP* (=GG-D*GCVLL). 
 
4.1.1.2. Chromatographic conditions 
Throughout the developmental stage of the F-G-Assay and the subsequent development of the 
isolation  method,  various  solvent  compositions,  flow  rates,  columns,  oven  temperatures  and 
analytical columns and combinations thereof were tested. Note: only experimental conditions 
which led to significant improvements of the method are mentioned in the following text. 
The initial aim was to establish an analytical method for the separation and detection of both 
analytes (FFP* and GGPP*) after the F-G-Assay. For this purpose isoprenoid standards were 
applied in varying concentrations to the assay. The described assay conditions for the enzymatic 
pre-column derivatization (F-G-Assay) and the  following HPLC-FLD detection were initially 
adapted and subsequently optimized (see section 3.1.). Firstly, various RP18 columns were tested 
under slightly varying HPLC conditions, with regards to flow rate and solvent composition in an 
isocratic or gradient elution. The most promising results were initially achieved with a Zorbax 
SB-C18 column. For each test run an F-G-Assay was prepared and the resulting solution was   81 
injected into the HPLC system. Detailed settings of the system and conditions are summarized in 
Table 8. 
Further optimization of the method, in terms of peak shape, could be achieved using a column 
with Fused Core
TM technology (further details in section 4.1.3.). 
 
4.1.1.3. Detector settings 
Due to possible differences in solvent composition, eluting time and especially differences in the 
detector  brand,  it  was  necessary  to  adjust  the  FLD  excitation  and  emission  wavelengths. 
Measurements  have  to  be  performed  with  the  detector  set  at  the  peak  maximum  for  both 
wavelengths  to  obtain  reproducible  results.  This  was  achieved  by  using  identical  injection 
volumes from the same HPLC vial for the analytical runs. Firstly, the excitation wavelength was 
gradually increased in 5 nm steps in the range of 320 to 355 nm. The maximum was determined 
to be 340 nm, which was used for the following emission wavelength scan. An emission scan 
from 500-540 nm indicated a maximum peak at 525 nm. 
 
column  Zorbax SB-C18 (150 x 2.1 mm, 5 µm) 
Gradient  see section 3.4.1. 
flow rate  700 µL/min 
oven temperature  20 °C 
run time  23 min 
FLD settings (excitation/emission wavelength)  340 / 525 nm 
retention times (FPP/GGPP)  4.9 / 14.4 min  
 
Tab. 8. Chromatographic conditions and fluorescence detector settings on the Jasco HPLC system with the Zorbax 
C18 column, adapted from Tong et al.
94 
 
4.1.2. Assay optimization 
The conditions for the enzymatic reaction (F-G-Assay) described by Tong et al.
94 were adjusted 
and optimized. The following results were assessed by comparison of peak areas of each analyte 
after chromatographic separation and fluorescence detection. 
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4.1.2.1. Incubation settings 
In the first set of experiments incubation protocol I was compared to incubation protocol II (see 
section  3.1.1.).  Both  incubation  methods  were  carried  out  at  37  °C  for  120  minutes.  No 
differences were observed between both conditions and thus the thermomixer was favored due to 
easy handling. 
Furthermore the incubation time for each enzymatic reaction was tested. In order to determine the 
time dependant conversion of both isoprenoids to their respecitve dansyl-labeled products, eight 
individual assays were prepared and the reactions were terminated at different time points. As 
depicted in Fig 6 a and b, complete conversion was achieved with an incubation time of 60 
minutes. An additional 30 minutes were allowed to guarantee the reaction reached the plateau 
phase; hence a maximum incubation period of 90 minutes was selected for all experiments.  
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Fig. 6. Time dependant isoprenoid conversion by either transferase to their respective dansyl-labeled penta-peptide. 
Product enrichment (a) FPP* and (b) GGPP* at each time point was monitored by the FLD after HPLC 
separation. Peak areas are shown in µV. 
 
4.1.2.2. Enzyme concentration, specificity and linearity 
The amount of each enzyme needed for sufficient conversion of either isoprenoid to its dansyl-
label was tested (data not shown). The optimal total amount of FTase and GGTase was found to 
be 250 ng/µL, respectively.  
 
Furthermore, enzyme specificity was tested and each enzyme was incubated with combinations 
of  FPP and GGPP (500 ng/ml,  resp.) and the according dansyl labels. Of the eight possible 
combinations only the combinations of FPtase, FPP and dansyl-GCVLS and of GGPtase, GGPP 
and dansyl-GCVLL showed detectable peaks.    83 
 
To further demonstrate linearity of the calibration curves both isoprenoids, FPP and GGPP, were 
individually  added  to  the  assay  containing  the  respective  enzyme,  at  the  pre-determined 
concentration. The 5-point calibration curves were carried out in a range of 4-500 ng/mL and 
showed a minimum correlation of r
2 = 0.999 for both isoprenoids (see Figure 7 a and b). An 
exemplified chromatogram (Figure 7 c) shows the clear separation of the analyte. 
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Fig. 7. (a and b) Five-point calibration curves (5 – 500 ng/mL) of FPP* and GGPP* after pre-
column derivatization. The respective r
2-values are given in the graph. (c) Representative 
chromatogram of pure standard solutions after pre-column derivatization.   
 
4.1.3. Implementation of a Fused Core
TM RP18 column  
The  initial  HPLC  and  F-G-Assay  conditions  were  tested  using  the  Zorbax  SB-C18  column. 
Subsequent  to  these  tests,  further  improvement  of  the  method  was  achieved  by  the 
implementation of a rather novel column technology. The Ascentis
® Express column, utilizing 
Fused Core
TM technology was tested, which resulted in improved peak shapes and consequently, 
lower limits of detection (LODs).    84 
The chromatograms in Fig 8 show a 2-step method transfer to the new column. The first step 
involved the replacement of the column and a reduction in the flow rate to 400 µL/min while the 
gradient remained constant (Figure 8 b). The second step was an  adjustment of the  gradient 
(Figure 8 c) (note: the injection volume was different for this run). The resulting enhanced peak 
width led to a 4-fold decrease in the LOD (see Table 9). During this transfer it became also 
obvious that a dansyl-labeled phospholipid, which was tested as an internal standard (IS) at that 
time (see also Figure 8) showed two baseline separated peaks (see chromatogram b at Rt= ~12 
minutes) instead of one shown in the upper chromatogram at 7 minutes. This separation further 
points out the resolving capability of the newly applied column. 
 
  Zorbax SB-C18  Ascentis
® Express 
Settings     
Flow   0.7 mL/min  0.4 mL/min 
Gradient  time [min]  Solvent B [%]  time [min]  Solvent B [%] 
  0    ￿ 1.5   20  0    ￿ 1.5   35 
  1.5 ￿ 4  20 ￿ 55  1.5 ￿ 8  35   ￿ 100 
  4    ￿ 15  55  8    ￿ 14  100 
  15  ￿ 18  55 ￿ 20  14  ￿ 16  100 ￿ 35 
  18  ￿ 23  20  16  ￿ 20  35 
Run time   23 min  20 min 
     
Peak parameters  FPP* / GGPP*  FPP* / GGPP* 
Rt [min]  4.9 / 14.4  4.7 / 11.9 
LOD [ng/mL]  2 / 2  0.5 / 0.5 
Tailing factor  ~ 1.4 / 1.7  ~ 1.4 / 1.6 
FWHM [min]  ~ 0.45 / 0.7  ~ 0.23 / 0.33 
 
Tab. 9. A direct comparison of the HPLC settings using the Zorbax RP18 column compared to the Ascentis
® 
Express analytical column. For both optimized methods flow rate, gradient conditions and total run time 
are described in the table. The lower part of the table describes the improvements in peak performance, 
including retention time (Rt), limit of detection (LOD), the tailing factor for peak symmetry and the peak 
width, depicted as full width at half maximum (FWHM). 
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Fig. 8. Exemplified chromatograms for the method transfer from the (a) Zorbax RP18 column to the (b and 
c) Ascentis
® Express column in two steps. Designated are the two analytes FPP* and GGPP* and the 
IS, showing two baseline separated peaks on the Ascentis
® Express column. The chromatogram in 
(c) shows the optimized peak performance compared to chromatogram displayed in (a). 
 
 
Lastly, a chromatographic overlay (Figure 9) on a different HPLC system (Hitachi HPLC system) 
clearly demonstrated the superiority of the Ascentis
® Express column in respect to peak width 
and shape.  
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Fig. 9. Chromatographic overlay of two runs on the same HPLC system 
(Hitachi)  injecting  the  same  solution  with  the  same  injection 
volume. Grey trace shows the run on the Zorbax RP18 and the 
black trace on the Ascentis
® Express column at same flow rates. 
FPP* and GGPP* are designated in both chromatograms.   86 
4.1.4. FPP and GGPP extraction from brain matrix  
Throughout  the  developmental  phase  of  the  isolation  method  for  FPP  and  GGPP  initial 
experiments for a specific type or combination of an extraction method were mostly conducted 
using spiked (FPP and GGPP were added in high concentrations, between 500 and 1000 ng/mL) 
water samples. All results were evaluated via HPLC fluorescence detection of FPP* and GGPP* 
following the pre-column F-G-Assay of the dried residues. Selected conditions were applied to 
matrix samples from either human, mouse (C57Bl/6) or pig brain and SY5Y cells. The applied 
matrix is indicated throughout the text.    
 
4.1.4.1. Liquid/liquid extractions (LLE) 
Tong and colleagues described a liquid/liquid extraction (LLE) for the isoprenoid extraction from 
cells.
94 As a straight-forward attempt this extraction procedure was applied to spiked brain matrix 
samples. Despite using very small amounts of tissue, between 10 and 30 mg of mouse brain 
homogenate,  this  isolation  technique  (see  section  3.3.4.)  resulted  in  rather  impure  extracts, 
containing  relatively  large  amounts  of  un-precipitated  protein.  Consequently,  the  following 
enzymatic pre-column derivatization was employed and the resulting solution analyzed with the 
optimized HPLC-FLD method. No peaks were detectable at the respective retention times (Rt) of 
each analyte.  
Based on these findings the initial experiments aimed to provide cleaner extracts by means of an 
extraction  via  a  two  phase  hydrophilic-lipophilic  system  or  the  usage  of  different  organic 
solvents.  
 
4.1.4.1.1. LLE using a 2-phase system 
A screening for solvents was conducted to determine the best conditions for the LLE. Based on 
the chemical properties of the isoprenoids with a hydrophilic head group attached to a lipophilic 
chain, initial extraction solvents consisted of an organic solvent and water, generating a 2-phase 
LLE system. 1-butanol, diethyl ether, petroleum ether, diisopropyl ether and ethyl acetate were 
chosen. A typical work-up of the samples was as follows: 1 mL of spiked water samples were 
extracted twice for 15 minutes with 1 mL of the according solvent after which the organic phases 
were combined and dried under reduced pressure. The dried residue was subjected to the F-G-
Assay followed by HPLC-FLD analysis. Petroleum ether itself resulted in impurities in the F-G-  87 
Assay impeding the enzymatic reaction and no signal of the analytes was detected after HPLC 
separation; the isolation via diethyl- and diisopropyl ether and ethyl acetate also showed no signal 
of the analytes. 1-butanol however, was an effective extracting solvent but led to lower peak 
intensities, as compared to the isolation method used by Tong et al.
94 
 
4.1.4.1.2. LLE using a 1-butanol solution 
Bruenger and Rilling
92 and later Tong et al.
94, used a 1-butanol based extraction solvent. On the 
basis  of  the  preliminary  results  as  described  under  section  4.1.4.1.  these  two  methods  were 
compared for the isoprenoid extraction from spiked mouse brain samples. For this purpose a 
mouse cerebrum was homogenized in 3 mL Buffer II and divided in 3 x 1 mL aliquots. One 
sample was processed as described in section 4.1.4.1 and the other two aliquots were processed 
as  followed.  NH4OH  solution  was  added  to  the  mixture  resulting  in  a  150  mM  ammoniac 
solution. Subsequently, 1.2 mL 1-butanol saturated with water was added and each mixture was 
immediately homogenized using an ultraturax for 1 minute. Following centrifugation (20.000 x g; 
5 min; RT) the upper, butanol layer was removed and retained. The extraction was repeated and 
the supernatants were combined and dried under reduced pressure. 
All  three  extractions  led  to  a  high  degree  of  impurities  in  the  following  F-G-Assay,  which 
completely inhibited the enzymatic reaction.  
 
4.1.4.1.3. LLE using different organic solvents 
The results from the solvent screening described under section 4.1.4.1.1., in addition to the fact 
that the isoprenoids are provided by the distributor in an ammoniac solution and that previous 
work conducted by Tong et al.
94 as well as by Bruenger and Rilling
92 described the utilization of 
an ammoniac solvent, demonstrated the necessity of incorporating NH4OH into the mixture.  
The following set of experiments evaluated the extraction power, the influence of protein in the 
matrix and the stability of the isoprenoids using SY5Y cells. To further evaluate these results 
with  respect  to  overall  recovery,  a  standard  F-G-Assay  was  used  as  a  reference.  The  first 
experiment aimed to generate a cleaner extract using an ammoniac n–hexane/isopropanol mixture 
(Elution mix 2) instead of a 1-butanol/methanol mixture (Elution mix 3= equals the mixture used 
by Tong et al.
94) to generate an ammoniac two phase system. Therefore, the Elution mix 3 was 
compared to extractions using Elution mix 2 and an ammoniac diethyl ether solution. Table 10   88 
shows the conditions and the relative FLD response (peak areas) for FPP* and GGPP* compared 
to  the  F-G-Assay.  The  results  indicate  a  similar  extraction  power  of  the  Elution  mix  2  as 
compared  to  the  Elution  mix  3.  The  ether  based  extraction  was  unsatisfactory,  although  in 
comparison  to  the  pure  ether  (section  4.1.4.1.1.)  the  mixture  including  NH4OH  showed 
improvements. Under non-alkaline conditions no peaks were detectable. In general, this result 
showed no improvement over the previously published extraction method using cell matrix and 
was therefore not further investigated. Nevertheless, the enhanced solubility of the isoprenoids in 
Elution mixture 2 was used for the subsequent SPE applications (section 4.1.4.3.).   
 
Extracting 
solvent 
Elution mix 2  Elution mix 3  Dieethylether/NH4OH 
(95:5 v/v) 
Protocol 
section 3.3.4.  section 3.3.4. 
- addition of solvent 
- 3 min sonification 
- 10 min shaking at RT 
￿ centrifugation  
(3000 x g; 10 min; RT)  
Recovery [%]       
FPP   62.9  70.5  13.0 
GGPP  46.0  62.9  24.3 
 
Tab. 10. A direct comparison of three different protocols using different organic solvents. Elution efficiency was 
assessed by relative recovery compared to a standard F-G-Assay. 
 
4.1.4.2. Matrix assisted LLE (Extrelut
®) 
The  preliminary  results  obtained  from  the  development  of  the  method  described  in  section 
4.1.4.1.2. indicated the need for a cleaner extraction procedure leading to pure extracts. Isolations 
using Extrelut
® columns represents a common approach for the extraction, e.g. of drugs from 
body fluids.
324 The diatomaceous earth filling of the columns absorbs proteins and contaminants 
retaining drugs or metabolites for the subsequent organic elution. Hence the suitability of this 
technique for the current method was tested using mouse brain as biological matrix. Following 
the  generic  protocol  (section  3.3.2.1.)  for  Extrelut
®,
  samples  were  added  to  the  column  and 
incubated for 15 minutes prior to elution. Four combinations of eluent solvents were tested, as 
summarized in Table 11. The chromatograms (data not shown) displayed a significant injection   89 
peak, at a retention time similar to that of FPP, interfering considerably with the detection of 
FPP; this was due to impurities in the samples. Only the Elution mix 3 and the basic alkaline 
MeOH/CH3CN/acetone  mixture  resulted  in  detectable  peaks  of  GGPP  but  with  very  low 
intensities  (Figure  10).  Overall,  the  chromatograms  showed  high  background  noise  due  to 
impurities.   
 
Eluting 
solvent 
THF/ethyl acetate/n-
henxane/2-propanol 
(160:160:160:15 v/v/v/v) 
Elution 
mix 3 
Ethyl 
acetate 
MeOH/NH4OH 
/CH3CN/acetone 
(40:65:30:30 
v/v/v/v) 
Protocol  15 min incubation 
   
Peak detection         
FPP   -  -  -  - 
GGPP  -  +  -  + 
 
Tab.  11.  A  direct  comparison  of four  different  organic solvents mixtures  for the  elution  from the Extrelut
® 
columns. Feasibility of the protocol was judged by the detection of a peak after enzymatic conversion. + 
stands for a detection of a peak at the respective Rt. - stands for the absence of an assignable peak at the 
respective Rt.  
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Fig.  10.  Chromatograms  after  elution  with  (a)  Elution  mix  3  and  (b)  the  basic  alkaline 
MeOH/CH3CN/acetone mixture (see Table 11), resulting in detectable peaks of only GGPP*. 
Chromatograms show a high background noise within the first 8 – 9 minutes. Chromatograms 
are cut off after 15 minutes to highlight the impurities coming of the column after sample 
injection.  
 
 
4.1.4.3. Solid phase extraction (SPE) 
Prior experiments using liquid/liquid based extractions (sections 4.1.4.1. and 4.1.4.2.) indicated 
proteins  as  a  major  source  of  contamination.  Consequently,  the  development  of  the  current 
extraction procedure included steps for protein precipitation (PPT) in combination with solid 
phase extraction (SPE). 
 
4.1.4.3.1 Comparative SPE extractions in reversed and normal phase mode 
A preliminary experiment was carried out to determine whether FPP and GGPP eluted preferably 
under reversed or normal phase conditions (RP and NP, resp.). Therefore, the isoprenoids were 
dissolved in an organic solvent (n-hexane) and in water. Table 12 summarizes the experimental 
set-up and the final conditions.  
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SPE-phase    DCS-CN    DSC-Si  DSC-diol 
Protocol  [mL]         
Conditioning (C)  1  n-hexane    H2O 
  1  2-propanol    MeOH 
  1  MeOH    1-butanol 
Equilibrating (E)  2  H2O    n-hexane 
Sample (S)  1  spiked H2O    spiked 1-butanol/n-hexane (1:1 v/v) 
         
Elution (Elu)  2  Elution mix 2    MeOH/H2O (1:1 v/v) 
 
Tab. 12. SPE protocols for three different (-CN = cyano, -Si = silanol and diol) SPE cartridges and the applied 
solvents for each step of the protocol (conditioning (C), equilibrating (E), sample loading (S) and elution 
(Elu) step).  
 
 
For  FPP  the  two  NP  extractions  (DSC-Si  and  DSC-diol)  led  to  higher  peak  intensities  as 
compared  to  the  RP  condition  (DSC-CN)  but  revealed  the  opposite  for  GGPP.  Overall,  the 
recovery, as determined by a comparative F-G-Assay, using the same isoprenoid concentrations, 
was low.  
 
4.1.4.3.2. SPE extraction from an organic solvent in reversed phase mode 
The  previous  experiment (section  4.1.4.3.1.)  did  not elucidate the  optimal  conditions for  the 
isolation procedure and therefore modifications of the method were required.  
Table 13 shows the final protocol which was used; n-hexane was selected as the organic solvent. 
Neither test condition resulted in peaks for either isoprenoid. The following experiments were 
conducted under the assumption that the isoprenoids were not retained sufficiently when the 
samples were loaded onto the column. 
The experiment was repeated with the phenomenex X-AW SPEs (Table 13) while the fraction 
form the sample load and the elution step were collected and combined, dried, derivatized and 
measured. However, this did not lead to any significant improvements in the level of detection of 
FPP and GGPP. 
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SPE-phase 
  Oasis 
WAX 
Strata 
X-AW 
DSC-
NH2 
Oasis 
MAX 
Protocol  [mL]         
C   1  H2O 
  1  MeOH 
E   2  n-hexane 
S   1  spiked n-hexane 
     
Elu 1   2  10% MeOH inH2O 
Elu 2   2  2-propanol/MeOH (1:1 v/v) 
 
Tab. 13. SPE protocols for four different (-WAX and –X-AW= weak anion exchanger (two different 
companies), -NH2 = amino and –MAX = strong anion exchanger) SPE cartridges and the 
applied solvents for each step of the protocol (conditioning (C), equilibrating (E), sample 
loading (S) and elution (Elu) step). Two elution steps were conducted separately (Elu 1 and 
Elu 2). 
 
4.1.4.3.3. SPE extraction using anion exchanger cartridges  
Previous experiments tested various anionic stationary phases for their potential to retain the two 
isoprenoids. However, elution with pure organic solvents did not result in a detectable amount of 
the  isoprenoids;  therefore  the  following  set  of  experiments  was  designed  to  determine  the 
influence of the pH of the spiked solution. In the following experiments samples were prepared in 
a range from pH 1-12 (Table 14 and Figure 11). 
As clearly shown in the graph (Figure 11) the acidified spiked water sample (pH 1) led to very 
low intensities of the two isoprenoids. A neutral or basic character of the spiked water resulted in 
improved recoveries in combination with the X-AW and the WAX cartridges. The DSC-NH2 and 
MAX SPEs resulted in poor signals and were consequently excluded from further testing. 
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SPE-phase    Oasis WAX*     Strata X-AW    DSC-NH2    Oasis MAX  
Protocol  [ml]               
C   1  MeOH (2x)    MeOH    MeOH (2x)    MeOH 
  1      CH3CN         
E   2  H2O 
S   1  spiked H2O at pH 1, 6-7 and 12 
     
Wash (W)  1  2% MeOH    2% MeOH    2% FA    5% NH4OH 
                 
Elu 1   1  MeOH    NH4OH/MeOH
/ CH3CN 
(1:7:12 v/v/v) 
  5% NH4OH 
in MeOH 
  2% FA in 
MeOH 
Elu 2   2  5% NH4OH in 
MeOH 
  2% NH4OH in 
CH3CN 
       
    * Generic protocol             
 
Tab. 14. Optimized SPE protocols for four different (-WAX and –X-AW= weak anion exchanger (two different 
companies), -NH2 = amino and –MAX = strong anion exchanger) SPE cartridges and the applied solvents 
for each step of the protocol (conditioning (C), equilibrating (E), sample loading (S), wash (W) and 
elution (Elu) step). Two elution steps were collected separately (Elu 1 and Elu 2). * The Oasis-WAX 
protocol was the generic protocol as recommended by the supplier. For each protocol samples were 
applied at pH 1, 6-7 and 12. 
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Fig. 11. Comparison of peak intensities after (a) elution step 1 and (b) elution step 2 in dependency of the pH of 
the sample solution (see Table 14 for applied conditions).  
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A repetition of the experiments using the generic WAX protocol (Table 14) for both the X-AW 
and WAX cartridges could not reproduce previous findings. The wash step with 2% formic acid 
(FA) was suspected to be the critical step of the applied protocol. Consequently the strata X-AW 
protocol was further developed. 
The following experiments attempted to improve the design of the previously employed protocol 
at a neutral pH. Initially all conditions were kept constant (Table 14) except for modifications of 
the  elution  step.  For  both  protocols  only  one  elution step  was  conducted  and an  acetonitrile 
conditioning step was included; a summary of the adapted conditions and results is shown in 
Table 15. The results show the relative recoveries compared to a standard F-G-Assay with the 
same FPP and GGPP concentrations. In brief, the X-AW cartridges with a 1 mL 2% MeOH wash 
step and the previously used 5% NH4OH solution in MeOH yielded a superior 85% recovery for 
FPP and 75% for GGPP. 
 
Strata X-AW    Protocol 1    Protocol 2 
Protocol  [mL]       
C   1  CH3CN 
  1  MeOH 
E   2  H2O 
S   1  spiked H2O at pH 7 
W   1  2% MeOH 
     
Elu   2  NH4OH/MeOH/ 
CH3CN 
(1:7:12 v/v/v) 
  5% NH4OH in 
MeOH 
Recovery [%]         
FPP     42.5    84.5 
GGPP    11.5    75.1 
 
Tab.  15.  Comparison  of  two  varying  elution  conditions  using  Strata  X-AW  SPE 
cartridges.  Shown  are the  applied  solvents  for  each  step of the protocol 
(conditioning  (C),  equilibrating  (E),  sample  loading  (S),  wash  (W)  and 
elution (Elu) step). Results are shown as relative recovery compared to a 
standard F-G-Assay. 
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4.1.4.3.4. SPE extraction using lipophilic and mixed mode interactions 
The  following  experiment  studied  the  pH  dependency  of  the  spiked  water  samples  with  3 
different stationary phases (Table 16). Acidic (pH 1) and neutral (pH 6-7) conditions were chosen 
for the sample solutions. For all three cartridges the same protocol was followed. The second, 
separately  collected  elution  step  was  conducted  with  an  alkaline  solvent  to  increase  the 
hydrophilic properties of the isoprenoids for a facilitated elution. 
 
SPE-phase    HLB  Strata X  DSC-18 
Protocol  [mL]   
C   2  MeOH 
  2  CH3CN 
E   2  H2O 
S   1  spiked H2O at pH 1 and 6-7 
W   1  2% MeOH 
         
Elu 1   1  MeOH/ CH3CN (3:7 v/v) 
Elu 2   2  NH4OH/MeOH/ CH3CN (1:7:12 v/v/v) 
 
Tab.  16.  Application  of  the  identical  protocol  for  three  different  SPE  phases  (HLB  = 
hydrophilic/lipophilic balance, -X = RP18 phase, DSC-18 = RP18 phase). Shown are the 
applied solvents for each step of the protocol (conditioning (C), equilibrating (E), sample 
loading (S), wash (W) and elution (Elu) step). Two elution steps with different solvent 
compositions were conducted separately (Elu 1 and Elu 2). For each protocol samples were 
applied at pH 1 and 6-7. 
 
 
Figure 12 summarizes the results of the tested mixed mode (HLB) and lipophilic interactions 
based (Strata X and DSC-18) cartridges. The Discovery DCS-18 columns proved to be unsuitable 
under these conditions. The results obtained with the Oasis HLB and Strata X showed good 
intensities for both columns, which was emphasized when both fractions were applied. The latter 
resulted in the highest signals for the extraction using the HLB cartridges, when a neutral solution 
was applied.    
As a result further investigations were undertaken to improve the mixed mode HLB protocol. 
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Fig. 12. Comparison of peak intensities after (a) elution step 1 and (b) elution step 2 in dependency of the pH of 
the sample solution (see Table 16 for applied conditions).  
 
 
4.1.5. Optimization of the HLB protocol 
4.1.5.1. Influence of the elution solvent 
To simplify the 2-step elution method described under section 4.1.4.3.4. the following experiment 
was planned to show the influence of the chemical properties of the eluting mixture. All solvents 
contained the identical concentration of NH4OH, and the organic composition was varied. As 
shown  in  Table  17,  4  different  eluting  solvents  (highlighted  solvents  are  varied) were  tested 
without  further  modification  of  the  protocol.  In  summary,  a  direct  correlation  between  the 
lipophilicity of the organic phase (eluent) and the ability to disrupt lipophilic interactions was 
observed. 
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HLB    Protocol 1    Protocol 2    Protocol 3    Protocol 4 
Protocol  [mL]               
C   1  CH3CN 
  1  MeOH 
E   2  H2O 
S   1  spiked H2O at pH 7 
W   1  2% MeOH 
             
Elu   2  NH4OH/ 
MeOH/ 
CH3CN 
(1:3:16 
v/v/v) 
  NH4OH/ 
MeOH/ 
CH3CN 
(1:7:12 
v/v/v 
  NH4OH/ 
2-propanol/ 
CH3CN 
(1:7:12 
v/v/v) 
  NH4OH/ 
MeOH/ 
acetone 
(1:7:12 
v/v/v) 
Recovery [%]                 
FPP    61.5    63.8    51.3    68.6 
GGPP    23.2    24.2    75.0    82.2 
 
Tab. 17. Optimization of the HLB protocol by varying the elution solvent composition. Shown are the applied 
solvents for each step of the protocol (conditioning (C), equilibrating (E), sample loading (S), wash (W) 
and elution (Elu) step). Results are shown as relative recoveries compared to a standard F-G-Assay. 
 
 
Further modifications were required and implemented as discussed in the following sections.  
From  the  aforementioned  eluting  solvents,  (Table  17)  the  acetone  mixture  was  selected  to 
generate an elution profile by collecting four 1 mL steps and measuring the individual isoprenoid 
concentrations. Table 18 shows the recoveries of the individual elution steps in comparison to a 
standard F-G-Assay.  
 
Elution step  1  2  3  4  Total 
recovery 
FPP recovery [%]  58.6  4.1  1.5  1.1  65.2 
GGPP recovery [%]  56.7  3.5  1.8  1.4  63.4 
 
Tab. 18. Elution profile for Protocol 4 (Table 17) by applying 4 individual 1 mL elution 
steps. Results are shown as relative recovery for each elution step compared to a 
standard F-G-Assay. Total recovery is given as the sum of all 4 steps.   98 
As shown in Table 18 the highest intensity was detected in the 1
st fraction but detectable levels 
were  also  observed  in  the  other  3  fractions.  These  results  indicated  that  the  organic  solvent 
composition was not optimal for a complete elution of the analytes (2 mL collection). It was 
assumed that this specific organic composition lacked the capacity required to completely disrupt 
the  lipophilic  interactions  and  hence  a  mixture  containing  n-hexane  was  employed  in  future 
experiments (section 4.1.5.3.). N-hexane was selected since it has the highest eluting power in a 
RP system. 
The  experimental  setup  previously  employed  was  also  applied  for  the  mixture  containing  n-
hexane. Elution steps were collected in 500 µL increments. The elution profiles show a complete 
elution after 2 mL for FPP and GGPP (Figure 13 a and b). Consequently a 2 mL elution step was 
chosen for further testing.  
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Fig. 13. HLB elution profiles using n-hexane for (a) FPP and (b) GGPP with 0.5 mL elution steps, separately 
collected and measured. Peak areas are given as µV.  
 
4.1.5.2. Wash/elution profiles 
The following experimental procedure addressed the question of the influence of the composition 
of the wash solution on the recovery of the analytes. Commonly used wash solvents for the HLB 
SPE cartridges are water/MeOH or 2% formic acid (FA) mixtures. For the current screening, 
MeOH/water  solutions  in  10%  increments,  in  a  range  from  0-100%  MeOH  were  tested. 
Furthermore, a wash step using 2% FA in water was tested in parallel. All wash steps were 
carried  out  with  2  mL  and  subsequently  the  eluent,  following  the  protocol  mentioned  above 
(section 4.1.5.1.), was collected and measured (Figure 14).   99 
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Fig.  14.  Wash/elution  profiles  for  FPP  and  GGPP  with  increasing  methanol 
concentrations. Elution steps were separately collected and measured. Results 
are shown as relative recovery compared to a standard F-G-Assay. 
 
Figure 14 shows no significant influence of increasing methanol concentrations over the entire 
range from 0 – 100% MeOH. In stark contrast the wash step with 2% FA in water resulted in a 
complete signal loss. 
 
4.1.5.3. Comparison of the HLB and X-AW protocol 
Summarizing the result of the previous screening assays from spiked water samples two methods 
showed feasible results. To further focus the investigations on one single method the following 
two experiments were carried out. In a first step the developed protocol for the strata X-AW 
cartridges  (section  4.1.4.3.3.)  was  compared  with  the  Oasis  HLB  protocol  (section  4.1.5.1.). 
Figure  15  shows  the  results  from  the  direct  comparison  in  relative  recovery  compared  to  a 
standard F-G-Assay. There was a roughly 20% better recovery for FPP with the HLB protocol 
while there was no difference concerning GGPP. 
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Fig. 15. Relative comparison of the FPP and GGPP recoveries of the 
employed X-AW and HLB protocol compared to a standard F-
G-Assay.    100 
Since part of the retention mechanism for the HLB cartridges is based on lipophilic interactions 
the following experiment addressed the question of how a spiked, partly organic sample solution 
would  influence  the  retention  during  the  wash  and  elution  step.  Therefore,  both  steps  were 
collected separately and measured after the enzymatic reaction. The sample solution consisted of 
12.5% ACN based on the following reasons. Common SPE applications are carried out after a 
PPT  step  mostly  using  an  organic  solvent  such  as  ACN.  Relying  on  the  manufacturer’s 
specifications organic concentration in the sample solution should not exceed 12.5%. 
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Fig. 16. Comparison of the optimized X-AW and HLB protocol after the application of a 
sample solution containing 12.5 % ACN. The wash (W) and elution (Elu) step 
were collected and measured separately. Results are shown as relative recovery 
compared to a standard F-G-Assay. 
 
 
Overall the results shown in Figure 16 revealed that the application of a partly organic sample 
solution  hampered  a  sufficient  retention  during  the  wash  step.  Furthermore,  the  additional 
comparison of the X-AW and HLB protocol under these conditions showed a 13% better total 
recovery for FPP and a 9% reduced total recovery for the HLB protocol.  
 
Summarizing and interpreting the results above, the HLB protocol was determined to be the most 
adequate method for use in future experiments employing matrix samples. 
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4.1.6. Employment of the HLB protocol for spiked cell matrix 
4.1.6.1. HLB application with untreated cell homogenate 
Further investigations of the hitherto developed HLB protocol addressed the potential influence 
of  matrix  components  on  the  extraction  and  the  subsequent  detection.  For  this  purpose 
homogenates from SY5Y cells were spiked and used as matrix samples. For the homogenate a 
total of approximately 8 million cells was collected and re-suspended in 1 mL water, spiked with 
FPP and GGPP and sonified. The HLB protocol (section 4.1.5.1.) was applied and the eluate 
processed via the standard protocol. The chromatograms showed very low intensities for both 
peaks, mostly due to a very high degree of impurities after re-uptake of the dried residue for the 
F-G-Assay. 
 
4.1.6.2. HLB application with pre-treated cell matrix 
Two  main  reasons  could  be  accounted  for  the  dramatic  drop  of  signal  intensities  when  the 
unprocessed  cell  homogenate  was extracted (section  4.1.6.1).  Firstly,  under  conditions  which 
allow enzymatic activity of endgogenous phosphatases, in cells or tissue, might cleave off the 
diphosphate of the isoprenoids. Secondly, the cell components, mostly proteins and membrane 
lipids might partly pass the column and hamper the sensitive enzymatic conversion of either 
isoprenoid  to  its  dansyl-label.  Another  possibility  is  that  these  structures  might  bind  the 
isoprenoids and prevent them from being eluted during the SPE extraction. To investigate these 
possible influences the following experiments were conducted: one sample treated with a PPT 
step, one sample mixed with phosphatase inhibitor (PI) from Roche Diagnostics and one sample 
with the PI and the PPT step (Figure 17). The PPT was conducted using 1:1 ACN (maintained at 
-20 °C) and the samples were diluted to 12.5 % ACN in water and during the HLB protocol the 
wash step was omitted. 
The results (Figure 17) clearly demonstrated the inhibitory effect of the PI on the activity of the 
endogenous phosphatases and furthermore underscored the importance of the PPT step. 
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Fig.  17.  Influence  of  the  sample  pre-treatment,  including  protein 
precipitation (PPT) and the employment of a phosphatase 
inhibitor  (PI).  Results  are  shown  as  comparative  peak 
intensities for FPP* and GGPP* deriving from the identical 
spiked concentrations. 
 
4.1.6.3. Influence of phosphatase inhibitors 
The  findings  described  under  section  4.1.6.2  clarified  the  importance  of  the  addition  of  a 
phosphatase inhibitor. Due to their composition different PIs most likely exert varying effects on 
various phosphatases. In regard to the current application it was questioned whether different 
inhibitors have diverse effects in preventing the degradation of either FPP or GGPP, hence a 
series of experiments was conducted to test the commercially available Halt
® PI versus a mixture 
of  NaF/imidazole.  Both  inhibitor  mixtures  were  separately  added  to  cell  homogenates  and 
extracted thereafter. The results are displayed in Figure 18 a and show for the NaF/imidazole 
mixture an equal inhibiting effect on the degradation of FPP like seen with the Halt
® PI. The 
effect on the protection of GGPP is strongly reduced.  
The second set of experiments investigated the already tested Halt
® PI versus the Phosstop
® PI, 
which is also commercially available. The tests were conducted in mouse brain homogenates 
with 3 samples per group (Figure 18 b).  
As shown in Figure 18 b there was a significant difference regarding the potency of each PI. 
These findings strongly support the idea that the Halt
® PI had a stronger effect on preventing the 
degradation of GGPP and the Phosstop
® inhibited phosphatase activity, which led to reduced 
levels of FPP. Since the NaF/immidazole mixture had similar effects on FPP as the Halt
® PI but 
was less effective in preventing the degradation of GGPP further experiments in matrix were 
carried out using a combination of both commercially available PIs (Halt
® and Phosstop
®). 
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Fig. 18. Influence of phosphatase inhibitors on the recovery of FPP and GGPP levels. (a) Comparison of Halt
® 
and a mixture of sodium fluoride and imidazole. (b) Comparison of Phosstop
® and Halt
® phosphatase 
inhibitor (n=3). Means ± SD; *p<0.05.  
 
 
4.1.7. Employment of the HLB protocol with spiked brain matrix samples 
Based  on  the  previous  results,  the  HLB  application  was  tested  on  more  complex  biological 
matrix-brain homogenates. Preliminary tests were conducted with spiked pig brain homogenates 
in buffer II with both PIs (Halt
® and Phosstop
®). The ultimate aim of this set of experiments was 
to determine the best combination of a LLE or a PPT step with the developed HLB protocol. 
Therefore, different approaches were selected, the most relevant of which are listed below: 
 
·  extraction of fatty acid esters 
·  PPT with ACN (section 4.1.6.2.) 
·  LLE as described by Tong et al.
94 
·  LLE as described by Bruenger and Rilling
92 
·  LLE with a NH4OH/MeOH solution combined with an 1-butanol extraction 
 
However, each of the aforementioned set of conditions led to clogging of the HLB column and 
hence early termination or in instances where the protocol could be fully executed, large amounts 
of impurities in the F-G assay, resulted in incomplete enzymatic reaction and hence low levels of 
detection of FPP and GGPP. Consequently, none of the aforementioned protocols will be further 
discussed. 
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4.1.8. Two dimensional clean-up using Extrelut
® and HLB   
Previous test runs (section 4.1.7.) revealed that an isoprenoid isolation from complex matrices 
e.g. brain homogenates, with a single clean up step, using either liquid/liquid based procedures or 
solid phase extraction, did not lead to satisfactory results. Contamination of the extracted samples 
hampered the sensitive enzymatic reactions of the F-G-Assay. The experiment described herein 
presents a combination of the two extraction procedures (two dimensional extraction), Extrelut
® 
and solid phase extraction (HLB protocol). 
The first set of experiments addressed the issue of determining the adequate elution mixture for 
the  initial  Extrelut
®  step  using  spiked  buffer  II  samples.  The  eluting  solvents  used  for  the 
Extrelut
® step are shown in Table 19. These samples were dried under reduced pressure and the 
resulting pellet was re-dissolved in 5% MeOH and applied to the HLB protocol shown in Table 
17. The results are shown as relative peak areas (Table 18) with condition 3 set as the 100% 
reference.  
 
Protocol   1  2  3  4 
Sample  spiked Buffer II 
Incubation   15 min 
Extrelut
® elution mix 
3 x 2 mL 
1-Butanol/  
NH4OH/EtOH 
4:5:11 (v/v/v) 
n-hexane/ 
2-propanol / 
NH4OH 
12:7:1 (v/v/v) 
H2O-saturated 
1-butanol / 
NH4OH 
10:1 (v/v) 
n-hexane 
  evaporation to dryness and reuptake in 5 mL 5% MeOH 
HLB protocol  section 4.1.5.1.  
Recovery [%]         
FPP  40.9  117.8  100.0  - 
GGPP  28.4  19.0  100.0  - 
 
Tab. 19. Comparison of four different organic mixtures for the elution of FPP and GGPP of the Extrelut
® columns 
combined with a unique SPE protocol (as shown in section 4.1.5.1.). Relative recoveries are shown in 
comparison with protocol number 3, overall showing the highest peak intensities. Protocol 4 did not show 
any detectable peaks. 
 
 
The recoveries shown in Table 19 indicated that a simple organic solvent such as n-hexane is 
inappropriate to elute the isoprenoids. The most convincing results in this experimental setup   105 
were achieved via elution with the settings under number 3. Despite the fact that the recovery for 
FPP  was  higher  with  the  n-hexane/2-propanol/NH4OH  mix,  the  overall  recovery  for  both 
isoprenoids was superior when the H2O-saturated 1-butanol / NH4OH 10:1 (v/v) was applied (￿ 
Elution mix 1). 
An identical experimental setup as described in Table 19 protocol 1-3 was repeated with spiked 
matrix samples (mouse brain homogenate). After elution of the Extrelut
® columns, the solutions 
from all three solvents resulted in un-dissolved residues. To separate the solid residue from the 
solutions a centrifugation step was included and the supernatant processed as described for the 
HLB protocol (section 4.1.5.3.). Overall, the HLB application and enzymatic conversion was 
most successful in combination with the 1-butanol elution mix (Table 19 protocol 3), resulting in 
the highest peak intensities.  
 
4.1.9. Employment of an internal standard 
4.1.9.1. A dansyl-labeled phospholipid as internal standard 
N-(5-dimethylamino-1-naphthalenesulfonyl)-1,  2-dioleoyl-sn-glycero-3-phosphoethanol-amine 
(DP)  was  initially  chosen  as  a  possible  internal  standard  (IS)  candidate.  The  compound  is 
commercially available, has a dansyl label comparable to the analytes. Furthermore, the general 
structure of phospholipids with their polar head group and the lipophilic tail section resembles 
that  of  the  isoprenoids.  At  first  glance,  the  chromatogram  of  the  IS  appeared  ideal,  as  the 
retention time (Rt = 7.1 min) lay between that of the two isoprenoids. As described in section 
4.1.3., the implementation of the Ascentis
® Express HPLC column, revealed the instability of this 
specific phospholipid under these test conditions. As shown in the chromatograms (Figure 8) the 
single  peak  which  occurred  at  7.1  min  (Figure  8  a)  after  separation  on  the  Zorbax  SB-C18 
column,  was  revealed  to  be  two  overlapping  peaks  which  were  baseline  separated  on  the 
Ascentis
® Express (Rt ~ 12 min) (Figure 8 b). These findings terminated future work employing 
DP as a potential IS.  
 
4.1.9.2. DNP as internal standard 
Dansyl-para nonylphenol (DNP)
316 offeres structural similarity to  FPP* and GGPP* and was 
tested as an IS. It was synthesized as described in section 3.2.1. Subsequent to synthesis, DNP   106 
was isolated via RP- high performance thin layer chromatography (RP-HPTLC) (section 3.2.2.) 
and its identity confirmed via 
1H-NMR; the spectrum and signals are shown in Figure 19. 
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Fig. 19. 300 MHz 
1H-NMR spectrum of DNP after HPTLC clean-up. Instrumental settings are displayed on the right 
and the chemical structure of DNP with the signal assignment given in the spectrum. The acetonitrile (ACN) 
and dimethyl sulfoxide (DMSO) signals are from impurities of the extraction and NMR solution (deuterated 
DMSO).   
 
 
After HPLC separation (Figure 20), the peak for DNP had a retention time of 11.6 min, occurring 
shortly after GGPP*. Hence it was concluded that DNP could effectively be used in combination 
with the current conditions of the isolation method developed for FPP and GGPP.  
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Fig. 20. Exemplified HPLC-FLD chromatogram showing the peaks for FPP* (Rt=4.1 
min), GGPP* (Rt=11.0) and the newly implemented DNP (Rt=11.6 min) as the 
IS for the application.  
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Based on these findings the combined extraction procedure as described in the flow chart (see 
Figure 3), was used together with DNP as an IS for the quantification of endogenous FPP and 
GGPP levels. 
 
4.2. Method employment   
The following study illustrates the validation of the aforementioned (see 4.1.8.) extraction and 
determination  of  endogenous  FPP  and  GGPP  levels  in  human  brain  tissue.  Importantly,  the 
procedure meets  all  criteria outlined by  the  Food  and Drug  Administration (FDA)  for  a  full 
method  validation  for  bioanalytical  methods.
317  These  criteria  include  selectivity,  analyte 
confirmation,  linearity,  stability, accuracy,  precision  and  repeated  measurements at the  lower 
limit of quantification (LLOQ). The technique shown here also makes use of a weighting factor 
for the calibration curves to improve accuracy.   
 
4.2.1. Validation results 
4.2.1.1. Selectivity 
“Selectivity is the ability of an analytical method to differentiate and quantify the analyte in the 
presence of other components in the sample.” 
317  
Initially, the degradation of endogenous  FPP and GGPP levels in the  two brain homogenate 
batches was shown. Therefore, zero samples were prepared (section 3.5.2.) and subjected to the 
enzymatic reaction. The resulting samples showed no detectable isoprenoid concentrations and 
no other interfering peaks. To further ensure the consistency of this brain matrix, samples were 
spiked before and after storage at room temperature and analyzed, showing again no significant 
differences in their chromatograms. 
Furthermore,  the  selectivity  of  the  assay  was  successfully  demonstrated  when  no  significant 
interfering signals were observed in six blank brain homogenate samples of different origin at the 
retention times for FPP* (Rt = 4.1 min) and GGPP* (Rt = 11.0 min), as well as in the related zero 
samples spiked with the IS (Rt = 11.6 min). 
 
4.2.1.2. Analyte confirmation 
Following selectivity it was essential to characterize each analyte (FPP* and GGPP*) to confirm 
the identity. The separated peaks were collected after the FLD and measured via high accuracy   108 
FT-ICR mass spectrometry (MS). The spectra are shown in Figure 21 and the measured accurate 
masses  for  FPP*  and  GGPP*  corresponded  well  to  the  calculated  exact  masses  (<5  ppm 
measurement uncertainties for all experiments), thus confirming the identities of the derivatized 
isoprenoids. 
 
 
Fig. 21. Accurate mass measurements of (a) FPP* (m/z 913.635) and (b) GGPP* (m/z 1007.823) after manual HPLC 
peak collection from spiked human brain samples. Measurements were conducted on a FT-ICR MS in 
negative ion mode (< 5 ppm measurement uncertainties for both experiments). 
 
4.2.1.3. Linearity  
Good linearity was shown over the investigated calibration range of 10–400 ng/mL for FPP and 
50–1000 ng/mL for GGPP in human brain homogenate on five consecutive days. The best fit for 
the calibration curves was achieved using a weighting factor of 1/x
3 for FPP and 1/x
2 for GGPP 
evaluated by comparing the r
2 values and the sums of the absolute values of the relative errors for 
the calibration curves using different weighting factors (Table 20 a and b).  
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Relative error (% RE) of various curve weighting values for FPP 
nominal conc. (ng/mL)  1/x
0  1/x  1/x
0.5  1/X
2  1/x
3 
10  201.9  40.4  106.7  -4.7  -0.5 
20  97.9  26.2  54.1  15.2  4.3 
40  30.4  0.6  11.0  2.8  -11.4 
60  26.2  13.9  16.4  24.9  4.7 
80  12.3  6.6  6.5  19.1  -1.0 
100           
200  0.0  8.3  2.1  26.8  3.5 
400  4.1  18.7  9.5  41.1  14.6 
sum of abs %-RE  372.9  114.8  206.3  134.5  39.9 
r
2  0.959  0.896  0.933  0.834  0.995 
 
 
Relative error (% RE) of various curve weighting values for GGPP 
nominal conc. (ng/mL)  1/x
0  1/x  1/x
0.5  1/X
2  1/x
3 
50  3.5  15.9  -22.8  -6.8  -3.7 
75  21.9  28.8  4.9  12.0  11.6 
100  0.0  0.0  0.0  0.0  0.0 
125  3.0  6.3  -6.9  -4.7  -6.3 
150  3.1  5.4  -5.0  -4.3  -6.5 
250           
500  4.7  3.4  3.0  -1.8  -5.9 
1000  -1.9  -3.8  -2.4  -7.8  -12.1 
sum of abs %-RE  38.2  63.8  45.0  37.4  46.1 
r
2  0.993  0.969  0.997  0.991  0.985 
 
Tab. 20. Overview over the evaluation of various weighting factors for the calibration curves 
for (a) FPP* and (b) GGPP*. The best fit calibration curves (highlighted in dark 
grey) were determined by comparing the r
2 values and the sums of the absolute 
values of the relative errors (% RE). Rows with missing RE values were excluded in 
accordance with the FDA guideline.
317  
 
 
The  results  are  summarized  in  Table  21.  The  correlation  coefficients  (r
2)  were  consistently 
greater than 0.992 and 0.989, resulting in mean values of 0.994 ± 0.0012 and 0.991 ± 0.0014 for 
FPP and GGPP, respectively. The relative deviations of the calculated standard concentrations   110 
from their nominal values were always less than 15% for all values including the LLOQ and thus 
meeting the FDA requirements.
317 
 
FPP    weighting factor  correlation coefficient 
       
calibration range  10 - 400 ng/ml  1/x
3  r
2 > 0.992 
  (~ 0.03 – 1.06 µmol)    0.994 ± 0.0012 
slope   0.030415 ± 0.015836     
intercept  0.318673 ± 0.268067     
       
GGPP       
calibration range  50 - 1000 ng/ml  1/x
2  r
2 > 0.989 
  (~ 0.11 – 2.15 µmol)    0.991 ± 0.0014 
slope   0.010204 ± 0.006947     
intercept  -0.15870 ± 0.124934     
 
Tab. 21. Summary of the results for the determination of linearity for FPP and GGPP in human brain tissue using 
the evaluated weighting factors evaluated in Table 20. 
 
 
4.2.1.4. Lower limit of quantification (LLOQ) 
Determination of the LLOQ at 10 ng/mL for FPP and at 50 ng/mL for GGPP was carried out in 
six spiked human brain homogenate samples, yielding an average of 9.8 ng/mL ± 4.3% (bias -
2.1%) for FPP and 45.6 ng/mL ± 6.2% (bias -8.9%) for GGPP. The general criteria for accuracy 
and precision for the lowest quantification level were thus fulfilled. An overlay in Figure 22 
illustrates a chromatogram at the LLOQ (lower trace) compared to its respective blank sample 
(upper trace).   111 
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Fig. 22. Representative chromatograms at the LLOQ. Upper trace, blank 
brain  homogenate;  lower  trace,  FPP  (Rt=4.1  min)  and  GGPP 
(Rt=11.0) at the LLOQ, DNP as the IS at Rt=11.6 min.  
 
 
4.2.1.5. Accuracy and Precision  
The values for intra- and inter-day accuracy and precision are summarized in Table 22, fulfilling 
the international acceptance criteria for bioanalytical method validation, requiring a maximum of 
15% RSD for the respective values of each QC.
317 
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Intra- and Interday Accuracy and Precision in brain homogenates 
FPP 
   nominal   mean calc.  accuracy  precision 
  concn (ng/mL)  concn (ng/mL)  (bias %)  (% CV) 
intraday   30  29.1  -2.9  8.7 
(n=4)  150  153.9    2.6  4.5 
  300  285.3  -4.9  6.1 
interday   30  29.5  -1.8  11.3 
(n=4)  150  147.5  -1.7  9.7 
  300  303.7    1.2  9.3 
         
GGPP 
   nominal   mean calc.  accuracy  precision 
  concn (ng/mL)  concn (ng/mL)  (bias %)  (% CV) 
intraday   80  84.8    6.0  5.2 
(n=4)  400  428.3    7.1  4.6 
  800  825.5    3.2  8.8 
interday   80  79.9  -0.2  8.8 
(n=4)  400  426.2    6.5  6.0 
  800  823.5    2.9  8.1 
 
Tab. 22. Summary of the intra- and interday accuracy and precision for FPP and GGPP in human 
brain homogenates. 
 
4.2.1.6. Recovery  
A wide spectrum of SPE materials LLE procedures was screened during the developmental phase 
of this study. The best results were obtained using the combined approach of matrix-assisted LLE 
(Extrelut
®) and the HLB (Figure 3 and section 4.1.8.). The recoveries for FPP and GGPP were 
determined in the low, medium and high range of the calibration curves. Mean recovery values 
for FPP were 64.6, 63.1 and 52.9% and 15.0, 16.2 and 26.5% for GGPP, respectively. Despite 
relatively poor recoveries, especially for GGPP, the results were reproducible throughout the 
validation.  This  was  further  confirmed  by  the  recovery  tests  using 
3H-FPP  and 
3H-GGPP, 
yielding a FPP retrieval of 54% for all three concentrations; GGPP retrieval at the low, medium 
and  high  concentration  ranges  was  18.5,  12.7  and  23.1%,  respectively.  A  summary  of  these 
findings can be found in Table 23. 
   113 
Sample  FPP / 
3H-FPP [%]  GGPP / 
3H-GGPP [%] 
QC-L     
mean  64.6 / 54.0  15.0 / 18.5 
SD  0.70  0.95 
RSD [%]  1.09  6.32 
     
QC-M     
mean  63.1 / 54.0  16.2 / 12.7 
SD  2.58  0.44 
RSD [%]  4.08  2.74 
     
QC-H     
mean  52.9 / 54.0  26.5 / 23.1 
SD  3.06  1.29 
RSD [%]  5.77  4.87 
 
Tab. 23. Summary of the recoveries for FPP and GGPP using QC samples at three different 
concentrations / QC samples spiked with deuterated FPP and GGPP at three different 
concentrations. 
 
4.2.1.7. Stability  
The stability tests showed no significant degradation of FPP or GGPP in brain homogenate after 
storage at room temperature, in the presence of two phosphatase inhibitors, at -80 °C for 1 and 3 
months and after three freeze and thaw cycles. Storage of FPP* and GGPP* in the autosampler 
showed unsatisfying results for 20 h at 4 °C due to degradation of the analytes and IS, whereas 
results measured at the other time points showed acceptable results as noted in Table 24. 
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Stability data of FPP and GGPP under various experimental conditions (n=3) 
condition  nominal  accuracy  precision 
  conc. [ng/mL]  (bias %)  (% CV) 
  FPP        GGPP  FPP  GGPP  FPP  GGPP 
2 h at RT  30  80  6.2  1.1  1.1  3.4 
  300  800  -8.3  2.3  2.2  8.3 
1 F/T cycle  30  80  13.4  13.5  1.2  1.8 
  300  800  4.1  9.4  5.3  1.2 
3 F/T cycles  30  80  9.5  11.3  1.0  4.2 
  300  800  12.0  9.3  2.9  1.1 
1 month at -80°C  30  80  6.0  11.8  7.9  4.0 
  300  800  2.2  11.9  9.2  3.2 
3 month at -80°C  30  80  -6.2  7.9  3.1  3.8 
  300  800  12.0  12.6  3.4  2.6 
             
autosampler  (n=4)      FPP*  GGPP*  FPP*  GGPP* 
0 h  150  400  -10.1  8.5  9.2  6.1 
5 h  150  400  -7.5  9.4  6.2  0.4 
10 h  150  400  -11.9  11.7  2.6  3.2 
20 h  150  400  -67.6  33.5  69.0  7.3 
 
Tab.  24.  Summary  of  the  stability tests  for  FPP  and  GGPP  under  various  conditions.  Autosampler 
stability  was  tested  for  FPP*  and  GGPP*.  Highlighted  values  are  outside  the  acceptance 
criteria of the FDA guideline.
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4.2.1.8. Partial validation for mouse brain samples 
The developed and validated method for the detection of endogenous brain FPP and GGPP levels 
was  primarily  designed  for  studies  in  post  mortem  human  AD  brains  to  assess  a  possible 
isoprenoid disturbance in the course of the disease. A more than obvious shortcoming of this kind 
of matrix is its availability or much more the possibility of generating data from in vivo studies.   
In order to bypass the latter limitation the following experiments were carried out to obtain in 
vivo brain data from mouse studies. However, brain matrix from pig was investigated for its 
feasibility.  
According to the FDA guideline for bioanalytical method validation
317 a partial validation can 
range from a simple comparison of the calibration curves to an intensive validation, similar to 
that described in section 4.2. In the context of this work it was found to be adequate to limit the 
partial validation to a comparison of the calibration curves for FPP and GGPP in human, pig and   115 
mouse brain matrix. For all three isolations the identical protocol was applied (section 4.1.8.), 
including the IS and the weighting factor for the calculation of the concentrations. The calibration 
curves which are displayed (Figure 23) show the nominal and calculated concentrations. Table 25 
gives the according correlation coefficients, the calculated concentrations and their variation from 
the nominal values. 
 
FPP  r
2 = 0.998 ± 0.0009 
Nominal  conc. 
[ng/mL] 
Mean  calculated 
conc. [ng/mL] 
RSD 
[%] 
Bias 
[%] 
10  9.96  0.82  -0.43 
20  20.5  4.17  2.49 
40  39.38  3.09  -1.55 
70  66.39  5.05  -5.15 
100  95.37  8.43  -4.63 
200  221.91  0.70  10.96 
400  444.32  2.46  11.08 
       
GGPP  r
2 = 0.995 ± 0.0035 
50  47.84  3.95  -4.31 
80  83.69  3.47  4.61 
100  110.80  n.d.  10.80 
150  150.00  8.27  0.0 
250  253.34  3.02  1.33 
500  462.32  5.33  -7.54 
1000  1023.02  5.97  2.30 
 
Tab.  25.  Summary  of  the  partial  validation  for  mouse  brain 
samples. Calibration curves were generated in human, 
mouse  and  pig  brain.  The  mean  of  three  values  are 
mentioned together with the calculated RSD and bias. 
n.d. = not determined 
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Fig. 23. Linearity for (a) FPP and (b) GGPP. Calibration curves were generated in human, mouse and pig brain and 
the means of the three values were plotted against the nominal concentration; variations are given as means 
± SD. Concentrations, exact values and r
2-values are shown in Table 25. 
 
 
Overall,  these  results  indicate  that  the  extraction  and  detection  methods  which  have  been 
developed thus far are suitable for application on in vivo brain tissue samples acquired from mice. 
 
4.3. Method transfer to an UHPLC-MS/MS application 
Although the majority of the data presented in the current work were generated by the fully 
validated HPLC-FLD application a technical aim of the current work was to show the possibility 
to transfer the newly developed method to an ultra-fast and highly sensitive UHPLC-MS/MS 
system. This method transfer implicated the capability of providing larger separation efficiencies, 
much faster run times and greater sensitivity leading to lower detection limits in comparison to 
fluorescent detection. The instrument chosen for this application was an electrospray ionisation 
(ESI) triple quadrupole (QqQ) mass spectrometer hyphenated with an UHPLC system.  
 
4.3.1. Determination of the MRM settings 
All initial experiments for the development of this method were carried out from standard F-G-
Assay  using  high  concentrations  of  isoprenoids  (i.e.  250ng/mL).  The  first  step  was  a  direct 
infusion into the ESI source of the API 4000 QTrap linear ion trap (QqLIT) mass spectrometer 
via a syringe pump at a flow rate of 5 µl/min. In addition to providing optimal signal intensity for 
each analyte, specific fragmentation patterns were also recognized for each prenylated peptide 
through product ion scans. Ions relating to FPP* and GGPP* were clearly visible in both the 
negative  and  positive  ionisation  mode;  however,  the  positive  mode  yielded  higher  ionisation 
efficiencies  and  better  signal  intensities  (data  not  shown).  On  determining  sufficient  signal   117 
intensities  in  the  positive  ion  mode,  the  compounds  were  subjected  to  low  energy  collision 
induced dissociation (CID). The according product ion (MS
2) mass spectra for FPP* and GGPP* 
are shown in Figures 24 a and b. The prominent product ions were observed at m/z 810 and 878 
for FPP* and GGPP*, respectively. These fragment ions are consistent with a loss of the C-
terminal amino acid, serine (-105 Da) and leucine (-131 Da), respectively. These product ions 
were chosen for MRM analysis and signal intensities were optimized mainly by adjusting the 
collision  energy  (CE),  ionspray  voltage  (IS),  temperature  (TEM)  and  collision  gas  pressure 
(CAD).  Moreover,  these  parameters  were  further  fine-tuned  after  the  employment  of  the 
chromatographic separation and resulted in the final settings described in section 3.4.4.  
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Fig. 24. Representative product ion scans (MS
2) for each analyte. Both spectra show the parent ion (m/z 916 for 
FPP*  (a)  m/z  1010  for  GGPP*  (b).  Furthermore,  the  complete  structures  of  both  analytes  with  their 
respective transitions are shown (m/z 916 ￿ 810 (a) and m/z 1010 ￿ 878 (b)) 
 
4.3.2. Analyte confirmation 
Due to the combined triple quadrupole (QqQ)-LIT instrument employed, further fragmentation 
could be monitored. The product ion of interest was selected in the third quadrupole (Q3) before 
undergoing further fragmentation in the LIT. This is known as MS
3 analysis and was employed to 
verify  the  product  ion  identification  through  structural  elucidation.  As  shown  by  the 
representative MS
3 spectrum of  FPP* in  Figure 25, further mass peaks were observed which 
could be unequivocally assigned to fragments of the parent molecule (Figure 25). An analogue 
fragmentation pattern was achieved for GGPP* (data not shown). 
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Fig. 25.  Rrepresentative MS
3 spectrum of FPP* and the corresponding fragment peaks 
of m/z 810. The according fragments are shown with their chemical structures 
and the site of fragmentation. 
 
4.3.3. Adjustments of the chromatographic separation on the UHPLC system 
The  chromatographic  analysis  of  the  two  analytes  was  transferred  from  the  original  HPLC 
method to a UHPLC separation, greatly reducing total chromatographic run time from 20 min to 
only 3 min using the same column with same dimensions on both systems. Consequently, the   119 
retention time for FPP* was reduced from 4.1 to 1.08 min and for GGPP* from 12.1 to 1.56 min. 
The backpressure on the UHPLC system was at no point higher than 550 bar at a flow rate of 600 
µL/min  at  20  °C.  Figure  26  a  shows  a  representative  MRM  chromatogram  of  the  newly 
developed  method  and  Figure  26  b  illustrates  the  chromatographic  improvements,  especially 
concerning  analysis  time  (20  min  to  3  min)  and  peak  performance  achieved  by  the 
implementation of the UHPLC separation compared to the HPLC system and finally shows the 
optimized UHPLC-MRM chromatogram in direct comparison. 
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Fig.  26.  (a)  Representative  UHPLC-MS/MS  (MRM)  chromatogram  at  the  LLOQ  for  FPP*  (Rt=1.08  min)  and 
GGPP*  (Rt=1.56  min).  (b)  Illustration of  the  improvements  achieved  by  the  method transfer  from the 
HPLC-FLD system (lower chromatogram) to the UHPLC-FLD and finally to the UHPLC-MRM method. 
 
4.3.4. Linearity and LLOQ 
Improvements in selectivity and sensitivity were achieved by using MRMs on a state-of-the-art 
triple quadrupole MS system. With only one eights of the previously reported injection volume of 
80 µL the LLOQ was determined at 5 ng/mL, equivalent to 12.5 pg absolute amount of FPP and 
GGPP per injection, respectively. This represents a 16 fold increase in sensitivity for FPP* and 
80  fold  for  GGPP*  as  compared  to  the  HPLC-FLD  assay  and  consequently  allowing  the 
preparation of smaller tissue samples for the isolation of endogenous FPP and GGPP. The RSD at 
the level of the LLOQ were 7.4% for FPP* and 12.3% for GGPP* and were well within the 
acceptance  criteria  of  the  FDA  guideline.
317  Subsequently,  linearity  was  determined  over  a 
calibration  range  from  5  and  250  ng/mL  for  both  isoprenoid.  Blank  samples  showed  no 
interfering peaks. While the best fit for the calibration was achieved using a weighting factor of 
1/x
3 for FPP and 1/x
2 for GGPP, the correlation coefficients were greater than 0.9964 for FPP and   120 
0.9937 for GGPP. The calculated standard concentrations were always within 15% RSD of the 
nominal concentration. 
 
4.3.5. Matrix effects 
To  further  ensure  the  absence  of  interfering  ion  suppression  in  the  ESI  source  of  the  mass 
spectrometer  at  the  time  of  retention  of  FPP*  and  GGPP*,  infusion  chromatograms  were 
conducted separately for each analyte. The total ion count (TIC) chromatograms in Figure 27 a 
and b depict that there was no matrix interference from the brain homogenate samples at the 
respective retention times of the analytes. 
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Fig. 27. Infusion chromatograms for (a) FPP* and (b) GGPP*.   ---> marks the 
time  point  for  the  injection  on  the  UHPLC  system.  ￿  indicate  the 
retention time of FPP* and GGPP* under normal separation conditions, 
respectively.  
 
4.3.6. HPLC-FLD and UHPLC-MS/MS correlation 
For  a  final  assessment  of  the  method  transfer  from  the  HPLC-FLD  to  the  UHPLC-MS/MS 
system  the  correlation  of  FPP  and  GGPP  concentrations  obtained  from  both  systems  were 
calculated, respectively. For this cross-validation 14 human brain samples were prepared and the   121 
resulting solution after the pre-column derivatization was divided into two aliquots and to be 
measured on each system separately. Concentrations of the samples were back calculated using a 
calibration curve processed identically. Results shown in Figure 28 a and b show a correlation of 
0.9254 for the FPP* and 0.9530 for the GGPP* results, respectively.  
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Fig. 28. Data correlation for (a) FPP and (b) GGPP results obtained from the identical solutions via the 
HPLC-FLD and UHPLC-MS/MS method. The dashed lines correspond to the ideal behavior 
(slope = 1) and the correlation coefficients (n=14) are shown, respectively.  
 
4.4. Analysis of human brain samples 
4.4.1. White and grey matter distribution 
White  and  grey  matter  brain  samples  from  5  different  human frontal  cortex  specimens  were 
prepared and analyzed for their FPP and GGPP levels according to the developed and validated 
HPLC-FLD method described in section 4.2. The specific patient information can be viewed in 
Table  7.  The  results  of  these  experiments  are  summarized  in  Table  26.  This  data  clearly 
demonstrated a significantly higher concentration of GGPP in all samples as compared to FPP 
and a much higher abundance in the white matter, which is expressed in the ratio in Table 26. 
FPP shows a less distinct distribution between the two areas. 
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Results of human frontal cortex samples – white and  grey 
matter 
Sample  FPP concentration  
(pmol/mg protein) 
GGPP concentration 
(pmol/mg protein) 
ratio 
FPP/GGPP 
1  white  9.7  61.8  0.16 
  grey  10.2  50.0  0.20 
2  white  9.9  36.2  0.27 
  grey  8.4  24.2  0.35 
3  white  7.9  27.8  0.28 
  grey  11.3  15.6  0.72 
4  white  6.3  18.9  0.33 
  grey  7.3  9.3  0.79 
5  white  3.4  14.7  0.23 
  grey  2.4  8.2  0.29 
 
Tab. 26. Results for human frontal cortex white and grey matter samples. Concentrations 
are  given  in  pmol/mg  protein.  The  ratio  depicts  the  higher  concentration  of 
GGPP compared to FPP. 
4.4.2. Post mortem interval (PMI) 
The herein described study addressed the question of whether, varying post mortem intervals 
(PMI), the period between the time of death and the time of removal of the brain, could have an 
influence on isoprenoid degradation. A delay between the time of death and the brain removal 
and subsequent deep freezing of the brain could result in depletion of FPP and GGPP due to lysis 
of  the  tissue  and  especially  due  to  the  activity  of  endogenous  phosphatases.  Previous 
investigations described in section 4.1.6.3. clearly demonstrated a loss of FPP and GGPP when 
homogenates were co-incubated without PIs.  
Brain samples (grey matter) were selected according to their PMI and divided into short and long 
PMI groups, 3.38 +/- 0.31 hours; age: 79.25 +/- 3.97 years and 11.75 +/- 0.77 hours; age: 78.0 +/- 
1.47 years, respectively. The concentrations of FPP and GGPP which were measured in 
both sets are shown in Figure 29 a and b. The results demonstrate no influence of a longer 
PMI  as  compared  to  the  short  PMI.  Furthermore,  the  results  again  showed  a  higher 
abundance of GGPP compared to FPP. 
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Fig. 29. Influence of the PMI on (a) FPP and (b) GGPP concentrations. Concentrations were compared between 
short (3.38 ± 0.31 hours) and long (11.75 ± 0.77 hours) PMI in human grey matter samples. Means ± 
SD; n.s. = non significant (unpaired t-test), (n=4).  
 
4.4.3. Human AD brain investigation 
As mentioned in the introduction, multiple members of the family of small GTPases may be 
involved  in  the  onset  and  the  progression  of  AD.  All  of  these  proteins  require  an 
isoprenylation/prenylation step with either FPP or GGPP for correct function. Hence, the study 
described herein focused on the abundance of the isoprenoids, FPP and GGPP in AD. 
In order to determine the abundance of the isoprenoids in the grey and white matter, a clear 
separation  of  both  areas  in  the  brain  samples  was  essential.  The  successful  preparation  was 
confirmed by western blot analysis using a neuronal cell nucleus marker protein (NeuN) (Figure 
30). 
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Fig. 30. Preparation of human brain tissue from control and AD samples. Quality of separation of grey from 
white matter was confirmed by enrichment of the protein NeuN, which is a marker of neuronal cell 
bodies in grey matter. Protein abundance was determined by western blot analysis (n=5). 
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To  further  investigate  the specificity  of  the isoprenoid  elevation,  the  study  included  separate 
white and grey matter frontal cortex samples from each patient. The relevant patient information 
is shown in Table 7 and the protocol for the brain preparation is described in section 3.3.1. 
 
FPP and GGPP levels were determined simultaneously using the aforementioned established and 
validated  HPLC-FLD  method  (section  4.2.).  An  overlay  of  representative  chromatograms  is 
shown in Figure 31 a. Figure 31 b depicts that GGPP levels were significantly higher in brain 
tissue of AD patients (56%) as compared with control samples. FPP levels were also significantly 
higher in the AD brain tissue (36%) (Figure 31 b). In both, AD patients and controls, GGPP 
levels were markedly higher than FPP levels and these data are in accordance with the results 
reported in section 4.4.2. 
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Fig. 31. Elevated FPP and GGPP levels in the frontal cortex grey matter of male AD brain compared with 
controls. (a) Representative chromatographic overlay of grey matter brain samples. Upper trace: AD 
sample; middle trace: control sample; lower trace: blank sample. (b) Endogenous FPP and GGPP 
levels in human brain grey matter in the control and AD group. Means ± SD, *p<0.05; (n=13). 
 
 
In order to determine if this up regulation was due to an increased enzyme activity of the FPPS 
and GGPPS protein or if a transcriptional regulation was involved, mRNA data of the previously 
mentioned  matrix  samples  were  investigated.  The  FPPS  and  GGPPS  mRNA  levels  were 
quantified via qRT-PCR. These measurements were carried out in the laboratories of Prof. W.G. 
Wood. The results from these experiments were in accordance with the previous findings on 
elevated FPP and GGPP levels. In summary, the gene expression of FPP synthase (FPPS) and 
GGPP synthase (GGPPS) was confirmed and the increase in FPP levels in the frontal cortex of   125 
AD affected brain was  associated with a significant up-regulation of  FPPS expression at the 
mRNA level as depicted in Figure 32. GGPPS mRNA levels were also increased however no 
statistically significant differences were observed (Figure 32).  
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Fig. 32. Gene expression of the FPP and GGPP synthase in human AD 
and control brain samples. Gene expression was determined 
by  qRT-PCR  (data  kindly  provided  by  Prof.  W.G.  Wood). 
Data were normalized to GAPDH and results are shown as 
means ± SD; *p<0.05; n.s. = non significant; (n=10). 
 
Contrary to the findings on altered isoprenoid levels, cholesterol levels and gene expression of 
HMG-CoA  reductase  were  similar  in  AD  and  control  samples  (see  Fig  33  a  and  b).  Gene 
expression was again determined in the laboratory of Prof. W.G. Wood and cholesterol data was 
determined from the same homogenate, as from which the isoprenoids were measured. 
 
control AD control AD
0
25
50
75
100
125
white matter
*
grey matter
n.s.
n.s.
n
m
o
l
/
m
g
 
p
o
r
t
e
i
n
cholesterol
control AD control AD
0
1
2
3
4
5
6
white matter grey matter
n.s. n.s.
n
o
r
m
a
l
i
z
e
d
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
HMGR
a b
control AD control AD
0
25
50
75
100
125
white matter
*
grey matter
n.s.
n.s.
n
m
o
l
/
m
g
 
p
o
r
t
e
i
n
cholesterol
control AD control AD
0
1
2
3
4
5
6
white matter grey matter
n.s. n.s.
n
o
r
m
a
l
i
z
e
d
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
HMGR
a b
 
Fig. 33. Cholesterol levels and HMG-CoA reductase gene expression in brain grey and white matter tissue of 
AD and control subjects. (a) Cholesterol levels in brain tissue of control and AD samples; (n=13). (b) 
Gene expression of HMG-CoA reductase (HMGR) in brain tissue of controls and AD samples. Gene 
expression was determined in grey and white matter by qRT-PCR (data kindly provided by Prof. W.G. 
Wood). Data were normalized to GAPDH and results are shown as means ± SD; n.s. = non significant; 
(n=10). 
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The specificity of the isoprenoid elevation is further supported by similar observations in white 
matter brain tissue (Figure 34). Here, the same AD brains show a 59% and 43% elevation for 
GGPP and FPP, respectively. Again this observation is not accompanied by an alteration of the 
cholesterol concentration (Figure 33 a). 
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Fig. 34. Elevated FPP and GGPP levels in the frontal 
cortex white matter of male AD brain samples 
compared to controls. Means ± SD, *p<0.05; 
(n=13). 
 
Further investigations addressed the question whether elevated HMG-CoA reductase expression 
levels or its activation status are accountable for increased isoprenoid abundance.    
Based  on  the  aforementioned  statement,  the  identical  AD  and  control  samples  used  for  the 
determination of endogenous FPP and GGPP were subjected to an HMG-CoA reductase activity 
assay and as described in the previous paragraph, measured for their mRNA levels by qRT-PCR 
in the laboratory of Prof. W.G.Wood.  
Note: HMG-CoA reductase is inactive in the phosphorylated form. For this reason it was essential 
for this experiment to work with phosphatase inhibitors during sample preparation. Interestingly, 
the results revealed that the mRNA levels were unaltered (see Figure 35 b) in both the grey and 
white matter of the diseased brain while the activity was significantly reduced by 39% in the grey 
matter. A reduction by 34% in the white matter was statistically not significant. 
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Fig.  35.  HMG-CoA  reductase  activity  in  brain  grey  (a)  and  white  matter  (b)  tissue of  AD  and  control 
subjects. Means ± SD; n.s. = non significant; *p<0.05; (n=10). 
 
 
These results are strongly linked to the unaltered cholesterol levels and clearly demonstrated a 
specific elevation of the isoprenoids and their respective synthases.    
 
4.5. In vivo mouse studies 
4.5.1. Mouse simvastatin study 
To establish if FPP and GGPP regulation were more susceptible to perturbation than cholesterol, 
FPP, GGPP and cholesterol levels were determined in the brains of mice, chronically treated (21 
days) with the HMG-CoA reductase inhibitor, simvastatin. Figure 36 b shows the differences 
between the treated and the control group. An exemplified chromatogram from either treatment 
group is compared to a blank sample, see Figure 36 a. 
The overall findings from this trial show that FPP and GGPP are significantly reduced by 52% 
and 33%, respectively. Cholesterol levels were also reduced but to a lower extent (22%) as shown 
in Figure 36 c. 
   128 
5 10 15 20
time (min)
i
n
t
e
n
s
i
t
y
´FPP´
´GGPP´
IS
control
simva
blank
5 10 15 20
time (min)
i
n
t
e
n
s
i
t
y
FPP*
GGPP*
IS
control
simva
blank
control simva control simva
0
10
20
30
40
50
60
70
80
FPP GGPP
***
**
p
m
o
l
/
m
g
 
p
r
o
t
e
i
n
control simva
0
50
100
150
200
250
300
350
*
cholesterol
n
m
o
l
/
m
g
 
p
r
o
t
e
i
n
a
b c
5 10 15 20
time (min)
i
n
t
e
n
s
i
t
y
´FPP´
´GGPP´
IS
control
simva
blank
5 10 15 20
time (min)
i
n
t
e
n
s
i
t
y
FPP*
GGPP*
IS
control
simva
blank
5 10 15 20
time (min)
i
n
t
e
n
s
i
t
y
´FPP´
´GGPP´
IS
control
simva
blank
5 10 15 20
time (min)
i
n
t
e
n
s
i
t
y
FPP*
GGPP*
IS
control
simva
blank
control simva control simva
0
10
20
30
40
50
60
70
80
FPP GGPP
***
**
p
m
o
l
/
m
g
 
p
r
o
t
e
i
n
control simva
0
50
100
150
200
250
300
350
*
cholesterol
n
m
o
l
/
m
g
 
p
r
o
t
e
i
n
a
b c
 
 
Fig. 36. Brain FPP, GGPP and cholesterol levels in female C57Bl/6 mice (3 month of age) treated with the 
HMG-CoA reductase inhibitor simvastatin. (a) Representative chromatographic overlay of mouse brain 
samples. Upper trace: control, middle trace: simvastatin treated sample and lower trace: blank sample. 
(b) FPP and GGPP levels in the cerebrum of control and simvastatin treated mice. (c) Brain cholesterol 
levels in control and simvastatin treated mice. Results are shown as means ± SD; ***p<0.001, **p<0.01 
and *p<0.05; (n=6). 
 
 
In  contrast  to  the  findings  in  AD  post-mortem  brain  tissue  (section  4.4.4.)  these  results 
demonstrate that an inhibition of the HMG-CoA reductase affects both isoprenoid and cholesterol 
levels, albeit at varying magnitude and this effect is reflected when correlating the data from the 
control and treatment group. Figure 37 a shows a correlation of r
2= 0.824 (p < 0.0001) of the 
GGPP to its immediate precursor FPP and Figure 37 b demonstrates the correlation (r
2=0.3449; p 
= 0.0447) of FPP as a precursor for cholesterol.  
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Fig.  37.  Data  correlation  of  FPP  and  its  downstream  product.  Results  are  taken  from  the  in  vivo  mouse 
simvastatin  study  (see  Fig.  36).  (a)  Correlation  of  FPP  and  its  immediate  product  GGPP.  (b) 
Correlation of FPP and the endproduct of the MVA-pathway cholesterol. Goodness of correlation is 
shown as the correlation coefficient (r
2) and the statistical significance. Data are shown as pmol or 
nmol / mg protein (n=12).  
 
To further investigate the potential effects of reduced isoprenoid levels in this in vivo model on 
prenylation  of  proteins,  western  blot  analysis  was  conducted  using  a  PanRac  and  a  PanRas 
antibody. The  PanRac antibody detects antigenic determinants common to Rac1, Rho A and 
Cdc42 all of which are geranylgeranylated. The second antibody was raised against antigenic 
determinants which are common to H-, K- and N-Ras which are farnesylated. Figure 38 a and b 
show a reduction in band intensities for both antibodies following simvastatin treatment. One 
could clearly observe an enhanced effect of the drug treatment for the farnesylated proteins, 
showing  a  significant  (p  =  0.026)  reduction  by  27%  (Figure  38  b).  The  impact  on 
gernaylgeranylation with 15% was statistically not significant (p = 0.2471) (Figure 39 b).  
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Fig. 38. Western blot analysis of mouse brain homogenate after chronic simvastatin treatment (female C57Bl/6 
mice; 3 month of age). (a) 21 kDa band of the PanRac (geranylgeranylated proteins) antibody in 
control brain and brain homogenate of treated mice. According graph shows the evaluation of band 
intensities. (b) 21 kDa band of the PanRac (farnesylated proteins) antibody in control brain and brain 
homogenate from treated mice. According graph shows the evaluation of the band intensities. Means ± 
SD, n.s. = non significant; **p<0.01; (n=4 for control and n=3 for simvastatin group). 
 
4.5.2. The transgenic mouse model – Thy-1 APPSL mice 
After  examination  of  human  AD  brains  and  of  mouse  brains  after  chronic  simvastatin 
administration we further investigated if a transgenic mouse model, widely discussed to mimic 
AD would show a comparable isoprenoid distribution as demonstrated in humans. The Thy-1 
APP mice comprise the double Swedish mutation and the London mutation, leading to higher 
yields of the Aβ peptide and consequently to plaque formation. 
We investigated brains of 12 month old Thy-1 APP female mice and their age matched wild type 
controls.  The  results  shown  in  Figure  39  a-c  depict  no  significant  changes  of  isoprenoid  or 
cholesterol levels in the transgenic mouse model when compared for each group. However, the 
calculation of a two-way ANOVA, show a significant (p<0.0001) difference when calculated 
over both variables, FPP and GGPP. 
In  summary,  elevated  isoprenoid  levels  in  AD  affected  brains  were  observed,  however, 
cholesterol  levels  remained  unchanged.  The  subsequent  in  vivo  simvastatin  study  in  mice 
indicated the possibility to reduce endogenous isoprenoid and cholesterol levels in the central 
nervous  system  (CNS).  Furthermore,  this  study  demonstrated a  downstream  effect of  altered 
isoprenoid  abundance,  on  members  of the  small  GTPases.  Nevertheless,  in  this  experimental 
setup the transgenic mouse model did not produce similar findings in terms of the isoprenoid 
levels, as compared to human AD brains.   131 
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Fig. 39. Brain FPP, GGPP and cholesterol levels in female Thy-1 APP mice and controls (12 month of age). (a) 
FPP, (b) GGPP and (c) cholesterol levels in the cerebrum of Thy-1 APP mice and their respective 
controls. Means ± SD; n.s. = non significant; (n=5). 
 
4.5.3. MVA-pathway alterations in aged mice 
We demonstrated significant alterations in isoprenoid levels in human AD brain versus controls. 
All brains in this study were from male donors and their age (section 3.11.1.3.) ranged from 
roughly 75 to 85 years. We next addressed the question how isoprenoid and cholesterol levels are 
physiologically  regulated  during  the  process  of  aging.  Therefore,  brains  from  three  different 
C57Bl/6 mouse age groups, young (3 month), middle-aged (12 month) and aged (24 month) were 
investigated.  
A  pilot  study  was  conducted  to  address  the  question  whether  FPP  and  GGPP  abundance  is 
dependant on the gender of the mice. For this experiment the isoprenoid levels were compared 
between female and male mice in the aforementioned three different age groups. The results are 
displayed in a table format (Table 27) listing the mean values and respective SD values from each 
group and sex. Furthermore, the p-values for the inter-group comparisons are given. The results 
show no gender dependant differences in FPP and GGPP levels in the brains of female and male 
C57Bl/6 mice. 
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C57Bl/6  Female  Male    
  mean conc. 
[ng/mg protein]  
+/- SD 
mean conc. 
[ng/mg protein]  
+/- SD  p- value 
FPP           
young   41.04  10.89  36.89  3.48  0.4404 
middle   38.28  6.08  35.14  9.99  0.5640 
aged   46.66  5.99  53.46  3.44  0.1429 
GGPP           
young   226.8  70.16  205.7  48.42  0.5945 
middle   268.7  51.04  204.8  72.64  0.1464 
aged   359.3  106.2  357.7  77.89  0.9841 
 
Tab.  27.  Cerebral  FPP  and GGPP levels of  young  (3  month),  middle (12month)  and  aged  (24 
month) C57Bl/6 mice. Means ± SD; (n=5). 
 
 
Since the human AD study was conducted with brains derived from male donors and no obvious 
difference was visible according to the sex of the mouse, further research focused on male mice. 
The results from the table concerning the three different generations of male mice are included in 
Figure  40  to  emphasize  the  actual  differences  in  isoprenoid  levels.  There  is  no  significant 
elevation of FPP and GGPP levels between the 3 and the 12 month old mice. Significant changes 
are apparent as the mice reach approximately 24 month, as shown by significantly elevated levels 
of both isoprenoids between both the young and the aged, and the middle-aged and the aged 
group.  In average FPP levels were elevated by 48% in the aged (24 month) group. GGPP levels 
were subjected to an even greater increase of 73% on average. 
In terms of cholesterol levels, a close correlation with the isoprenoid levels became apparent. 
Specifically, only the aged group depicted elevated total cholesterol levels in brain homogenate. 
Though  the  mean  elevation  in  the  24  month  old  group  became  obvious,  the  difference  in 
concentrations  failed  to  reach  the  level  of  statistical  significance.  However,  cholesterol 
measurement in the crude fraction of the identical brain did show a significant increase over age 
(p = 0.0322, one-way ANOVA) (data no shown). 
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Fig. 40. Brain FPP, GGPP and cholesterol levels in three different age groups, young (3 month), middle (12 
month) and aged (24 month). (a) FPP, (b) GGPP and (c) cholesterol levels in the cerebrum of male 
C57Bl/6 mice. Means ± SD; n.s. = non significant, ***p<0.001, **p<0.01 and *p<0.05; (n=5). 
 
 
4.6. In vitro screening of selected MVA-pathway inhibitors  
In vitro cell-culturing is a simple biological model for testing the impact of a drug on a specific 
metabolic  pathway(s).  Usually  effects  can  be  screened  via  various  methods  including 
measurements of metabolite formation; however this generally involves a cumbersome sample 
preparation.  
A common and widely used cell model in AD research is the neuroblastoma derived SH-SY5Y 
cell line and a derivative of this cell line, mimicking AD pathology with respect to Aβ formation, 
are SH- SY5Y-APP wt cells. As previously shown by our group, certain inhibitors of the MVA-
pathway reduce cholesterol levels, have an influence on membrane fluidity, leaflet composition 
and cellular Aβ load.
238 
Different  inhibitors  and  slightly  varying  conditions  were  chosen  to  investigate  the  effects  of 
specific enzyme inhibition on FPP and GGPP levels in SH-SY5Y-APP cells. Absolute isoprenoid 
and choletsterol levels in these cells are depicted in the following table (Table 28).    134 
SH-SY5Y-APP  FPP  GGPP  Cholesterol 
  mean conc.  
[pmol/mg protein] 
± SD  mean conc.  
[pmol/mg protein] 
± SD  mean  conc.  
[pmol/mg protein] 
± SD 
  17.2  1.3  13.4  1.3  381.1  8.5 
 
Tab. 28. Absolute FPP, GGPP and cholesterol concentrations measured in untreated SH-SY5Y-APP cells. Means ± 
SD; (n=9). 
 
 
As  mentioned  in  the  materials  and  methods  section  (section  3.6.2.)  several  inhibitors  were 
previously  tested in  our working  group  for  their  influence on  the  parameters  given  in  Table 
29.
238,270  As  demonstrated  in  the  abbreviated  outline  of  the  MVA-pathway  (Figure  41),  the 
inhibitors  were  selected  based  on  their  level  of  inhibition  of  the  pathway,  relative  to  the 
isoprenoids.  
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Fig. 41. Abbreviated mevalonate/isoprenoid/cholesterol pathway. 
Highlighted  are  the  inhibitors,  applied  in  the  in  vitro 
experiments  (see  Table  29)  as  well  as  their  respective 
enzyme target. A complete overview of the pathway can 
be seen in Figure 1. 
 
Lovastatin, belonging to the group of “statins” was used to inhibit the first and rate-limiting step 
of the whole MVA-pathway. Farnesyltransferase inhibitor FTi 277 and geranylgeranyltransferase 
inhibitor GGTi 286, were chosen to block those enzymes using FPP and GGPP as substrates. 
Moreover,  U  18666A  was  selected  as  an  inhibitor  of  cholesterol  synthesis,  following  the   135 
branching point of FPP towards cholesterol synthesis. Conditions were applied as previously used 
as described in the dissertation of I. Peters. 
238,270  
 
  Cholesterol 
FPP- 
Transfer 
GGPP- 
Transfer 
Lovastatin  ￿  ￿  ￿ 
GGTi 286  ￿  ￿  ￿ 
FTi 277  ￿  ￿  ￿ 
U 18666A  ￿  ￿  ￿ 
 
Tab. 29. Effect table of different inhibitors on cholesterol levels and FPP- and 
GGPP- transfer to the respective dansyl labels. Results were evaluated via 
fluorescence  spectroscopy  and  are  adapted  from  the  dissertation  from 
I.Peters.
238,270.  ￿  symbolizes  unaffected  results  under  the  respective 
treatment compared to control cells and ￿ stands for a reduction. 
 
 
The same treatment scheme used in section 4.6.1. were applied for the determination of FPP and 
GGPP.  
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Fig. 42. SH-SY5Y-APP isoprenoid levels incubated 24 h with 5 µM lovastatin. (a) 63% relative reduction of 
FPP and (b) 94% relative reduction of GGPP. Means ± SD, n.s. = non significant; **p<0.01; (n=2). 
 
Figure 42 a and b illustrate that the 24 h lovastatin (5 µM) treatment had a strong effect on the 
cellular isoprenoid levels. FPP levels were significantly (p = 0.0456) decreased by 63%, while 
the impact on GGPP (p = 0.0072) was even stronger and reached 94% reduction in average.   136 
To further understand the effects of blocking the MVA-pathway (downstream from FPP) by the 
aforementioned inhibitors, the following set of experiments was carried out. Cells were incubated 
for  24  hours  with  U  18666A  (1  µM),  an  inhibitor  of  the  desmosterol  reductase  and  the 
oxidosqualene cyclase. The results in Figure 43 clearly show an FPP elevation of 56% (p = 
0.0006) while GGPP levels were unchanged.  
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Fig. 43. SH-SY5Y-APP isoprenoid levels incubated 24 h with 1 µM U 18666 A. (a) 56% relative elevation of 
FPP and (b) unchanged GGPP levels. Means ± SD, n.s. = non significant; ***p<0.001; (n=4). 
 
 
The  last  experimental  setup  aimed  to  provide  information  on  isoprenoid  levels  when  either 
transferase was blocked. FTi 277 and GGTi 286 block specifically those enzymes, respectively 
which  use  FPP  and  GGPP  as  a  substrate  for  post  translational  modifications.  These  two 
experiments  were  designed,  taking  the  possible  instability  of  the  drugs  into  account.  Each 
inhibitor  was  added  at  time  points  0,  5,  10, 15  and 20  hours (1  µM  respectively)  to  give  a 
cumulative concentration of 5 µM, respectively. The two graphs in Figure 44 a and b display for 
FTi 277 a significant (p = 0.0034) FPP reduction by 24% while GGPP levels were unaltered (p = 
0.1175). The GGTi 286 treatment had no significant influence on isoprenoid abundance in this 
experimental setup. 
   137 
control FTi 277 control FTi 277
0
20
40
60
80
100
120
140
(24h; 5 x 1 µM)
r
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
 
[
%
]
**
n.s.
control GGTi 286  control GGTi 286 
0
20
40
60
80
100
120
140
n.s.
n.s.
(24h; 5 x 1 µM)
r
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
 
[
%
]
a b FPP FPP GGPP GGPP
control FTi 277 control FTi 277
0
20
40
60
80
100
120
140
(24h; 5 x 1 µM)
r
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
 
[
%
]
**
n.s.
control GGTi 286  control GGTi 286 
0
20
40
60
80
100
120
140
n.s.
n.s.
(24h; 5 x 1 µM)
r
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
 
[
%
]
a b
control FTi 277 control FTi 277
0
20
40
60
80
100
120
140
(24h; 5 x 1 µM)
r
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
 
[
%
]
**
n.s.
control GGTi 286  control GGTi 286 
0
20
40
60
80
100
120
140
n.s.
n.s.
(24h; 5 x 1 µM)
r
e
l
a
t
i
v
e
 
a
b
u
n
d
a
n
c
e
 
[
%
]
a b FPP FPP GGPP GGPP
 
Fig. 424.  SH-SY5Y-APP isoprenoid levels incubated 24 h with 1 µM FTi 277 and GGTi 286, freshly 
added at the following time points: 0, 5, 10, 15 and 20 hours. (a) Influence of FTi 277 on FPP and 
GGPP levels. (b) Influence of GGTi 286 on FPP and GGPP. Means ± SD, n.s. = non significant; 
**p<0.01; (n=3). 
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5. DISCUSSION 
5.1. Previous studies of FPP ad GGPP quantification  
As described in the introduction, FPP and GGPP are precursors for various end-products of the 
MVA-pathway.  Their  function,  regulation  and  role  in  cell  physiology  have  been  previously 
discussed  in  detail.
1,17,83,325  Despite  their  critical  roles  in  a  wide  array  of  fundamental  cell 
processes, our knowledge on the cellular regulation of the two isoprenoids FPP and GGPP is 
limited. Preventing advancement was mainly due to analytical difficulties concerning a robust 
isolation technique and a sensitive detection method. The analytical progress in detecting FPP 
and  GGPP  now allows  investigations of  isoprenoid regulation in  vitro and  in  vivo,  which  is 
documented herein.  
 
Researchers  have  investigated  peripheral  isoprenoid/protein  complexes  via  methods  including 
mass spectrometry
127, and semi-quantitative immunoassays.
12,326 A major shortcoming of earlier 
described methods was the determination of solely FPP
85,92,93; moreover, these methods were 
cumbersome and costly due the use of radio labeled substrates. Data contained within the current 
work,  on  the  determination  of  the  free  isoprenoids,  is  crucial  in  elucidating  the  regulatory 
mechanisms  governing  isoprenylation.  An  impressive  amount  of  research  has  focused 
specifically on brain cholesterol distribution and regulation
327,328, but also on the longer chain 
isoprenoids or derivatives dolichol, ubiquinone and HemeA.
329,330 
FPP  is  the  precursor  for  not  only  cholesterol  but also  for  dolichol,  ubiquinone  and  HemeA. 
Additionally, like GGPP it is a substrate for the isoprenylation of distinct members of the small 
GTPases.
331,332 There is a lack of data regarding FPP and GGPP tissue concentrations using valid 
detection methods.  
 
The most relevant work for the sensitive detection of FPP and GGPP involved the enzymatic 
coupling of both compounds to their respective dansyl labeled pentapeptides.
94 This method was 
initially  applied  for  the  determination  of  cellular  levels  (in  vitro).  A  modified  method  was 
published for the determination of FPP and GGPP in mouse tissues, including the brain
95 (for a 
method comparison please also refer to Table 30).  
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The  method  described  by  Tong  and  colleagues
94  comprised  the  derivatization  of  the  two 
isoprenoids  to  their  respective  dansyl-labeled  pentapeptides  and  subsequent  fluorescence 
detection. Similar methods were also reported by Saisho et al. who applied a fluorescence tag, 9-
antroylcyanide,  after  alkaline  phosphatase  conversion  of  the  diphosphate  to  farnesol.
93  This 
reaction however is limited by the generated FPP–FOH gradient. 
 
5.2. Method development  
5.2.1. Modifications to the pre-existing assay conditions  
The enzymatic reaction with the subsequent HPLC-FLD separation and detection method was 
adapted from Tong et al.
94 Changes in assay conditions and the settings for the chromatographic 
separation were necessary to optimize the method. The incubation time of the enzymatic reaction 
was  shortened from  two  hours  to 1.5  hours.  The  most relevant  change  was  achieved  by  the 
implementation of the Fused Core
® column technology of the Ascentis
® Express column. The 
physicochemical nature of the column bed particles with an impenetrable 1.7 µM core, covered 
by a porous 0.5 µM silica layer, led to a reduced mass transfer and consequently, to an increased 
peak efficiency.
333,334 Improvements upon the published method by Tong and colleagues were as 
follows:  
 
1.  Retention  time  and  peak  shape  of  both  analytes  were  improved,  including  tailing 
factor  and  peak  width,  which  led  to  a  4-fold  increased  detection  limit  upon  the 
separation on the Zorbax column 
2.   Flow rate was noticeably reduced in two steps from 1 mL/min
94 to 0.7 mL/min on the 
Zorbax column. Using the the Ascentis
® Express column further reduced the flow rate 
to 0.4 mL/min.  
 
Additional changes to the FLD settings were necessary to achieve optimal peak intensities.  
 
5.2.2. Development of a robust FPP and GGPP isolation procedure from tissue 
An aim of the current work was to establish a robust isolation method for FPP and GGPP from 
brain tissue samples, before enzymatically labeling both isoprenoids (section 3.1.1.) and quantify 
FPP* and GGPP* reproducible. Obtaining clean residues from the extraction for the enzymatic   140 
conversion and analytical studies represented a precondition, since residues potentially inhibit the 
activity of the converting enzymes and lead to high chromatographic background noise.  
5.2.2.1. Liquid/liquid extraction (LLE) 
Initially, a LLE for FPP and GGPP from small tissue samples (~20 mg) was conducted according 
to Tong and colleagues.
94 The method was successfully applied to cell homogenates but not for 
tissue samples, such as for brain homogenate. A high degree of impurities, most likely due to 
irremovable precipitated proteins and lipids inhibited the enzymatic activity of the FTase and 
GGTase. Consequently, there was a demand for a new isolation technique. First attempts, as 
shown in the preliminary experiments, aimed to test various organic solvents for an optimized 
LLE based extraction. The solvents were selected for their compatibility with the diphosphates, 
with respect to solubility and stability. As suggested by Tong et al., experiments were carried out 
under  ammoniac  conditions,  which  prevented  the  hydrolysis  of  the  phosphate  esters  of  the 
pyrophophates.
94 The utilization of organic solvents added to the solubility of the isoprenoids. 
Furthermore,  initial  experiments  were  carried  out  with  spiked  water  samples,  which  were 
hypothesized to deliver recoveries close to 100% due to the absence of matrix interference.  
Saisho et al. showed n-hexane to be suitable for the isolation.
93 Bruenger et al. used ammoniac 
dieethylether and 1-butanol
92 similar to Tong et al.
94, mixtures of these organic solvents with 
NH4OH were employed and tested for the isolation of FPP and GGPP in the current work. Based 
on  these  experiments  it  was  concluded  that  NH4OH  was  needed  for  the  stability  of  both 
isoprenoids. As for the organic solvents the n-hexane and 1-butanol mixtures were shown to be 
suitable with recoveries between 45 and 70% from spiked cell homogenates. Nevertheless, LLE 
conditions  failed  to  show  clean  residues  for  the  enzymatic  reaction  when  applied  to  tissue 
homogenate.  
 
As  an  enhancement  of  common  liquid/liquid  based  extractions  a  matrix  assisted  LLE  was 
subsequently employed. This technique was previously used in collaboration with our group for 
the  extraction  of  exogenous  compounds  from  brain  matrix
324  and  was  tested  for  the  current 
application to provide cleaner sample extracts. The diatomaceous earth filling of the columns is 
used to retain proteins, lipids, ions etc. and organic solvents are selected to allow for elution of 
the  desired  analyte.  However,  attempts  with  several  different  organic  elution  solvents 
continuously resulted in high degrees of impurity, limiting the detection of FPP* and GGPP*. 
The impurities led to a high background noise during the initial 15 minutes of the analytical run,   141 
severely impeding FPP* and GGPP* detection. There was no detectable peak for FPP* due to co-
eluting impurities, while the impact on GGPP* detection was less significant due to the declining 
baseline signal. The detection of a GGPP* peak was taken as a proof for the enzymatic reaction 
to occur, but at this point a partial impairment due to impurities could not be excluded.   
 
5.2.2.2. Solid phase extraction (SPE) 
5.2.2.2.1. Normal phase or reversed phase mechanisms 
To overcome the issue of impurities after the LLE or matrix assisted LLE another conventionally 
used sample preparation step was investigated. Even though over the last couple of years new and 
sophisticated isolation techniques and tools were brought onto the market SPE remains the most 
widespread isolation technique for the isolation of drugs and/or metabolites from organic matrix 
samples.
335 Due to their large diversity in size, format and especially packing materials (from 
various suppliers), these cartridges are almost universally applicable for small molecules. The 
basic underlying mechanism is retention via various interactions between the analyte and the 
stationary phase of the cartridge. 
Similar to HPLC columns, SPE cartridges can be used under normal phase (NP) and reversed 
phase (RP) mode. The NP mode describes a more or less hydrophilic analyte in a mostly aprotic 
solvent. The elution power of applied elution solvents increases with an increasing dielectric 
constant. The RP mode describes the contrary. The physicochemical properties of FPP and GGPP 
clearly separate each molecule in a hydrophilic head group and a lipophilic tail theoretically 
allowing both aforementioned mechanisms. The C20 chain of GGPP allows the molecule to have 
stronger lipophilic interactions than the C15 FPP. 
 
According  to  the  suppliers  (Sigma-Aldrich)  description,  the  Discovery
®  cyanopropyl  bonded 
phase (DSC-CN) SPE cartridges can be used for RP mode of lipophilic analytes in aqueous 
solutions, while they are less retentive for polar analytes in NP mode when compared to the silica 
(DSC-Si) or the dihydroxy (DSC-Diol) bonded sorbents under the same conditions.  
With respect to the aforementioned details, the first SPE experiment was designed to determine 
the most favorable conditions. Interestingly, the comparison of the NP and RP mode showed a 
better retention for FPP under NP conditions for both cartridges. GGPP with the longer lipophilic 
tail group was retained stronger on the DSC-CN phase. However, the recoveries were insufficient   142 
and the results conflicting and hence required fine-tuning. From these initial results a general 
conclusion as to whether the NP or RP mode would result in better recoveries could not be met 
and further stationary phases with varying conditions needed to be tested. 
 
5.2.2.2.2. Anionic interaction mechanism 
Further screening of SPE cartridges and modifications of the applied protocols were necessary. 
Therefore, it was tested whether ionic interactions of the isoprenoid diphosphate groups with 
amino groups of the stationary phase would occur. Initial experiments with four different sorbent 
bound  amine-groups  for  the  interaction  with  anionic  structures  were  tested.  To  determine  a 
possible influence of the different amine functions of the cartridges, identical protocols were 
applied for all cartridges. The sample was applied in a neutral solution and the elution steps only 
varied in their organic composition; neither the elution steps nor the eluate from the sample step 
showed significant analyte concentrations after enzymatic conversion. In order to confirm that 
analyte loss did not occur due to instability of the diphosphate groups but due to a firm binding of 
the isoprenoids to the functional groups of the cartridge filling, the pH of the sample solution was 
modified to acidic, neutral and basic conditions. Furthermore, the protocols for the four different 
anion exchanger cartridges were slightly modified.  
The acidic pH of the sample solution or the addition of formic  acid  both resulted in almost 
complete analyte loss, which most likely occurred due to acidic hydrolysis of the diphosphates of 
both isoprenoids. The comparison of the Oasis
® WAX and Strata X-AW SPEs, both weak anion 
exchangers, clearly revealed the advantage of an alkaline elution. The difference between the first 
and the second elution step showed a clear dependency of the pH of the eluting solvents; the 
addition of NH4OH facilitated the elution of both isoprenoids with the organic solvent because 
the strong base led to a deprotonated, neutral functional group of the sorbent and shifted the 
equilibrium of the diphosphate towards the anionic form. Consequently the ionic interactions 
were enhanced and retention of the analytes did not occur. This was observed without any major 
influence at pH values between 6 and 12 of the sample solution. The two elution steps on the X-
AW cartridges yielded the best results and consequently that protocol was selected for further 
optimization as compared to mixtures containing acetonitrile. 
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A critical step during SPE procedures for recovery is the elution step and the composition of the 
deployed solution.  The  elution  conditions  require  a complete  offset  of  any  kind  of  chemical 
interactions between the analyte and the stationary phase. Results from a comparison of two 
different ammoniac elution solvents with different organic composition revealed that methanol as 
the more polar and protic solvent had the higher elution power. 
 
5.2.2.2.3. Mixed mode and apolar interaction mechanism 
As described in the previous section isoprenoids were shown to be possibly retained on the SPE 
cartridges via ionic interactions of their polar diphosphate group. Further screening assays were 
conducted  to  test  whether  lipophilic-lipophilic  interactions  of  the  apolar  carbohydrate  chains 
could  result  in  an  optimized  retention  during  the  sample  loading  step.  Moreover,  these 
interactions  were  compared  to  mixed  mode  SPEs.  Mixed  mode  SPE  cartridges  like  the 
hydrophilic-lipophilic balance (HLB) from Oasis
® offer a possible retention via polar and apolar 
interactions of the stationary phase with the analyte and were therefore designed to be applicable 
for a wide spectrum of analytes. 
 
Two mixed mode (HLB and Strata X) and a purely C18 (DSC-18) phase were subjected to the 
identical protocol. Samples were applied in solutions with a pH of 1 and 6-7. A solution under 
basic  conditions  was  not  tested,  since  a  strong  basic  environment  would  lead  to  multiple 
negatively  charged  isoprenoids,  consequently  hampering  the  apolar  interactions  with  the 
stationary phase. Overall, it was confirmed that again an acidic pH led to significant analyte loss. 
Furthermore,  in  contrast  to  the  previously  described  pH  dependency  of  the  anion  exchanger 
columns (section 5.2.2.2.2.) during elution, the alkalinization of the eluent in this experimental 
setup did not have a relevant impact, suggesting that the basic mechanism relies purely on apolar 
interactions. The eluate on the DSC-18 phase did not show a significant analyte concentration 
most likely due to a strong retention. 
 
In  summary,  the  HLB  cartridges  showed  the  strongest  signal  intensities  under  the  tested 
conditions and were therefore used for further improvements of the protocol.  
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In  order  to  achieve  a  complete  elution  with  preferably  small  amounts  of  solvent,  several 
ammoniac solvent compositions were compared. The screening revealed the need for a strong 
organic solvent in terms of eluting power on a RP system. Based on the lowest dielectric constant 
of the most common organic solvents n-hexane was chosen and tested in an elution profile assay. 
For the test conditions five separate 500 µL steps of a n-hexane/2-propanol/NH4OH mixture were 
applied  to  the  cartridges  during  the  elution  step.  Each  volume  was  collected  and  measured 
separately and revealed a full elution after the third step.  
 
During the aforementioned test runs the main focus was to achieve adequate analyte retention and 
subsequently a complete elution. For matrix samples it is further important to include a wash step 
into  the  SPE  protocol  during  which  impurities  on  the  column  bed  are  reduced  and  analyte 
concentration is not affected. Such steps are especially important to overcome ion suppression 
when measuring on a MS system but are also necessary to lower background noise in common 
HPLC detectors like FLD or UV. Additionally in the case of the current application, the wash 
step was necessary to provide cleaner samples for the enzymatic reaction. The most commonly 
used wash solvents are mixtures of methanol and formic acid. The latter was applied in a 2% 
solution and resulted in a complete analyte loss, due to the earlier mentioned acidic inorganic 
ester hydrolysis of the diphosphates. Methanol was used in concentrations up to 100% and did 
not reveal any significant analyte loss during the wash/elution profiling. 
 
The subsequent SPE screening led to two distinct protocols with two different SPE cartridges. 
Directly comparing the two protocols the HLB method was slightly superior and was thereafter 
employed for spiked SY5Y cell matrix analysis. Cell matrix was chosen to demonstrate matrix 
interference on a lower level than tissue samples. Cells are a less complex system concerning the 
abundance of potentially interfering compounds, especially lipids. This was demonstrated by the 
direct  application  of  tissue  homogenate  samples,  which  led to  an immediate  clogging of  the 
cartridges. However, results with SY5Y matrix were not satisfactory due to one of the following 
reasons or combinations thereof: 
 
·  analyte  loss  due  to  endogenous  phosphatase(s)  activity  preventing  the  enzymatic 
conversion of the free alcohols   145 
·  low  concentration  of  FPP*  and  GGPP*  due  to  impurities  hindering  the  enzymatic 
conversion 
·  low detection due to a high degree of impurities resulting in a poor signal to noise ratio 
·  low elution from FPP and GGPP from the SPE due to matrix interactions 
5.2.2.2.3. Improvements of the HLB application 
Limitations to the HLB protocol developed thus far, in terms of purity of the eluate, required 
modifications of the protocol. One main contributor to the failure of the SPE application with cell 
matrices was thought to be the activity of endogenous phosphatases. Preliminary tests showed 
that  despite  handling  the  samples  at  4  °C,  distinct  analyte  loss  occurred.  Experiments  with 
phosphatase inhibitors clearly showed the beneficial effect of the enzyme suppression in terms of 
higher recoveries for both isoprenoids. The two commercially available inhibitors and a mixture 
of imidazole and sodium fluoride, acting on alkaline and acid phosphatase were compared. The 
markedly higher effect of the Halt
® compared to the Phosstop® inhibitor on GGPP and vice versa 
on FPP degradation, resulted in a combinatorial mixture for further experiments. In summary, the 
introduction of two different phosphatase inhibitors suppressed phosphatase activity sufficiently. 
To overcome the problem of a high degree of impurities from brain matrix samples leading to 
column  clogging  and/or  possibly  reducing  isoprenoid  recovery,  several  pre-SPE  sample 
preparation attempts were tested. The most promising approach was the combination of PPT and 
the HLB protocol, which is a widely used approach for plasma samples.  
However, none of the approaches including the PPT overcame the aforementioned problems and 
the detection of FPP and GGPP remained strongly impeded or completely hindered. 
As shown in section 4.1.4.2. the amplification of LLE with a matrix assisted LLE led to partly 
detectable peaks and was therefore tested in combination with the SPE protocol developed as a 
possible approach for the FPP and GGPP isolation from matrix samples. The earlier mentioned 
problematic background  in  the  chromatograms  was  the  result  of  a high degree  of  impurities 
which  were  not  retained  on  the  Extrelut
®  columns.  In  the  following  set  of  experiments  this 
problem was overcome by the combination of the Extrelut
® extraction and the HLB protocol to 
result  in  a  two  dimensional  sample  clean-up  procedure  (section  4.1.8.).  Based  on  previous 
findings  during  the  development  of  the  SPE  protocol,  NH4OH  containing  mixtures  were 
compared to pure n-hexane for the elution from the Extrelut
® column. As previously shown the 
alkalization of the eluent was necessary for the extraction of the isoprenoids. Overall, the best   146 
results were obtained by elution with a water saturated 1-butanol mixture, similar to a solvent 
used by Bruenger et al.
92 Following the Extrelut
® elution a centrifugation step was implemented 
in order to remove dissolved proteins and to prevent column clogging of the SPE cartridges. 
 
5.2.3. Precision and internal standard 
One of the key factors in quantitative analytics is the precision of a measurement.
317 Precision, 
also  often  referred  to  as  reproducibility  describes  the  closeness  of  individual  data  points  of 
repeated measurements, from a single homogenous sample, under identical conditions. Variations 
during analytical runs mainly originate from varying injection volumes of the HPLC autosampler, 
differences  in  detector  sensitivity  or  from  sample  loss  during  analyte  clean-up  steps.  To 
compensate  for  these  errors,  calibration  standards  are  used  to  validate  the  results.  The  most 
commonly used methods are the standard addition method and the external or internal calibration, 
while  the  latter  is  the  gold  standard  and  often  preferentially  used  because  of  its  higher 
precision.
336 The ideal IS, when using fluorescence detection is chemically inert, elutes closely to 
the analyte but not at the same Rt and its chemical structure largely,  if not completely (e.g. 
stereoisomers) resembles the analyte. The Rt and structure might even be the same when a mass 
based detector is used. In such cases the heavy isotope labeled forms of the analyte are optimal 
internal standards.
337 In respect to the method developed within the current body of work, the 
internal calibration technique was chosen due to the extensive sample clean-up and the associated 
possible sample loss. 
 
The  implementation  of  an  internal  standard  was  a  significant  improvement  over  previously 
described  methods  detecting  FPP  and  GGPP  without  an  IS.
92,94,95  Concerning  the  structural 
similarities  between  the  IS  and  the  analyte  the  following  section  illustrates  the  challenges 
associated with the application described in the current work.  
 
The  assay  for  the  simultaneous  determination  of  FPP  and  GGPP  contained  two  structurally 
slightly different analytes. Moreover, due to the intermediate enzymatic reaction the analytes are 
structurally  very  different  for the  sample  preparation  steps  and  for  the HPLC-FLD  detection 
(Figure 5). Furthermore, stability of the IS was an issue due to the long drying steps (approx. 5 h 
after the Extrelut
® and 2 hours after the HLB step) in the SpeedVac during sample preparation 
(Figure 3). An ideal non-radioactive IS for this application would be a compound undergoing the   147 
same  enzymatic  conversion  to  one  of  the  dansyl-labeled  pentapeptides.  However,  limited 
commercial  availability  and  a  time  consuming  synthesis  severely  limited  the  possibility  for 
applying such an IS. Furthermore, subsequent studies would have been necessary to determine 
the influence of an additional compound during the enzymatic reaction. The implementation of 
14C-radioactive labeled FPP and GGPP would have been a possible route; however technical 
limitations  prevented  the  use  of  its  implementation  e.g.  radioactive  laboratory  facilities  for 
HPLC-FLD.  Furthermore,  the  development  of  a  non-radioactive  method  would  provide  a 
simplified technique and would target a wider audience. 
 
Hence, to satisfy the aforementioned requirements, 1, 2-dioleoyl-sn-glycero-3-phosphoethanol-
amine was chosen as an IS which offered a lipophilic carbohydrate chain attached to a dansyl 
head-group and was commercially available. It showed a Rt (7.1 min) between FPP* and GGPP*, 
however,  it  was  deemed  inadequate  due  to  its  chemical  instability  under  the  experimental 
conditions employed.  
 
Further investigations led to DNP as an appropriate IS and synthesis conducted as described by 
Naassner  et  al.
316as  the  compound  was  commercially  not  available.  Preparative  clean-up  via 
HPLC provided a clean IS, characterized by means of a 300 MHz H-NMR spectrum and HPLC-
FLD measurements of DNP solutions e.g. good peak to noise ratio and absence of interfering 
peaks. The Rt of the IS was 1.1 min after the elution of GGPP*.  
Overall,  DNP  as  an  IS  has  some  shortcomings  concerning  its  structure,  as  compared  to  the 
analytes (Figure 19) but was nevertheless shown to be a suitable candidate as shown by the 
implementation in the method validation, described in the following paragraphs.   
 
5.3. Method validation 
The  method  development  as  described  in  the  proceeding  paragraphs  was  consequently  fully 
validated,  including  within-run  and  between-run  accuracy  and  precision  proving  the 
reproducibility of the assay and the accuracy of the results. Concentrations were back-calculated 
using an eight-point calibration curve. The terminology “validation” is very variable, ranging 
from  a  simple  proof  of  linearity  to  full  validations  described  by  the  Food  and  Drug 
Administration  (FDA)  or  the  International  Conference  on  Harmonisation  of  Technical   148 
Requirements for Registration of Pharmaceuticals for Human Use (ICH). The complexity of the 
FDA guideline will be discussed in the following paragraphs.    
 
After the successful method development for the extraction and detection of FPP and GGPP from 
cellular  brain  matrices,  subsequent  experiments  were  conducted  to  prove  the  validity  of  the 
method and appropriateness for quantitative analysis of human brain samples.  
 
The initial step was the FPP* and GGPP* analyte confirmation by high accuracy FT-ICR MS 
measurements. FPP* and GGPP* peak fractions were collected from spiked tissue samples after 
HPLC separation and analyzed subsequently with high mass accuracy on the FT-ICR MS. The 
measured accurate masses for FPP* and GGPP* corresponded well with the calculated exact 
masses (<5ppm), thus confirming the identity of the labeled isoprenoids. 
 
The following method validation procedures met all criteria outlined by the FDA for full method 
validation  of  bioanalytical  methods.
317  These  criteria  included  selectivity,  linearity,  stability, 
accuracy,  precision, recovery  and  repeated  measurements  at  the  lower  limit  of  quantification 
(LLOQ). The technique developed in the current work also employed a weighting factor for the 
calibration  curves  to  improve  accuracy.  The  following  sections  briefly  depict  each  single 
aforementioned criterion and its importance in the development of the method. 
 
5.3.1. Selectivity 
The  major  challenge  for  establishing  the  selectivity  of  this  method  was  the  presence  of 
endogenous FPP and GGPP levels in all brain samples. Additional to the analyte confirmation, it 
was  necessary  to  clearly  demonstrate  that  the  observed  peaks  for  FPP*  and  GGPP*  only 
originated from the two isoprenoids  FPP and GGPP. Therefore, it was required to obtain an 
isoprenoid free matrix, which was achieved by storage of the homogenized tissue batch at RT; 
endogenous  phosphatases  degraded  endogenous  pyrophosphate  pools.  The  resulting  zero  and 
blank  samples  showed  no  interfering  peaks  at  the  respective  retention  times  and  thus 
demonstrated the selectivity of the method. 
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5.3.2. Linearity 
The calibration range for each isoprenoid was chosen according to test runs of brain samples 
prior the validation. From these trials it became apparent that GGPP abundance was higher in 
human brain samples and consequently the calibration range was shifted to higher concentrations. 
Furthermore, the LOD and LLOQ for GGPP were higher for GGPP than for FPP. 
A common method to obtain a good curve fit in bioanalytics is the use of a weighting factor, 
which proved to be beneficial for both analytes. Consequently, all correlation coefficients (r
2) 
were greater than 0.99 for both analytes and the relative deviation values (calculated vs. nominal) 
were lower than 15%, thus fully meeting the FDA requirements.
317 
 
5.3.3. LLOQ 
Within the calibration range the LLOQ is given special interest. Peak area and the peak-to-noise 
ratio become very small leading to possibly greater variability between the measured and true 
values. Separate  measurements of six individual spiked brain samples at the  LLOQ revealed 
accuracy and precision values below 10%, well within the FDA allowance of 20% variation.
317  
 
5.3.4. Accuracy and Precision 
Intra- and inter-day accuracy and precision describes the closeness of single measurements from 
their true value and the variation from each other within different measurements on one day and 
within consecutive days. The FDA accepts 15% variation
317 and with the fulfillment of these 
requirements,  isoprenoid  values  obtained  with  the  developed  method  were  shown  to  be 
reproducible. The samples which were chosen for these tests were in the lower, middle and upper 
calibration range, but with distinct nominal concentrations from the standard samples. Moreover, 
these QC samples were taken from different brain homogenates than the calibration samples to 
exclude any matrix dependency.   
 
5.3.5. Recovery 
During the developmental stage of the method a wide range of extraction methods and materials 
were tested. Challenges were encountered in sufficiently extracting and determining  FPP and 
GGPP from brain samples. As discussed earlier, the physiochemical properties of the isoprenoids 
impede a simple sample preparation and as a downside of the double clean-up step, employing   150 
matrix  assisted  LLE  and  SPE,  analyte  loss  was  somewhat  problematic.  The  recoveries  were 
determined in two different ways. Firstly, by utilizing the developed method to analyze samples 
which were spiked before and after the clean-up steps. Secondly, the experiments were repeated 
with radioactive labeled FPP and GGPP, without the intermediate enzymatic reaction, to exclude 
any interference from the enzymatic conversion of the isoprenoids on overall recovery. These 
data substantiated the primary findings. Overall the determinations of the recoveries in the low, 
medium and upper concentration range were reproducible. 
 
5.3.6. Stability  
Tests  for  the  stability  of  an  analyte  can  cover  a  whole  spectrum  of  different  conditions. 
Depending  on  the  nature  of  the  sample,  the  preparation,  handling  and  the  applied  analytical 
procedures, these experiments should be designed to investigate all possible influencers for the 
analyte  at  hand.  For  the  current  application  storage  conditions  were  of  highest  importance, 
including long-time storage and freeze-thaw cycles, stability at RT and in the autosampler. The 
results  revealed  an  excellent  stability  of  the  analytes  under  the  applied  conditions  with  the 
exception of long time (> 10 h) storage in the autosampler, in the dark at 4 °C. Consequently, all 
experiments were planned and executed so that all samples could be measured within a 10 h time 
span.    
 
5.3.7. Partial method validation for mouse brain samples 
Earlier studies by our group revealed detectable lovastatin and simvastatin and to a lower extent 
pravastatin levels  in  the  brains  of  chronically  treated  mice. These  studies,  as  well as  further 
studies with simvastatin in guinea pigs showed a cerebral influence of statins on the expression of 
various genes.
255,338 The developed method presented herein, enables the expansion of previously 
published  in  vitro  statin  studies
202,274  and  to  test  the  influence  of 
mevalonate/isoprenoid/cholesterol pathway inhibitors on APP processing in vivo. 
For the interpretation of the pharmacological modulation of isoprenoid levels and its impact on 
Aβ production, the measurement of cerebral FPP and GGPP levels is essential.   
It appears less reliable to measure statin effects on brain cholesterol levels for two reasons: (1) 
enzymes  of  the  isoprenoid  and  prenylation  pathway  have  a  higher  affinity  to  FPP  than  the 
squalene synthase leading to cholesterol;
123 consequently FPP and GGPP concentrations might be   151 
far more susceptible to fluctuations in upstream mevalonate abundance and (2) FPP and GGPP 
are  intermediates,  consequently  having  a  higher  turnover  in  the  cell  than  the  end-product 
cholesterol
123 and thus acting as a more sensitive indicator for the activity of the MVA-pathway. 
Thus, FPP and GGPP measurements will add further information to cholesterol determinations.  
Following this notion it was of interest for the current work if cerebral isoprenoid levels were 
influenced  by  chronic  simvastatin  treatment  in  mice.  Moreover,  further  investigations  were 
conducted  to  measure  age-dependant  changes  of  cholesterol  and  isoprenoid regulation in  the 
CNS. Due to sample availability such studies are far more feasible to be measured in rodents than 
in  humans.  Due  to  these  reasons  the  isolation  of  FPP  and  GGPP  and  with  subsequent 
quantification was further extended to measure isoprenoid levels in mouse brains. As explained 
in  the  results  section  (section  4.2.1.8.)  pig  brain  homogenate  was  used  for  the  calibration 
standards in studies with mouse brain samples. Therefore, the calibration curves in human brain 
matrix were compared to the identical nominal concentrations in pig and mouse brain matrices. 
An overlay of the three calibration curves showed alignment with the calculated results within the 
accepted variations and the r
2 values for the linear regression of the mean values were greater 
than 0.99. Consequently the method was also applied for mouse brain samples. 
 
5.3.8. Method transfer to an UHPLC-MS/MS system 
Prior the method transfer the assay was fully validated according to the latest FDA guideline.
317 
This validation showed the robustness of the sample preparation which was unchanged for the 
method transfer. Moreover, the previously described pre-column derivatization technique for FPP 
and GGPP via enzymatic coupling to their respective dansyl-labeled pentapeptides was kept for 
the  UHPLC-MS/MS  assay  for  the  following  reasons.  Firstly,  the  enzymatic  removal  of  the 
pyrophosphate group greatly increases hydrophobicity and thus chromatographic retention of the 
isoprenoids on reversed-phase HPLC columns. Secondly, the increased proton affinity from the 
label  strongly  enhances  the  ionization  efficiency  for  FPP*  and  GGPP*.  And  finally,  the 
fluorescent activity of the label allows the complementary analysis of the same FPP and GGPP 
containing samples by HPLC-FLD.  
The assay was shown to be linear from 5 to 250 ng/ml and the LLOQ (5 ng/ml for both analytes) 
were  determined  accordingly.  Furthermore,  and  important  for  LC-MS  analysis,  infusion 
chromatograms clearly showed no interference of co-eluting compounds with signal intensities of 
both analytes at their respective retention times.   152 
Finally, a direct comparison of results obtained by the two methods, HPLC-FLC and UHPLC-
MS/MS, revealed a good correlation of the data, although a slight positive bias for the UHPLC-
MS/MS  method can be observed close to the  quantification limit. Transferring the data to a 
Bland-Altman-plot also revealed this bias for both analytes (data not shown) but values were still 
considered  acceptable  as  all  values  were  within  1.96  times  of  the  standard  deviation  of  the 
differences calculated for each value obtained from both assays.     
 
5.4. Method comparisons 
The rational for the development of a new isolation technique for FPP and GGPP was the fact 
that previous studies by Tong and colleagues focused on the detection of the two isoprenoids in 
in vitro models.
94 Prior the onset of the current work there was no method available for the 
simultaneous  determination  of  FPP  and  GGPP  in  tissue.  The  current  work  builds  upon  the 
analytical method developed by Tong and colleagues.
94 It demonstrates an optimized analytical 
protocol in combination with a newly developed isolation technique for these isoprenoids from 
human and rodent brain tissue. The incorporation of an internal standard allowed for the first time 
a  state  of  the  art  method  validation  according  to  the  most  recent  guideline  for  bioanalytical 
method validation. The publication of an article by Tong and colleagues describing the detection 
of  endogenous  isoprenoid  level  in  mouse  brain
95,  parallel  to  the  herein  described  work  was 
lacking the incorporation of an internal standard and the description of a data validation. The 
main differences between the mentioned methods are described in Table 30. 
Furthermore, the current work depicts the method transfer to a much faster, more sensitive and 
selective  UHPLC-MS/MS  method.  The  development  of  this  analytical  method  was  mainly 
conducted to provide a platform for a high-throughput screening of bigger sample sets combined 
with the benefit of using smaller tissue fractions in the future.  
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Method  
(publication) 
HPLC-FLD 
(Hooff et al. 2008)
265 
UHPLC-MS/MS 
(Hooff et al. 2010)
339 
HPLC-FLD  
(Tong et al. 2005)
94 
HPLC-FLD  
(Tong et al. 2008)
95 
Run time [min]  20  3  22  22 
Flow rate 
[µL/min] 
400  600  1000  1000 
Rt [min] 
FPP 
GGPP 
 
4.7 
11.9 
 
1.08 
1.56 
 
8.4 
16.9 
 
8.4 
16.9 
IS  DNP  -  -  - 
Validated assay  full  partial  -  - 
Detection in 
cells 
tissue [mg] 
 
- 
X 
 
- 
X 
 
X 
- 
 
X 
X 
Tab. 30. Overview  over  the  newly  developed  and  published  methods  for  the  simultaneous  quantification  of 
endogenous FPP and GGPP levels using liquid chromatography. Rt = retention time, IS = internal standard, 
- = not applicable, X = detection was shown in publication.  
 
5.5. Analysis of human brain samples 
5.5.1. Sample pre-examinations 
(A)  An  initial  examination  was  conducted  to  evaluate  grey  and  white  matter  isoprenoid 
distributions under physiological conditions in aged human brain samples. In analogy to higher 
cholesterol levels in white matter compared to grey matter
20 isoprenoid levels were suspected to 
show a similar distribution pattern.  
After the careful validation of the method, human grey and white frontal cortex samples from 
five different donors were subjected to the developed method.  
The results were the first reported determinations of isoprenoids in human brains. They revealed 
that  GGPP  abundance  was  significantly  higher  in  the  white  matter  compared  to  grey  matter 
samples (Table 31).  
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  mean white matter conc. 
± SD [ng/mg protein] 
mean grey matter conc. 
± SD [ng/mg protein] 
p-value 
(paired t-test) 
GGPP  14.34 +/- 8.4  9.66 +/- 7.73  0.0007 
FPP  2.84 +/- 1.03  3.02 +/- 1.32  0.62 
 
Tab. 301. Concentrations of FPP and GGPP in human brain grey and white matter. The table depicts the mean 
values, SD and the statistically significant higher concentration of GGPP in the white matter compared to 
grey matter abundance (n=5).  
 
A possible explanation for these findings might be the higher cholesterol abundance in the white 
matter  leading  in  a  negative  feedback  mechanism  to  reduced  mevalonate  turnover  into  the 
cholesterol  pathway,  while  simultaneously  maintaining  biosynthesis  of  vital  non-sterol 
isoprenoids.
13 FPP concentrations are generally lower and show a less distinct distribution.
95 A 
plausible  explanation  for  this  observation  is  that  FPP  is  the  branch  point  of  the 
mevalonate/cholesterol/isoprenoid  pathway  providing  the  substrate  for  two  separate  pathways 
including four different enzymes, which diminishes the FPP precursor pool, as explained in the 
introduction (Figure 1).
3  
 
(B) It was further investigated if the PMI would influence isoprenoid concentrations, due to a 
possible degradation in post-mortem tissue. As shown by Olaisen, brain temperature remains 
almost constant for approximately two hours after death before it starts dropping exponentially.
340 
The maintenance of temperature and even a slow decline still enables physiological processes, 
including enzyme activity to occur in tissue, even after blood flow and therefore the supply of 
most importantly oxygen has stopped. In tissues biochemical processes are immediately disturbed 
after blood flow interruption. Therefore, the PMI possibly changes cell physiological conditions. 
Although measured brain temperatures were not available for the samples investigated, one can 
assume a significant difference in average temperature, during the time of brain removal between 
the short (Ø = 3.38 h) and long (Ø = 11.75 h) PMI  groups. In summary,  PMIs and sample 
treatment and their associated possible alterations are a general issue and should be addressed as 
part of an investigation.
341,342  
 
Consequently, for the investigations described in the current work, samples were assigned to two 
groups with short and long PMI; donors from both groups were of similar average age. However,   155 
the current data clearly demonstrated that the longer interval between the death of the patient and 
the removal of the brain had no influence on the isoprenoid levels.  
 
(C) As the final pre-examination, selected samples were subjected to western blot analysis to 
confirm the quality of the visual (Figure 4) separation of grey and white matter within a sample. 
Recently, it has been reported that changes in grey matter of human AD brains is associated with 
hypo-metabolism, especially regarding neuropsychiatric symptoms and behaviour.
343,344 In order 
to determine the abundance of the isoprenoids in the grey matter, a clear separation of grey and 
white matter in the brain samples was  essential. Hence, anti-NeuN antibody that specifically 
indicates grey matter was used in Western blot analysis. NeuN was previously shown to be a 
useful histological marker for neuronal structures, areas with high densities of neuron cell bodies 
associated with the grey matter.
345  
 
5.5.2. Investigation of AD brain samples 
The proceeding investigations demonstrated the independence of isoprenoid levels from  PMI 
time. Moreover, the preparation technique for white and grey matter from human frontal cortex 
samples was proven to be reliable. Important to the following AD brain study was the detection 
of  differences  in  isoprenoid  concentrations  in  the  two  areas  of  the  frontal  cortex  samples, 
consequently leading to the investigation of both, white and grey matter samples of AD patients 
and the comparison to controls. 
As mentioned in the introduction, the mevalonate/isoprenoid/cholesterol pathway has generated 
much attention with regards to AD.
3,261 Of particular interest has been the proposed involvement 
of the two isoprenoids FPP and GGPP via their function in prenylating small GTPases. One of 
the protective effects of statins in brain has been attributed to a reduction in FPP and GGPP 
levels.
3,13 In spite of the keen interest in isoprenoids and AD, evidence supporting involvement of 
isoprenoids  has  only  been  indirect  due  to  a  lack  of  a  quantitative  analytical  method  for 
determining FPP and GGPP levels. These assumptions were based either on elevated levels of 
prenylated small GTPases in AD
124,261,278 or on well characterized models in which statins were 
able to reduce the Aβ load and ROS production via an isoprenoid dependant way.
346   
The current work provides for the first time data indicating that homeostasis of FPP and GGPP 
but not cholesterol is specifically altered in brain tissue of male AD patients (mean Braak stage 
5.1). The conclusion is based on the following: both FPP and GGPP levels were significantly   156 
higher in brain tissue of male AD patients as compared with male control samples of similar age. 
Brain cholesterol levels on the other hand did not differ between the two groups. Furthermore, 
HMG-CoA reductase gene (HMGR) expression was similar between the AD and control group 
and the determination of HMG-CoA reductase activity even revealed a slight reduction in the AD 
brain samples as compared to controls. The results are in line with a report by Omkumar et al. 
1992 describing a negative feed-back mechanism on HMG-CoA reductase activity by increased 
concentrations of ubiqinone outsite the CNS.
347 This hypothetical mechanism is supported by 
reports on elevated ubiquinone levels in AD affected brains.
206 Furthermore, results from the 
investigated AD brains showed significantly elevated gene expression of FPPS, substantiating the 
findings of elevated isoprenoid levels. The up-regulation of  FPPS is a  key finding as it is a 
precursor of both isoprenoids (GGPP, dolichol, ubiquinone), and of cholesterol (Figure 1).
13  
Regulation  of  FPP  and  GGPP  is  not  as  well  understood  as  cholesterol  regulation  and  this 
especially applies to the brain. Low cellular cholesterol levels are sensed by SCAP, which in turn 
triggers a cascade of events ultimately leading to the up-regulation of the HMG-CoA reductase 
and  increased  mevalonate  production.
348  Mevalonate  is  the  upstream  precursor  of  several 
products including FPP. Synthesis of FPP involves the enzyme FPPS and condensation reactions 
of IPP and GPP. As shown in the present study, both FPP levels and FPPS gene expression were 
elevated in male AD brains. What has not been clearly established is if changes in FPP levels are 
detected by SCAP leading to activation of the SREBP-2. In an in vitro model, employing Caco-2 
cells treated with lovastatin (mevalonate depleted), the addition of exogenous FPP did not alter 
mature  SREBP-2  abundance;  whereas  replenishing  mevalonate  counteracted  the  effects  of 
lovastatin on mature SREBP-2.
118 Based on elevated FPP levels and FPPS gene expression in 
contrast to unchanged cholesterol levels and HMG-CoA reductase gene expression, a tentative 
conclusion is that the increase in FPP levels in AD brain may not involve the SCAP/SREBP-2 
pathway.  
GGPP levels but not cholesterol levels were significantly higher in AD brain. FPP serves as a 
precursor of both GGPP and cholesterol. One interpretation of the data is a possible shunting of 
FPP to GGPP and away from cholesterol. This hypothesis is supported by earlier findings of 
elevated GGPP-derived ubiquinone levels in AD brains.
206 The same study revealed decreased 
FPP-derived dolichol levels substantiating the FPP shunt into the GGPP pathway and into protein 
prenylation, supported by findings of elevated Ras gene expression
349 proteins which depend on 
farnesylation.
350     157 
Furthermore,  the  current  work  showed  an  elevated  GGPP  synthase  gene  expression  in  AD 
affected brains compared to healthy control brains, however it did not reach significance. It is 
possible in the case of GGPP that enzymatic activity of GGPPS may be a critical regulatory 
contributor to its synthesis. The underlying  mechanisms for increased  GGPP as well as  FPP 
levels in AD brain tissue are unknown. A speculative explanation may involve proteins that are 
prenylated by the two isoprenoids. It was reported that both FPP and GGPP levels were increased 
when reticulocyte cytosol was incubated with recombinant protein substrates for FPP and GGPP 
prenylation, respectively.
116 
Figure 45 summarizes findings from the current work in context with previously published data 
regarding  AD  pathology  and  the  regulation  of  intermediates  and  products  of  the 
mevalonate/isoprenoid/cholesterol pathway. 
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Fig. 45. Isoprenoids,  small  GTPases  and  Alzheimer’s  Disease.  Levels  of  the  isoprenoids  ubiquinone, 
dolichol, dolichyl-phosphate (dolichyl-P) farnesyl- (FPP) and geranylgeranylpyrophosphate (GGPP) 
were reported to be modified in AD brain. It is known for many years that the long-chain isoprenoid 
dolichol is decreased in post-mortem AD brain tissue, while dolichyl-P and ubiquinone are elevated. 
Data from the current work showed that FPP and GGPP levels were significantly higher in brain 
tissue  of  AD  patients,  while  cholesterol  levels  were  unchanged.  These  data  indicate  distinct 
alterations of isoprenoid metabolism within the mevalonate/isoprenoid/cholesterol pathway. FPP and 
GGPP  play  a  fundamental  role  in  prenylation  of  small  GTPases,  which  function  as  molecular 
switches in various signalling pathways. In AD pathology, small GTPases have been connected with 
oxidative stress, the generation of Ab and synaptic dysfunction (for further details, refer to the text).  
 
In summary, the results of this study show that FPP and GGPP levels in grey and white matter 
were elevated in male AD frontal cortex brain tissue with an average Braak stage core of 5.1. 
While further work is needed to unequivocally demonstrate that FPP and GGPP regulation is   158 
altered in AD, including studies examining brain tissue of other neurodegenerative diseases and 
other  brain  areas,  the  present  findings  support  results  of  an  increased  abundance  of  certain 
prenylated small GTPases, as it has been shown for Rab8 and Rab6 in AD brain.
3,261,284 However, 
other  small  GTPases  including  Rab3  were  shown  to  be  down-regulated
283,  leading  to  the 
speculation  that  post-translational  unmodified  small  GTPases  are  involved  in  triggering 
mevalonate turnover, to  yield higher isoprenoid levels.  Following this notion, the underlying 
mechanisms governing protein prenylation remain to be elucidated and the specific role of certain 
Ras family members in AD pathology need to be unravelled.   
Such investigations together with the findings described in the current work may have utility in 
the development of new drugs similar to bisphosphonates which inhibit FPPS but can bypass the 
blood brain-barrier. 
 
5.6. Analysis of in vivo brain samples 
5.6.1. Pharmacological intervention of the brain MVA-pathway 
Although it has been previously hypothesized that statin treatment would lead to a reduction in 
brain FPP and GGPP levels
262, no published data was available. For a better understanding of the 
regulation of the mevalonate/isoprenoid/cholesterol pathway in the CNS an in vivo mouse study 
was conducted. C57B1/6 mice were chronically treated with simvastatin and the results of this 
study represent the first report on endogenous FPP and GGPP levels in mouse brains after statin 
treatment.  
 
Similar to the earlier described findings in human white and grey matter of control and AD brain 
samples, GGPP levels were higher than FPP levels in the investigated mouse brain samples. 
Those results are consistent with a simultaneous published report on FPP and GGPP levels in 
mouse brain.
95 Table 3 b shows a comparison between the findings described in literature and the 
data described in the current work. Both studies are similar in respect to the relative abundance of 
both  isoprenoids.  Interestingly,  the  report  described  by  Tong  and  colleagues  also  depicted 
absolute concentrations in kidney, liver and heart
95 showing substantially different abundance of 
FPP and GGPP (Table 3 b). An explanation for such differences is not well understood and future 
studies are needed.    159 
Concerning the findings of higher GGPP than FPP levels in the identical samples there is some 
evidence that more proteins are prenylated by GGPP than by FPP.
351 Other authors conclude a 
more  or  less  even  distribution  of  farnesyl-  and  geranylgeranylated  proteins.
123  As  discussed 
earlier, a straight forward explanation accounts solely for the utilization of FPP. The FPP pool 
serves as a supply for the synthesis of cholesterol, GGPP and longer chain isoprenoids and for 
protein  prenylation,  while  GGPP  is  used  for  only  two  of  such  processes,  namely  protein 
prenylation and longer chain isoprenoid synthesis, reducing its turnover rate as compared to FPP. 
As  for  the  simvastatin  effect,  it  has  been  previously  proposed
3  that  HMG-CoA  reductase 
inhibition would reduce brain FPP and GGPP levels but such data had not been reported due to 
analytical difficulties of isolation and detection sensitivity of FPP and GGPP. The effects of statin 
induced HMG-CoA reductase inhibition was effectively illustrated by data on brain FPP and 
GGPP levels, compared to those of the placebo group. The results revealed that simvastatin had a 
greater effect on reducing FPP levels followed by reductions in GGPP and cholesterol levels. 
These data fulfilled the rational expectation that brain simvastatin levels
255 decrease intermediates 
of  the  MVA-pathway.  The  data  sets  collected  during  this  study  showed  a  good  correlation 
especially  when  blotting  the  measured  FPP  against  GGPP  levels,  as  FPP  is  the  immediate 
precursor. The  correlation  of  FPP  and  its downstream  product  cholesterol  is  less  significant, 
albeit visible. These results nicely demonstrate the downstream effect of the inhibition of the 
HMG-CoA reductase as the rate limiting step of the mevalonate/isoprenoid/cholesterol pathway     
 
It  would  appear  that  HMG-CoA  reductase  inhibition  does  not  have  an  equal  effect  on  the 
downstream  products  of  mevalonate.  The  consequences  of  these  differential  effects  on 
isoprenoids and cholesterol on cellular function are unclear. One possibility is that there is a 
gradient of cellular effects based on the magnitude of reduction in the individual lipids with FPP 
associated cell functions more affected.   
In relation to the earlier described AD brain findings it is worth mentioning that HMG-CoA 
reductase inhibition affected both, isoprenoid and cholesterol levels in brain tissue of chronically 
treated mice. In the contrary, regulation of FPP and GGPP in the diseased AD brain appears to be 
altered which may not involve HMG-CoA reductase. 
 
Finally, homogenate from simvastatin treated and control mouse brains was subjected to semi-
quantitative WB analysis using a PanRas antibody directed against members of farnesylated Ras   160 
proteins (H-, N- and K-Ras) and an antibody detecting a common epitope on geranylgeranylated 
Rac-family  members  (Rac1,  RhoA  and  Cdc42).  The  mean  reduction  in  specific  protein 
abundance was pronounced in the farnesylated proteins (PanRas antibody), possibly correlating 
to  the  stronger  effect  of  simvastatin  treatment  on  FPP  than  GGPP  levels.  Overall  the  statin 
treatment markedly reduced protein abundance of the investigated small GTPases. It is worth 
mentioning  that  the  antibodies  employed  did  not  differentiate  between  post-translationally 
modified and unmodified proteins since the epitope regions did not involve the prenylation site. 
These findings are in line with recent reports showing simvastatin induced reduction of different 
members of the small GTPases in cell membranes.
12,202 One possible implication concerning the 
widely discussed beneficial effects of statins in AD might be through reducing the prenylation 
status of small GTPases like Rab6, which was found to be elevated in AD brains. Rab6 is thought 
to be involved in APP processing.
261,278 Other GTPases are also thought to have a putative role in 
AD pathology but remain to be elucidated.
3   
 
5.6.2. The transgenic Thy-1 APP mouse model 
The Thy-1 APP mice represent a transgenic mouse model of the C57Bl/6 mice posessing both the 
Swedish double and the London mutation. The 751 amino acid form of human APP with both 
mutations  is  controlled  by  the  murine  Thy-1  promoter,  which  leads  to  a  high  and  selective 
expression in neurons.
323 Furthermore, a Kozack element was introduced into the DNA sequence 
of the APP to yield higher gene expression. The amino acid sequence of APP contains the Kunitz 
protease inhibitor region, which has been shown to result in altered APP processing leading to 
higher  Aβ  levels in  cell  culture.
352  As  a  result,  plaque formation  is  accelerated  and  the  first 
plaques appear at an age of approximately 6 months. 
Due to the presence of these AD hallmarks this FAD model is widely used to mimic AD/SAD 
findings and to study Aβ lowering attempts. Nevertheless, it should be emphasized at this point 
that  this  and  other  animal  models  for  AD  can  only  reflect  a  relatively  small  portion  of  the 
characteristics of AD, which go far beyond a simple accumulation of Aβ.
353  
Thy-1 APP mice FPP, GGPP and cholesterol levels were unchanged as compared to their non-
transgenic counterparts, although there was a significant reduction of FPP and GGPP in the Thy-
1 mice calculated over both variables (two-way ANOVA). These results show that induced APP 
mutations and associated elevated Aβ levels are not necessarily related to higher isoprenoid levels 
as seen in human AD brains.      161 
5.6.3. Aging 
5.6.3.1. MVA-pathway alterations during aging 
Earlier described findings showed elevated isoprenoid levels in the grey and white matter of male 
AD patients versus healthy age matched controls. Individuals from this study were between 75 
and 85 years of age. Age is the major risk factor for developing AD
220,354 and levels of the 
isoprenoids FPP and GGPP during senescence were completely unknown. However, reports on 
MVA-derived cholesterol and the longer chain isoprenoids ubiquinone and dolichol are available. 
It is crucial to elucidate and understand physiological regulation of FPP and GGPP during aging, 
due to their fundamental role in the MVA-pathway and for cellular processes in general. Recently 
published reports strongly implicated the small GTPases as signalling players during aging
355, 
consequently involving the isoprenoids FPP and GGPP in senescence. Another recent report was 
able to demonstrate a constant and significant increase in HMGR gene expression in the cortex 
and hippocampus of rats ranging from 6 to 24 month of age.
21 These data are not supported by 
findings of HMG-CoA  reductase protein levels in rats between 3 and 24 month of age of a 
different strain. But the same study revealed a higher activity of the HMG-CoA reductase by a 
possible  impaired  phosphorylation/dephosphorylation  mechanism  leading  to  dolichol 
accumulation in the brain.
83 The authors hypothesized an alteration of the activity of branch point 
enzymes of the mevalonate/isoprenoid/cholesterol pathway. 
Based on these aforementioned speculations, three generations of male C57Bl/6 mice at the age 
of 3, 12 and 24 months (young, middle-aged and aged) were investigated. The findings clearly 
revealed an age-dependant elevation of FPP, GGPP and cholesterol brain levels. Interestingly, the 
endogenous levels between 3 and 12 month old animals of all three investigated analytes were 
unchanged and only the aged group showed a strong increase, which was significant for the two 
isoprenoids. These data substantiate the findings of the previously mentioned study of an age-
dependant modulation of branch point enzyme activities and/or abundance.
83  
To  the  author’s  knowledge,  the  CNS  mevalonate/isoprenoid/cholesterol  pathway  is  widely 
unaffected by a regulation of sex hormones. Most gender derived discrepancies concerning brain 
characteristics described in the literature are more or less in the context of a hormonal regulation, 
recently reviewed by Tobet et al.
356 The current findings of the comparison of the FPP and GGPP 
levels between male and female mice also seem to be unaffected by the gender. Interpretation of 
such data should be evaluated carefully with regard to species and gender, as various proteins   162 
were  described  to  be  differentially  expressed  in  brain  tissue
357  and  consequently  involved 
metabolites might also vary. 
 
5.6.3.2. Alterations in the Rho GTPases during aging 
As described in detail in the introduction (section 1.6.), members of the Rho family of small 
GTPases including RhoA, Rac1, and Cdc42 monomeric G-proteins are claimed to be participants 
in Aβ induced ROS generation
282 and in a down-regulation of transcriptional activity of the APP 
gene.
283  Furthermore,  Rac1  and  RhoA  are  major  regulators  in  the  production  of  actin-based 
morphological  plasticity  in  dendrites and  spines of  hippocampal  neurons.
6,8,9,10,11,284  Neuronal 
Cdc42, Rac1 and RhoA appear to play a role in the plasticity of the adult mammalian brain, 
affecting neuronal architecture, synaptic connectivity and efficacy.
282 It is therefore of valuable 
interest  to  study  protein  expression  of  these  small  GTPases  in  senescence,  for  a  better 
understanding of the physiology in respect to AD pathology 
The aforementioned possible shunt of mevalonate derived products into the isoprenoid/GGPP 
pathway during aging was demonstrated by strongly elevated FPP and especially GGPP levels, in 
the  aged  mouse  brain.  The  isoprenoid  GGPP  represents  the  physiological  substrate  for 
prenylation  of  the  ´classical´  Rho  family  members  (e.g.:  Rac1,  RhoA,  Cdc42).
166  A 
straightforward  prediction  of  the  findings  presented  in  the  current  work  would  point  to  an 
elevation of such proteins, as a consequence of the elevated substrate GGPP.  
However, studies following this work by our working group revealed significantly reduced levels 
of Rho proteins (unpublished data). These western blot results support the notion of an impaired 
synaptic plasticity and LTP during senescence.
211  
Continuative studies of our working group also revealed significantly reduced FTase and GGTase 
levels  (unpublished  data)  explaining  elevated  isoprenoid  levels  as  a  consequence  of  an 
insufficient abundance of small GTPases via a yet unknown mechanism. A different approach 
could explain these findings by a down-regulation of the transferases as a consequence of an 
abnormal upregulation of isoprenoid production, consequently also leading to a decreased small 
GTPases  abundance.  Either  of  the  explanations  has  yet  to  be  substantiated  by  further 
investigations of expression levels both on gene and protein level. 
Data from in vitro prenyltransferase activity assays using a fluorescence labeled C-terminal H-
Ras  motive  has  been  reported.
358  The  study  was  conducted  to  investigate  prenylation  of  the 
artificial peptide (resembling the H-Ras C-terminus) after incubation with various inhibitors on   163 
different levels of the MVA-pathway. These experiments showed a clear correlation of decreased 
isoprenoid levels with a reduction in membrane anchoring, hence prenylation, of the artificial 
peptide under physiological conditions.
358 As a shortcoming of this method isoprenoid levels 
were not determined and it should be noted that this high-throughput assay was developed to 
study  an  inhibitor  screening  assay  rather  than  investigating  physiological  cell  processes. 
Moreover, for an interpretation of the physiological regulation, as for example in aging or under 
pathological conditions like AD, it is clear that one would need to investigate prenylation of 
several members of the small GTPases as they are known to be differentially regulated.
3,123 Such 
studies on a gene, protein and activity level will provide additional information to previously 
published reports on protein isoprenylation with genetically engineered animals.
359 In respect to 
AD, a complete understanding of physiological processes concerning the activation of distinct 
members of the small GTPases, is necessary to address abnormal regulations during the onset and 
the progression of the disease.  
 
5.7. In vitro modulation of the mevalonate/cholesterol/isoprenoid pathway 
Despite  their  aforementioned  crucial role  in  a  wide  array of  fundamental cell processes, our 
knowledge on the cellular regulation of the two isoprenoids FPP and GGPP is limited. This was 
mainly  due  to  analytical  difficulties  concerning  a  robust  isolation  technique  and  a  sensitive 
detection method. Recent analytical progress together with the method developed in the current 
work has allowed investigations into a better understanding of isoprenoid regulation via  in vitro 
and in vivo models.
94,95  
Tong and colleagues described the first method for the simultaneous determination of FPP and 
GGPP in cultured cells.
94 To the present day, FPP and GGPP were determined by the same group 
in a few different cell lines, including mouse embryonic fibroblasts and human cancer cells such 
as  immortalized  colorectal  adenocarcinoma,  myelogenous  leukemia  and  multiple  myeloma 
cells.
94,95,118,263 For a summary of the various cell concentrations see Table 3 a. The current work 
describes for the first time FPP and GGPP levels in cultured neuronal cells (Table 28). Cellular 
levels of FPP and GGPP are generally in the picomolar range as depicted in Table 3, however 
significant  differences  in  isoprenoid  abundance can  be  observed  between  different  cell lines. 
Moreover, the relative distribution between FPP and GGPP varies between different cell lines. As 
depicted  in  the results  section,  GGPP  levels  are  22%  lower,  as  compared  to  FPP  in  SY5Y-
APP695  cells.  Lower  levels  of  GGPP  have  also  been  reported  for  U266  cells  (-  59%).
263   164 
However, in other cell lines levels of GGPP are equal or higher as compared to FPP (Table 3 
a).
94,95,118 Such variances were also observed in mammalian tissue. Compared to FPP, GGPP 
levels are lower in mouse kidney and liver tissue, equal in mouse heart tissue and higher in 
mouse and human brain tissue (Table 3 b).
95 It can be speculated that depending on the demand 
for  intermediates  of  the  MVA-pathway,  specialized  cells  may  differentially  regulate  the 
production of FPP and GGPP. 
The results from the chronically treated mice showed a reduction for FPP and GGPP of 52% and 
32%, respectively (section 4.5.1.). In comparison, a 24 h incubation with 5 µM lovastatin lowered 
FPP and GGPP by 63% and 94% in SY5Y-APP695 cells, respectively. Our data are in line with 
recent findings, which demonstrated a statin induced reduction in FPP- and GGPP-levels by 69% 
and  77%  in  NIH3T3  cells,  respectively.
94  Moreover,  lovastatin  treatment  of  human  multiple 
myeloma cells and Caco-2 cells also significantly reduced both, FPP and GGPP levels.
98,118  
To investigate in vitro MVA-pathway inhibition on a more distinct level, further experiments 
with  neuronal  SY5Y  cells  were  conducted  with  inhibitors  targeting  different  levels  of  the 
mevalonate/isoprenoid/cholesterol  pathway  (Figure  41).  Previous  experiments  within  our 
working group showed a cholesterol reduction following U 18666A and lovastatin treatment.
238 
Moreover, FTi 277 and GGTi 286 treatment led to specific reduction of FTase and GGTase 
activity.  Lovastatin,  as  an  upstream  inhibitor  markedly  reduced  both  isoprenoid  levels. 
Furthermore, inhibition of both the oxidosqualen cyclase down-stream of squalene synthase and 
the desmosterol reductase by U 18666A (section 4.6.2.), led to a 56% elevation of FPP. GGPP on 
the other hand was unchanged compared to control cells. These data substantiate recent reports 
showing that inhibition of squalene synthase using zaragozig acid, significantly elevated FPP and 
reduced GGPP levels in NIH3T3 mouse embryonic fibroblast cells.
94 
 
It has been shown that inhibition of FPPS using zolendronic acid modulates FPP and GGPP 
levels in human multiple myeloma cells.
98 Until now there has been a lack of evidence proving 
the effects of FTase or GGTase inhibition on cellular FPP and GGPP levels. Herein however, it 
was demonstrated that inhibition of FTase significantly decreased FPP levels, while inhibition of 
GGTase I had no effect in this experimental setup.  
It is well established that the reduction of cellular cholesterol levels using inhibitors of the MVA-
pathway or extraction by methyl beta cyclodextrin (MbCD) results in lower Ab levels in vivo and 
in vitro AD models.
271,272,362 However, evidence exists that FPP and GGPP are also involved in   165 
the cellular production of Ab. It has been previously reported that g-secretase is stimulated by 
GGPP
203 and both FPP and GGPP were found to increase Ab levels in H4 neuroglioma cells, 
expressing the Alzheimer relevant amyloid precursor protein APP695NL.
201 The data presented 
in  the  current  work  demonstrate  that  modulation  of  the  mevalonate/isoprenoid/cholesterol 
pathway results in changes of cholesterol as well of isoprenoid levels in human neuronal cells. 
Previous  investigations,  under  identical  conditions,  showed  that  Ab  levels  were  specifically 
reduced when cholesterol levels were lowered by inhibitors of the HMG-CoA reductase, while 
selective inhibition of either farnesylation or geranylgeranylation did not affect Ab production 
(section 4.6.2.). A summary of the data from both studies indicates that changes in endogenous 
cholesterol levels rather than isoprenoid levels, account for the observed modifications in Ab 
production. Accordingly, it is well established that APP processing is influenced by cholesterol 
abundance.
267,268,269,270  During  the  interpretation  of  the current  results one must  consider  that 
excess  of  FPP  or  GGPP  has  not  been  investigated  in  the  present  study.  Moreover,  in  the 
aforementioned  studies  APP  processing  in  cells  was  modified  after  incubation  of  cells  with 
micro-molar FPP and GGPP concentrations. The present findings demonstrated endogenous FPP 
and  GGPP  levels  in  the  picomolar  range,  which  may  not  significantly  interfere  with  Ab 
production.
201,203  
If isoprenoids do not affect Ab metabolism, the question remains how elevated levels of FPP and 
GGPP  could  contribute  to  AD  progression.  In  addition  to  the  earlier  discussed  functions  of 
members of the Rho family of small GTPases, for example RhoA, Rac1, and Cdc42 are also the 
major regulators in synaptic plasticity, both in dendrite morphogenesis and stability, as well as in 
growth cone motility.
6,8,9,10,11 Synaptic degeneration is a striking characteristic of AD and there is 
evidence  that  certain  small  GTPases  are  associated  with  AD.
261,283,284,301  Phosphorylated 
Rac/Cdc42  protein  levels  were  increased  in  hippocampal  membrane  fractions  and  abnormal 
distributed in hippocampal slices isolated from AD brain .
301 Rab-6, which is involved in the 
cellular regulation of vesicular transport, is increased in AD brain.
124,186,261 These proteins cannot 
function properly unless prenylated by FPP or GGPP and we propose that FPP and GGPP are up-
regulated in AD. 
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6. SUMMARY 
  
Over the last years there has been an increasing interest in the involvement of the MVA-pathway 
and  of  members  of  the  small  GTPases,  in  the  development  and  progression  of  AD.  Earlier 
investigations mainly focused on the role of cholesterol in disease pathology. This research was 
supported by retrospective cohort studies, initially showing beneficial effects of the long-term 
intake  of  cholesterol  lowering  statins,  on  the  incidence  of  the  development  of  sporadic  AD. 
Subsequent prospective studies were not able to substantiate these findings resulting in a fading 
interest  in  the  cholesterol  -  AD  connection.  However,  in  more  recent  literature  increasing 
attention has been paid to the isoprenoids, FPP and GGPP, due to their crucial role in the post-
translational  modifications  of  members  of  the  superfamily  of  small  GTPases.  In  AD,  these 
proteins were amongst others shown to be involved in mechanisms affecting APP processing, 
ROS generation and synaptic plasticity. A major factor impeding the clarification of the role of 
the MVA-pathway intermediates in these mechanisms was the lack of a sensitive and accurate 
method to determine FPP and GGPP levels in brain tissue. 
Hence, a state of the art HPLC-FLD method for the quantification of the isoprenoids FPP and 
GGPP in brain tissue was successfully developed. After the introduction of a double clean-up 
step  from  complex  brain  matrix  samples  and  the  synthesis  of  an  appropriate  IS  (DNP),  the 
method  was  fully  validated  according  to  the  latest  FDA  guideline  for  bioanalytical  method 
validation. Criteria included measurements at the LLOQ, linearity, determination of the recovery, 
accuracy, precision and stability tests. Furthermore, this method was transferred to a faster and 
more sensitive, state of the art UHPLC-MS/MS application. Additionally, the method was shown 
to be applicable for mouse brain tissue and data was generated from an in vivo mouse simvastatin 
study and for different mouse models. The method was adapted to allow for the routine in-house 
analysis of samples from in vitro cell experiments.  
According to the aims of the thesis (section 1.9.), the current work describes for the first time 
absolute isoprenoid concentrations in human frontal cortex white and grey matter. Furthermore, 
this is the first report of isoprenoid levels in the frontal cortex of human AD brains.  
 
Further  results  were  shown  from  mouse  brains  originating  from  different  mouse  models, 
including the Thy-1 APP mouse model mimicking AD pathology in terms of Aβ formation or 
C57Bl/6 mice at different ages. AD prevalence can be clearly correlated with increasing age.   167 
Therefore,  three  different  generations  of  mice  were  investigated.  The  study  demonstrated 
constant isoprenoid and cholesterol levels in the first half of their life followed by a significant 
increase of FPP and GGPP in the second half (between 12 and 24 month of age). Cholesterol 
levels were also elevated in the aged group, but again the effect was less pronounced than shown 
for the isoprenoids. These results lead to the tentative conclusion that cerebral isoprenoid levels 
are  elevated  during  aging  and  that  this  accumulation  is  amplified  during  AD  leading  to 
accelerated neuronal dysfunction.  
 
In a different mouse study, using the C57Bl/6 mice, in vivo drug intervention with the HMG-CoA 
reductase  inhibitor  simvastatin  revealed  strong  inhibition  of  the  rate  limiting  step  of  the 
mevalonate/isoprenoid/cholesterol  pathway  and  resulted  in  the  first  report  of  significantly 
reduced FPP and GGPP levels in brain tissue of statin treated mice. These results open for the 
first time the possibility to monitor drug effects on cerebral isoprenoid levels and correlate these 
data with a modulation of APP processing, which was shown by our group in previous studies. 
Interestingly, apart from the isoprenoid reduction following statin treatment the reduction of brain 
cholesterol was also significant but to a lesser extent. These findings support the notion that 
isoprenoid levels are more susceptible to statin treatment than cholesterol levels. Furthermore, 
this suggests a strong cellular dependence on FPP and GGPP, as the pool seems to be easily 
depleted, which finally could lead to cell death. The first investigations of farnesylated Ras and 
geranylgeranylated Rac protein levels by means of immuno-blotting, substantiated the notion of a 
decreased abundance of prenylated small GTPases under statin influence as a consequence of 
reduced isoprenoid levels. These findings demonstrate for the first time a correlation of FPP and 
GGPP levels with the abundance of small GTPases.  
 
These findings together with the results from the AD study prove that isoprenoid levels are not 
strictly subject to the same regulation as cholesterol levels (mevalonate/isoprenoid/cholesterol 
pathway). To further understand the physiological regulation in the cell, in vitro experiments with 
different  inhibitors  of  the  mevalonate/isoprenoid/cholesterol  pathway  were  conducted.  These 
results confirmed the isoprenoid and cholesterol reducing effects of statin treatment as observed 
in the aforementioned in vivo mouse study. Interestingly, cholesterol synthesis inhibition targeted 
after FPP as the branch point, led to significantly elevated FPP levels. FTase inhibition led to   168 
significantly reduced FPP levels, whereas inhibition of the GGTase I did not show a significant 
change of either isoprenoid levels.  
 
The following serves as a concise summary of the results from the current work: 
1.  Development,  validation  and  implementation  of  a  HPLC-FLD  method  for  the 
simultaneous absolute quantification of FPP and GGPP in human and mouse brain tissue. 
2.  Elevated  FPP, GGPP and cholesterol  levels  in  the white  matter  of  the human  frontal 
cortex compared to the gray matter. 
3.  Elevated  FPP  and  GGPP  levels  in  human  AD  brains,  while  cholesterol  levels  were 
unchanged. 
4.  Unchanged FPP, GGPP and cholesterol levels in the Thy-1 APP mouse model. 
5.  Reduced FPP, GGPP and cholesterol levels after chronic simvastatin treatment in an in 
vivo mouse model. 
6.  Elevated FPP, GGPP and cholesterol levels only between middle aged and aged mice, not 
between young and middle aged mice. 
7.  Reduced FPP, GGPP and cholesterol levels after lovastatin treatment in an in vitro SY5Y 
cell model; elevated FPP levels after inhibition of cholesterol synthesis downstream of 
FPP; reduction of FPP levels after FTase inhibition. 
8.  Method transfer to a faster,  more sensitive  and selective UHPLC-MS/MS  method  for 
future studies with a higher sample volume or more detailed analysis of distinct brain 
regions 
 
In conclusion, data from the human AD brains, in vitro and in vivo studies and the aging study in 
mice has allowed for a better understanding and deeper insight into isoprenoid regulation in the 
brain under physiological conditions, in the diseased stage and after drug administration. The 
developed analytical techniques and the data can be used to substantiate further investigations on 
a gene and protein level concerning the isoprenoid synthases, transfersases and distinct members 
of the small GTPases. 
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7. ZUSAMMENFASSUNG 
 
Unter Einbezug von Gen-Expressionsdaten und Protein Gehalten ist es für das Grundverständnis 
von biologischen Prozessen von elementarer Bedeutung spezielle  Metabolite in ausgewählten 
Biosynthesewegen  quantitativ  zu  erfassen.  Hierzu  ist  es  eine  Analytik  unabdingbar  die  den 
strengen Auflagen, wie sie in der Arzneistoffforschung und im klinischen Bereich vorzufinden 
sind, genügt.  
 
Im  Zusammenhang  mit  der  Entstehung  und  dem  Fortschreiten  der  Alzheimer  Demenz  (AD) 
spielt  speziell  der  Mevalonat-Biosyntheseweg  eine  bedeutsame  Rolle.  Frühere  Arbeiten 
beschäftigten  sich  hauptsächlich,  gestützt  durch  die  Ergebnisse  retrospektiver  Studien  mit 
Statinen,  mit  der  Rolle  des  Cholesterins.  Diese  Studien  deuteten  darauf  hin,  dass  die 
Langzeiteinnahme von Statinen das Risiko für das Auftreten der sporadischen AD verringerte. 
Folgende prospektive Studien konnten positive Effekte der Statine auf den Krankheitsbeginn und 
-verlauf aber nicht eindeutig klären, was möglicher Weise daran liegt, dass retrospektive Studien 
einen längeren Beobachtungszeitraum einschließen und möglicherweise frühe Krankheitsphasen 
erfassen.  Statine  sind  kompetitive  Inhibitoren  der  3-Hydroxy-3-Methylglutaryl-Coenzym-A-
(HMG-CoA-)Reduktase,  ausgehend  von  Acetoacetyl-CoA  einem  der  ersten  und  der 
geschwindigkeitsbestimmenden Schritte auf dem Weg der endogenen Synthese von Cholesterin 
über den Mevalonat-Biosyntheseweg. 
 
Aktuellere  Arbeiten  richten  den  Fokus  der  Forschung  stärker  auf  die  ebenfalls  aus  dem 
Mevalonat-Biosyntheseweges  entstammenden  Isoprenoide,  Farnesyl-  (FPP)  und 
Gernaylgeranylpyrophosphat (GGPP). Statine als Inhibitoren der HMG-CoA Reduktase hemmen 
die Bildung von Mevalonat und somit sowohl die Cholesterin– als auch die FPP- und GGPP- 
Synthese.  Beide  Isoprenoide  sind  maßgeblich  an  der  post-translationalen  Modifikation  von 
Proteinen  aus  der  Familie  der  kleinen  Rho-GTPasen  (RhoA,  Rac1,  Cdc42,  etc.)  beteiligt. 
Bezüglich  der  AD  konnte  gezeigt  werden,  dass  bestimmte  Mitglieder  dieser  Familie  in 
Mechanismen involviert sind die an der Entstehung von reaktiven Sauerstoffspezies (ROS) und 
neurotoxischem Amyloid beta beteiligt sind. Weiterhin spielen sie bei der synaptischen Plastizität 
eine zentrale Rolle. Bisherige Forschungen zur Aufklärung der genauen biochemischen Funktion   170 
von FPP und GGPP sowie deren Regulation, speziell in Hirngewebe, wurden durch das Fehlen 
einer sensitiven und validen Analytik eingeschränkt. 
 
Die  vorgelegte  Arbeit  beschreibt  die  Entwicklung,  Validierung  und  erfolgreiche  Anwendung 
einer HPLC-Fluoreszenz Methode zur Quantifizierung der beiden Isoprenoide FPP und GGPP in 
Hirngewebe. Der  Erarbeitung eines  komplexen  Protokolls zur  Methodenaufarbeitung und  der 
Synthese  eines  geeigneten  internen  Standards  folgte  eine  komplette  Validierung  nach  den 
aktuellen  FDA  Richtlinien  für  bioanalytische  Methodenvalidierung.  Anhand  der  Richtlinien 
wurden Linearität, Quantifizierungslimit, Wiederfindung, Genauigkeit, Präzision und Stabilität 
überprüft.  Dies  stellt  ein  Novum  dar,  da  derartige  Untersuchungen  zur  Reproduzierbarkeit 
üblicherweise nur für Xenobiotika durchgeführt werden. Des Weiteren wurde diese Methode auf 
eine schnellere, sensitivere und selektivere, hoch-moderne UHPLC-MS/MS Methode übertragen 
und neben der Validierung der Methode für humane Hirnproben wurde auch die Übertragbarkeit 
auf  Mäusehirne  gezeigt.  Eine  weitere  analytische  Methode  wurde  zur  Untersuchung  der 
Isoprenoid Spiegel von in vitro Versuchen adaptiert und für die Routine-Untersuchung im Labor 
implementiert. 
 
Entsprechend der Zielsetzung dieser Arbeit wurden erstmalig FPP und GGPP Konzentrationen in 
der weißen und grauen Substanz des menschlichen frontalen Kortex quantifiziert. Weiter konnten 
unter Verwendung der neu etablierten Methode zum ersten Mal erhöhte FPP und GGPP Spiegel 
im  frontalen  Kortex  von  AD  Patienten  verglichen  mit  gleichaltrigen  Kontroll-Hirn  Proben 
nachgewiesen  werden.  Für  die  Cholesterin  Spiegel  der  identischen  Proben  konnten  gezeigt 
werden, dass diese unverändert waren, was frühere Arbeiten bestätigt. 
 
Die  vorgelegte  Arbeit  liefert  weiterhin  neue  Ergebnisse  zu  der  Korrelation  von  cerebralen 
Isoprenoid-  und  Cholesterin-Spiegeln  in  einem  in  vivo  Thy-1  APP  Maus-Model,  welches 
typischer  Weise  herangezogen  wird  um  den,  der  AD  zugrunde  liegenden  Amyloid  beta 
Metabolismus zu untersuchen. Weiter wurden Studien an einem Alterungsmodell mit C57Bl/6 
Mäusen durchgeführt, die eine zunächst (zwischen Mäusen im Alter zwischen 3 und 12 Monaten) 
unveränderte FPP und GGPP Homöostase zeigten, während in der dritten und ältesten Gruppe 
(24 Monate) ein signifikanter Anstieg zu verzeichnen war. Diese Ergebnisse wurden auch durch 
die gemessenen Cholesterin Spiegel reflektiert, die ebenfalls nur im Alter erhöht waren. Da das   171 
Auftreten der AD deutlich mit dem Alter korreliert führten diese Ergebnisse, zusammen mit den 
Daten von den humanen AD Hirnproben zu der Hypothese, dass Isoprenoid Spiegel mit dem 
Alter  im  Gehirn  ansteigen  und  dieser  Effekt  bei  der  AD  möglicherweise  potenziert  ist.  In 
weiteren in vivo Versuchen mit C57Bl/6 Mäusen konnte erstmalig der pharmakologische Effekt 
von  Simvastatin  auf  die  Gehalte  von  FPP  und  GGPP  im  Gehirn  gezeigt  werden.  Die  orale 
Verabreichung des HMG-CoA Reduktase Inhibitors für 21 Tage führte zu stark reduzierten FPP 
und  GGPP  Konzentrationen  im  Gehirn  der  behandelten  Tiere.  Cholesterin  wurde  durch  die 
Behandlung ebenfalls reduziert, wobei dieser Effekt vergleichsweise schwach ausgeprägt war. 
Dies lässt  darauf schließen, dass Isoprenoid-Spiegel sensibler auf eine Hemmung der HMG-CoA 
Reduktase reagieren als Cholesterin-Spiegel. Diese Ergebnisse lassen sich mit der Literatur in 
Einklang bringen, dass die Zelle primär von einem gegebenen FPP und GGPP Pool abhängig ist. 
Hier findet ein erhöhter Umsatz statt, welcher primär der Isoprenylierung von lebenswichtigen 
Proteinen aus der Familie der kleinen GTPasen dient.  
 
Unter Einbeziehung der Isoprenoid- und Cholesterin Daten aus der AD Studie und der Ergebnisse 
der  Simvastatin  Behandlung  an  Mäusen  erlauben  diese  Daten  die  Interpretation,  dass  die 
jeweiligen  Endprodukte  (Isoprenoide  und  Cholesterin)  einer  unterschiedlichen  Regulation 
innerhalb  des  Biosyntheseweges  unterliegen.  Diese  Erkenntnis  führte  zu  der  neuartigen 
Bezeichnung  des  Mevalonat-Biosyntheseweges  als  Mevalonat/Isoprenoid/Cholesterin-
Biosyntheseweg.  Um  weitere  Einblicke  in  die  physiologische  Regulation  dieses  speziellen 
Biosyntheseweges zu erlangen, wurden einerseits in mehreren Kooperationen eine ganze Reihe 
von weiteren Metaboliten des Mevalonat-Biosyntheseweges an dem zuvor beschriebenen in vivo 
Alterungsmodels untersucht (Daten noch in Bearbeitung). In der Gesamtheit wurden, wie oben 
beschrieben bei FPP und GGPP die stärksten Veränderungen im hohen Alter festgestellt, was die 
bedeutende Rolle der beiden Isoprenoide in diesem Biosyntheseweg unterstreicht. Andererseits 
wurden  im  Zellmodel  (SY5Y  Zellen)  unterschiedliche  Inhibitoren  des 
Mevalonat/Isoprenoid/Cholesterin-Biosyntheseweges  untersucht.  Hierbei  konnte  der  Statin-
Effekt aus dem in vivo Versuch ebenfalls in vitro gezeigt werden. Inhibition der Squalensynthase, 
die den Cholesterin-Biosyntheseweg nach der FPP Synthesestufe hemmt, führte zu signifikant 
erhöhten FPP Spiegel, was auf eine Akkumulation des Isoprenoids hindeutet. Eine Hemmung des 
für die Farnesylierung verantwortlichen Enzyms, der FTase, zeigte eine signifikante Erniedrigung   172 
der  FPP  Spiegel,  was  gegebenenfalls  auf  einen  shunt  in  Richtung  GGPP  und 
Geranylgeranylierung schliessen lässt.  
 
Die  in  dieser Arbeit durchgeführten  Untersuchungen  zeigen  die  erfolgreiche  Anwendung  zur 
Untersuchung  des  Effekts  unterschiedlicher  Inhibitoren  des  Biosyntheseweges,  was  zukünftig 
gezielte  Studien  zum  Einfluss  von  Arzneistoffen  auf  die  cerebralen  Isoprenoid  Spiegel 
ermöglicht. Im Zusammenhang mit AD können diese Methoden zu eine Korrelation mit einer 
modifizierten  APP  (Amyloid  Precursor  Protein)  Prozessierung  herangezogen  werden.  Der 
Einfluss auf die Prozessierung war und ist Gegenstand von Untersuchungen in unserer Gruppe, 
und  diese  Methoden  vermögen  zusätzliche  Informationen  zu  diesen  speziellen  Metaboliten 
liefern. Ausserdem bilden diese Untersuchungen die Grundlage für weitere Forschungen an den 
prenylierten Proteinen (kleine GTPasen), in wieweit deren zelluläre Expression, Aktivierung und 
Funktionalität  von  diesen  beiden  Isoprenoiden  abhängig  ist.  Erste  immuno-chemische 
Untersuchungen  von farnesylierten  Ras und  geranylgeranylierten  Rac  Proteinen  mittels  semi-
quantitativer  Western Blot Analysen deuteten darauf hin, dass die Expression dieser Proteine 
unter Statin Behandlung reduziert ist, was als Konsequenz der verminderten Isoprenoid-Spiegel 
interpretiert werden kann. 
 
Zusammenfassend  und  übersichtlich  dargestellt  zeigen  die  folgenden  Punkte  die  wichtigsten 
Ergebnisse der vorgelegten Arbeit: 
 
1.  Entwicklung,  Validierung  und  Anwendung  einer  neuartigen  Methode  zur  zeitgleichen 
Quantifizierung von FPP und GGPP in Hirngewebe von Menschen und Mäusen. 
2.  Erhöhte FPP, GGPP und Cholesterin Spiegel in der weißen Substanz des menschlichen 
frontalen Kortex, verglichen zur grauen Substanz. 
3.  Erhöhte FPP und GGPP in humanen Hirnproben (frontaler Kortex) von AD Patienten; 
Cholesterin unverändert. 
4.  Unveränderte FPP, GGPP und Cholesterin Spiegel im Thy-1 APP Mausmodel 
5.  Erniedrigte  FPP,  GGPP  und  Cholesterin  Spiegel  nach  chronischer  Simvastatin 
Behandlung in vivo.  
6.  Erhöhte FPP, GGPP und Cholesterin Spiegel in alten Mäusen verglichen zu jungen und 
mittel-alten Mäusen.   173 
7.  Erniedrigte FPP, GGPP und Cholesterin Spiegel nach Lovastatin Behandlung in vitro; 
erhöhte  FPP  Spiegel  nach  Hemmung  der  Cholesterin-Synthese  folgend  auf  FPP; 
erniedrigte FPP Spiegel nach FTase Inhibition. 
8.  Methoden Transfer auf ein schnelleres, empfindlicheres und selektives UHPLC-MS/MS 
System für zukünftige Studien mit einer höheren Probenanzahl oder einer detaillierteren 
Analyse von spezifischen Hirnregionen. 
 
Schlussfolgernd kann man sagen, dass die Daten der AD Hirn-Studie und von de in vivo und in 
vitro Versuchen erstmalig einen tieferen Einblick in die cerebrale Regulation des Isoprenoid-
Zweiges  des  Mevalonat/Isoprenoid/Cholesterin-Biosyntheseweg  erlauben.  Die  Ergebnisse  der 
Arbeit beruhen auf einer neu entwickelten und validierten Analytik. Sie zeigen unterschiedliche 
Regulationsmechanismen unter dem Einfluss des Alterns, der Alzheimer Krankheit und unter 
pharmakologischer  Beeinflussung  des  Mevalonat-Biosyntheseweges  im  Vergleich  zu 
physiologischen Bedingungen. Die entwickelten analytischen Methoden und die im Laufe der 
Arbeit gesammelten Daten können dahingehend verwendet werden, zukünftige Studien bezüglich 
des Mevalonate-Biosyntheseweges auf Gen und Protein Ebene zu untermauern. Des Weiteren 
bieten  sie  die  Grundlage  für  die  Studie  ausgewählter  Proteine  aus  der  Familie  der  kleinen 
GTPasen.  Diese  Proteine  und  deren  Regulation  spielen  nicht  nur  bei  neurodegenerativen 
Krankheiten  wie  der  Alzheimer  Demenz  eine  Rolle  sondern  sind  auch  speziell  in  der 
Krebsforschung seit langem als Arzneistoff-Targets bekannt. 
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8. APPENDIX 
8.1. Figure and Table legends 
Fig. 1. Outline of the mevalonate/isoprenoid/cholesterol pathway. The overview depicts the major intermediates and 
enzymes involved in the biosynthesis of the isoprenoids and cholesterol. Single arrows (￿) depict a one step 
conversion, while double arrows (￿ ￿) omit one or several intermediates. - - - - symbolizes the blood brain 
barrier (BBB). A detailed description with all abbreviations can be found in section 1.1.1. and section 1.1.2. of 
the introduction. E- and Z-PT depict the prenyltransferases leading to the E- or Z- stereoisomers...................12 
Tab. 1. Summary of the published analytical methods for the determination of FPP and GGPP. The conversion by 
AP stands for an enzymatic conversion of the diphosphate to the free alcohol via alkaline phosphatase under 
basic conditions. Additional information about the methods is given in section 1.3.3.2. of the introduction....19 
Tab. 2. Brief overview over the 5 main subfamilies of the small GTPases (see also section 1.6.2.) with exemplified 
protein  members and their  respective  CaaX-motives  (  -  no  CaaX-motive  and consequently  no  C-terminal 
prenlyation). 
* For some members of the small GTPases different isoforms with partly varying CaaX-motives 
were identified (not shown in table). ** Depending on the small GTPases and the physiology/pathology of the 
cell prenylation by the respective prenyltransferase is either stringent or the proteins partly undergo cross-
prenylation (examples are given in section 1.6.1.).............................................................................................23 
Fig.  2.  Exemplified  overview  describing  the  chronological  post-translational  modification  (PTM)  of  Rac1.  The 
newly translated protein becomes geranylgeranylated and subsequently modified by Rce1p or Step24p, two 
endopeptidases cleaving off the terminal three amino acids (-LLL) of the CaaX-motive. The last step describes 
the  modification  by  the  isoprenylcysteine  carboxyl  methyltransferase  (Icmt),  using  S-adenosyl  methionine 
(SAM). The latter two reactions are mainly taking place in the endoplasmatic reticulum (ER) and in the Golgi 
apparatus (not shown in the figure). The final products (activated GTPases) possibly undergo further PTMs 
before being inserted into the target membrane. Final activation and deactivation depend on the GDP/GTP 
status governed by GEFs/GAPs and partially by the GDIs (refer to section 1.6.2. for further details). The 
activated, GTP loaded enzyme activates downstream, secondary messengers, finally leading to modulated gene 
transcription of distinct genes. Depicted in the current figure is the Rac1-MEKK-JNK pathway.
155 ................25 
Tab. 3a. Levels of FPP and GGPP in different cell lines. Levels were determined using a fluorescence HPLC 
method
94 in mouse embryonic fibroblast cells (NIH3T3), in human immortalized myelogenous leukemia cells 
(K562), in human immortalized colorectal adenocarcinoma cells (Caco-2) and in human multiple myeloma 
cells (RPMI-8226, H929, U266). Human neuroblastoma SY5Y cell results were generated within the current 
work. Means ± SD..............................................................................................................................................37 
Tab. 3b. Leves of FPP and GGPP in different tissues.
95 Mouse tissue was isolated from athmic nu/nu mice. Human 
brain tissue results were generated within the current work. Means ± 
aSD, 
bSEM.............................................37 
Tab. 4. Inhibitors for in vitro cell assays on human SY5Y cells (see section 3.6.). Depicted are the inhibitors, their 
respective enzyme target, the solvent they were dissolved in and the final concentration in the cell medium. An 
overview of the enzyme targets can be seen in Figure 41. .................................................................................55 
Fig. 3. Flow-chart of the final, complete sample preparation for brain tissue and cultured cells prior HPLC-FLD 
analysis...............................................................................................................................................................61   175 
Tab. 5. Respective in vitro incubation conditions for each inhibitor applied in the cell experiments with human 
SY5Y cells..........................................................................................................................................................70 
Fig. 4. Frozen tissue section (~2 x 2 cm) of human frontal cortex for the visual differentiation of white and grey 
matter prior the preparation................................................................................................................................75 
Tab. 6. Patient information of post mortem brain samples. At autopsy, brains were cut into coronal sections and a 
sample from each hemisphere was freshly frozen and stored at −80 °C. Glioblastoma multiforme (GBM) was 
the cause of death regarding this sample set and individual cancer progression was classified according to the 
WHO classification of tumors (I – IV) of the central nervous system.
320 Means ± SD......................................76 
Tab. 7. Patient information of post mortem samples. At autopsy, brains were cut into coronal sections (2-4) and a 
sample of frontal cortex tissue of each sample was freshly frozen and stored at −80 °C. Patients were classified 
as  AD  or  control  (neurological  healthy)  cases  according  to  the  Consortium  to  Establish  a  Registry  for 
Alzheimer's  Disease  (CERAD).  CERAD  have  developed  standardized  instruments  for  the  evaluation  of 
individuals clinically diagnosed with AD.
321 Means ± SD.................................................................................77 
Fig. 5. Pre-column derivatization of FPP (n=2) and GGPP (n=3) to their specific dansyl labelled pentapeptide (R= -
hydroxyl for D*GCVLS and R= -isopropyl for D*GCVLL) by specifically FTase or GGTase I. Enzymatic 
reaction  occurs  under  hydrogen  sulphide  (H2S)  and  diphophate  (-PP)  cleavage.  Analytes  detected  after 
separation are FPP* (=F-D*GCVLS) and GGPP* (=GG-D*GCVLL)..............................................................80 
Tab. 8. Chromatographic conditions and fluorescence detector settings on the Jasco HPLC system with the Zorbax 
C18 column, adapted from Tong et al.
94.............................................................................................................81 
Fig. 6. Time dependant isoprenoid conversion by either transferase to their respective dansyl-labeled penta-peptide. 
Product enrichment (a) FPP* and (b) GGPP* at each time point was monitored by the FLD after HPLC 
separation. Peak areas are shown in µV. ............................................................................................................82 
Fig. 7. (a and b) Five-point calibration curves (5 – 500 ng/mL) of FPP* and GGPP* after pre-column derivatization. 
The respective r
2-values are given in the graph. (c) Representative chromatogram of pure standard solutions 
after pre-column derivatization...........................................................................................................................83 
Tab. 9. A direct comparison of the HPLC settings using the Zorbax RP18 column compared to the Ascentis
® 
Express analytical column. For both optimized methods flow rate, gradient conditions and total run time are 
described in the table. The lower part of the table describes the improvements in peak performance, including 
retention time (Rt), limit of detection (LOD), the tailing factor for peak symmetry and the peak width, depicted 
as full width at half maximum (FWHM)............................................................................................................84 
Fig. 8. Exemplified chromatograms for the method transfer from the (a) Zorbax RP18 column to the (b and c) 
Ascentis
® Express column in two steps. Designated are the two analytes FPP* and GGPP* and the IS, showing 
two baseline separated peaks on the Ascentis
® Express column. The chromatogram in (c) shows the optimized 
peak performance compared to chromatogram displayed in (a).........................................................................85   176 
Fig. 9. Chromatographic overlay of two runs on the same HPLC system (Hitachi) injecting the same solution with 
the same injection volume. Grey trace shows the run on the Zorbax RP18 and the black trace on the Ascentis
® 
Express column at same flow rates. FPP* and GGPP* are designated in both chromatograms.........................85 
Tab. 10. A direct comparison of three different protocols using different organic solvents. Elution efficiency was 
assessed by relative recovery compared to a standard F-G-Assay. ....................................................................88 
Tab. 11. A direct comparison of four different organic solvents mixtures for the elution from the Extrelut
® columns. 
Feasibility of the protocol was judged by the detection of a peak after enzymatic conversion. + stands for a 
detection of a peak at the respective Rt. - stands for the absence of an assignable peak at the respective Rt.....89 
Fig. 10. Chromatograms after elution with (a) Elution mix 3 and (b) the basic alkaline MeOH/CH3CN/acetone 
mixture (see Table 11), resulting in detectable peaks of only GGPP*. Chromatograms show a high background 
noise within the first 8 – 9 minutes. Chromatograms are cut off after 15 minutes to highlight the impurities 
coming of the column after sample injection......................................................................................................90 
Tab. 12. SPE protocols for three different (-CN = cyano, -Si = silanol and diol) SPE cartridges and the applied 
solvents for each step of the protocol (conditioning (C), equilibrating (E), sample loading (S) and elution (Elu) 
step)....................................................................................................................................................................91 
Tab. 13. SPE protocols for four different (-WAX and –X-AW= weak anion exchanger (two different companies), -
NH2 = amino and –MAX = strong anion exchanger) SPE cartridges and the applied solvents for each step of 
the protocol (conditioning (C), equilibrating (E), sample loading (S) and elution (Elu) step). Two elution steps 
were conducted separately (Elu 1 and Elu 2). ....................................................................................................92 
Tab. 14. Optimized SPE protocols for four different (-WAX and –X-AW= weak anion exchanger (two different 
companies), -NH2 = amino and –MAX = strong anion exchanger) SPE cartridges and the applied solvents for 
each step of the protocol (conditioning (C), equilibrating (E), sample loading (S), wash (W) and elution (Elu) 
step). Two elution steps were collected separately (Elu 1 and Elu 2). * The Oasis-WAX protocol was the 
generic protocol as recommended by the supplier. For each protocol samples were applied at pH 1, 6-7 and 12.
............................................................................................................................................................................93 
Fig. 11. Comparison of peak intensities after (a) elution step 1 and (b) elution step 2 in dependency of the pH of the 
sample solution (see Table 14 for applied conditions). ......................................................................................93 
Tab. 15. Comparison of two varying elution conditions using Strata X-AW SPE cartridges. Shown are the applied 
solvents for each step of the protocol (conditioning (C), equilibrating (E), sample loading (S), wash (W) and 
elution (Elu) step). Results are shown as relative recovery compared to a standard F-G-Assay........................94 
Tab. 16. Application of the identical protocol for three different SPE phases (HLB = hydrophilic/lipophilic balance, -
X  =  RP18  phase,  DSC-18  =  RP18  phase).  Shown  are  the  applied  solvents  for  each step  of the protocol 
(conditioning (C), equilibrating (E), sample loading (S), wash (W) and elution (Elu) step). Two elution steps 
with different solvent compositions were conducted separately (Elu 1 and Elu 2). For each protocol samples 
were applied at pH 1 and 6-7..............................................................................................................................95   177 
Fig. 12. Comparison of peak intensities after (a) elution step 1 and (b) elution step 2 in dependency of the pH of the 
sample solution (see Table 16 for applied conditions). ......................................................................................96 
Tab. 17. Optimization of the HLB protocol by varying the elution solvent composition. Shown are the applied 
solvents for each step of the protocol (conditioning (C), equilibrating (E), sample loading (S), wash (W) and 
elution (Elu) step). Results are shown as relative recoveries compared to a standard F-G-Assay. ....................97 
Tab. 18. Elution profile for Protocol 4 (Table 17) by applying 4 individual 1 mL elution steps. Results are shown as 
relative recovery for each elution step compared to a standard F-G-Assay. Total recovery is given as the sum of 
all 4 steps............................................................................................................................................................97 
Fig. 13. HLB elution profiles using n-hexane for (a) FPP and (b) GGPP with 0.5 mL elution steps, separately 
collected and measured. Peak areas are given as µV..........................................................................................98 
Fig.  14.  Wash/elution  profiles  for  FPP  and  GGPP  with increasing  methanol  concentrations.  Elution steps  were 
separately collected and measured. Results are shown as relative recovery compared to a standard F-G-Assay.
............................................................................................................................................................................99 
Fig. 15. Relative comparison of the FPP and GGPP recoveries of the employed X-AW and HLB protocol compared 
to a standard F-G-Assay.....................................................................................................................................99 
Fig. 16. Comparison of the optimized X-AW and HLB protocol after the application of a sample solution containing 
12.5 % ACN. The wash (W) and elution (Elu) step were collected and measured separately. Results are shown 
as relative recovery compared to a standard F-G-Assay...................................................................................100 
Fig. 17.  Influence  of the sample pre-treatment,  including  protein  precipitation  (PPT)  and  the  employment  of  a 
phosphatase inhibitor (PI). Results are shown as comparative peak intensities for FPP* and GGPP* deriving 
from the identical spiked concentrations..........................................................................................................102 
Fig. 18. Influence of phosphatase inhibitors on the recovery of FPP and GGPP levels. (a) Comparison of Halt
® and a 
mixture  of  sodium  fluoride and imidazole.  (b)  Comparison  of  Phosstop
®  and  Halt
® phosphatase inhibitor 
(n=3). Means ± SD; *p<0.05............................................................................................................................103 
Tab. 19. Comparison of four different organic mixtures for the elution of FPP and GGPP of the Extrelut
® columns 
combined  with  a  unique  SPE  protocol  (as  shown  in  section  4.1.5.1.).  Relative  recoveries  are  shown  in 
comparison with protocol number 3, overall showing the highest peak intensities. Protocol 4 did not show any 
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Fig. 19. 300 MHz 
1H-NMR spectrum of DNP after HPTLC clean-up. Instrumental settings are displayed on the right 
and the chemical structure of DNP with the signal assignment given in the spectrum. The acetonitrile (ACN) 
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